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Summary 
 
The purpose of this work is to contribute to the understanding of the structure-activity 
relationships and behavior of the skin ceramides and transdermal penetration enhancers based 
on dimethylamino acid esters.  
First two chapters provide a theoretical background for understanding the main 
principles of transdermal drug delivery as well as composition and function of stratum 
corneum barrier. The experimental work is presented in the form of individual publications in 
chapters three to five.  
The first chapter describes transport routes through the human skin and gives an 
overview of enhancers of transdermal permeation with main accent on their chemical 
structure, mechanism of action, interaction with stratum corneum components and advantages 
and drawbacks of their use.  
The second chapter brings more detailed information on the specific content and 
composition of stratum corneum. The main attention is paid to the ceramides - a complex 
group of lipids that play a crucial role as cell signaling molecules and skin barrier 
constituents. In the skin, these sphingolipids form a major part of the stratum corneum 
intercellular lipid matrix, which is the barrier for penetration of most compounds. The 
development of such a protective layer was a critical step in the evolution of life on a dry 
land. Moreover, prominent skin diseases such as psoriasis and atopic dermatitis are associated 
with diminished ceramide levels and may be effectively improved by exogenous ceramides or 
their analogues. Since ceramides are not obtained from natural sources in pure form, they are 
of synthetic interest since 1950's. In this chapter, we describe sphingosine syntheses from 
1998 until 2008, and the synthetic approaches to the unique epidermal ceramides, including 
the 6-hydroxysphingosine-based ones, the alpha- and omega-hydroxy forms and the omega-
acyloxy species. Moreover, the structural requirements of ceramides for a competent skin 
barrier are discussed, including acyl chain length, trans double bond, acyl alpha-hydroxyl, 
stereochemistry, omega-linoleyloxy species and ceramide conformation. 
Chapter 3 focuses on the synthesis, evaluation of transdermal permeation-enhancing 
potency, biodegradability and reversibility of action of series of N,N-dimethylamino acid 
esters. Effects of chirality, linking chain length and polyfluorination together with the 
enhancer-drug interaction are discussed. No differences in activity were found between (R), 
(S) and racemic dodecyl 2-(dimethylamino)propanoate (DDAIP). Substitution of hydrocarbon 
tail by fluorocarbon one resulted in loss of activity. Replacement of branched linking chain 
between nitrogen and ester of DDAIP by linear one markedly improved penetration-
enhancing activity with optimum in 4-6C acid derivatives. Dodecyl 6-
(dimethylamino)hexanoate (DDAK) was more potent than clinically used skin absorption 
enhancer DDAIP for theophylline (enhancement ratio of DDAK and DDAIP was 17.3 and 
5.9, respectively), hydrocortisone (43.2 and 11.5) and adefovir (13.6 and 2.8), while DDAIP 
was better enhancer for indomethacin (8.7 and 22.8). DDAK was rapidly metabolized by 
porcine esterase, and displayed low acute toxicity. Electrical resistance of DDAK-treated skin 
barrier promptly recovered to control values, showing the reversibility of action of the 
enhancer. These results suggest that DDAK, a highly effective biodegradable transdermal 
permeation enhancer for a broad spectrum of drugs, is a promising candidate for future 
research. 
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As mentioned above, stratum corneum ceramides are major determinants of skin 
barrier function. Although their physiological and pathological role has been widely 
investigated, to date no structure-activity relationships have been established. Study described 
in chapter 4 concentrates on the synthesis of a series of short-chain ceramide analogues with 
polar head structure identical to ceramide NS, sphingosine length of 12 carbons and acyl 
chain length from 2 to 12 carbons. Their effect on skin permeability is evaluated using 
porcine skin and two model drugs, theophylline and indomethacin, and compared to that of a 
physiological ceramide NS. The results showed that ceramide chain length was crucial for 
their barrier properties. Ceramides with 4-8C acyl chain were able to increase skin 
permeability for both drugs up to 10.8 times with maximum effect at 6C acyl. No increase in 
permeability was found for ceramide analogues with 2C and 12C acyl and ceramide NS. The 
same relationships were obtained for skin concentrations of the model drugs. The relationship 
between ceramide acyl chain length and its ability to perturb skin barrier showed striking 
similarity to the behavior of short-chain ceramides in sphingomyelin/phospholipid membranes 
and confirmed that short-chain ceramides do not act as natural ceramides and their use as 
experimental tools should be cautious. 
Topical skin lipid supplementation may provide opportunities for controlling ceramide  
deficiency in diseases such as atopic dermatitis or psoriasis. However, the exact mechanisms 
by which exogenous ceramides correct the barrier abnormalities are not known. Although 
exogenous short-chain NBD-labeled C6-ceramide was shown to rapidly traverse stratum 
corneum (SC) and to be uptaken and metabolized by viable epidermal layers, no such 
evidence is available for long-chain ceramides. Thus, the study described in chapter 5 aims at 
comparing skin penetration of fluorescent NBD-labeled C6, C12, and C24- ceramide and 
pseudo ceramide 14S24. Fluorescent lipids were synthesized from sphingosine or L-serine 
ester and omega-NBD-labeled hydroxysuccinimide-activated acids. 24-NBD-lignoceric acid 
was prepared from dodecan-1,12-diol using lithium tetrachlorocuprate coupling. NBD- 
ceramide at two concentrations, either alone or in equimolar mixture with cholesterol and 
lignoceric acid, were applied on viable human skin for 2 and 12 h, respectively. Only short-
chain NBD-C6- ceramide reached viable epidermis; NBD-C12- ceramide and both NBD-C24 
lipids penetrated solely into several upper SC layers of both intact and acetone-treated skin. 
These results show that the skin penetration of exogenous ceramide is chain length-dependent 
and that exogenous long-chain NBD-labeled ceramide and their analogues do not enter viable 
epidermis. This supports our hypothesis that short-chain ceramide cannot be used as general 
long-chain ceramide mimics. 
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Souhrn 
 
Tato práce si klade za cíl přispět k porozumění chování kožních ceramidů a akcelerantů 
transdermální penetrace založených na esterech dimethylaminokyselin. Zabývá se také 
vztahem mezi strukturou a účinkem těchto látek. 
První dvě kapitoly poskytují teoretický základ pro pochopení složení a funkce stratum 
corneum, která představuje hlavní bariéru pro průnik léčiv a dalších exogenních látek do 
organismu, a principů transdermálního podání léčiv. Experimentální práce je prezentována ve 
formě samostatných publikací v kapitolách tři až pět. 
Kapitola 1 se zabývá transdermálním podáním léčiv, poukazuje na jeho výhody a 
limitace. Hlavní pozornost je věnována akcelerantům transdermální penetrace – látkám, které 
umožňují dočasně snížit bariérové vlastnosti kůže a zajistit dostatečné koncentrace léčivé 
látky nutné pro lokální či systémový účinek. Akceleranty jsou zde popsány s hlavním 
důrazem na vlastnosti, chemickou strukturu a mechanismus účinku. 
Druhá kapitola přináší informace o specifickém složení lipidické matrix stratum 
corneum. Ceramidy, komplexní skupina lipidů, tvoří hlavní část této intercelulární bariéry pro 
průnik látek do organismu. Se sníženými hladinami ceramidů jsou spjata závažná kožní 
onemocnění jako psoriáza či atopická dermatitida. Aplikací ceramidů či jejich analogů může 
být výrazně zlepšen pacientův stav. Vzhledem k tomu, že nemohou být získány v čisté formě 
z přírodních zdrojů, jsou zdrojem zájmu syntetických chemiků již od roku 1950. Kapitola 2 
popisuje syntézy sfingosinu, publikované od roku 1998 do roku 2008, a syntetické přístupy 
pro přípravu unikátních kožních ceramidů. Jsou zde diskutovány strukturální požadavky, 
nutné pro tvorbu kompetentní kožní bariéry, včetně délky acylového řetězce ceramidu, trans 
dvojné vazby, acyl α-hydroxylu, stereochemie a konformace. 
Kapitola 3 se zaměřuje na syntézu, hodnocení akcelerační aktivity, biodegradability a 
reversibility účinku série esterů N,N-dimethylaminokyselin. Diskutovány jsou vlivy chirality, 
délky řetězce aminokyselinové části a polyfluorinace alkoholové části společně s interakcí 
akcelerant – léčivo na účinek akcelerantu. Nebyly zjištěny žádné rozdíly v účinnosti mezi (R), 
(S) a racemickým dodecyl 2-(dimethylamino)propanoátem (DDAIP). Substituce 
uhlovodíkového řetězce za polyfluorovaný měla za následek úplnou ztrátu aktivity. Náhrada 
rozvětveného spojovacího řetězce mezi aminoskupinou a esterovou funkcí lineárním 
způsobila výrazné zlepšení penetrační aktivity s optimem u 4-6C derivátů. Dodecyl 6-
(dimethylamino)hexanoát (DDAK) byl účinnější než klinicky používaný akcelerant DDAIP 
pro theofylin (urychlovací poměr DDAK a DDAIP byl 17,3, respektive 5,9), hydrokortizon 
(43,2 a 11,5) a adefovir (13,6 a 2,8), zatímco DDAIP byl lepší akcelerant pro indomethacin 
(8,7 a 22,8). DDAK byl relativně rychle metabolizován prasečí esterázou a vykazoval nízkou 
akutní toxicitu. Elektrický odpor kůže se po časově omezené aplikaci DDAK vrátil na 
hodnoty shodné s kontrolním vzorkem. Tyto výsledky naznačují, že akcelerant DDAK je, 
vzhledem k jeho spektru a intenzitě účinku, slibný kandidát pro další výzkum.  
Jak již bylo zmíněno, ceramidy stratum corneum jsou hlavní determinanty bariérové 
funkce kůže. Přestože je značná pozornost věnována výzkumu jejich fyziologické a 
patologické role, nejsou dnes dostupné žádné informace o vztazích mezi strukturou a účinkem 
na funkci kožní bariéry. Studie popsaná v kapitole 4 se zaměřuje na syntézu krátkých 
ceramidových analogů s polární hlavou identickou s kožním ceramidem NS, délkou 
sfingosinové části 12C a délkou acylu od 2C do 12C. Jejich efekt na kožní permeabilitu byl 
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hodnocen s využitím prasečí kůže a dvou modelových léčiv, theofylinu a indometacinu, a 
srovnán s přirozeným ceramidem NS. Délka acylového řetězce zásadně změnila vliv 
ceramidového analogu na funkci kožní bariéry. Ceramidy s krátkým acylovým řetězcem o 
délce mezi 4-8C zvýšily permeabilitu kůže pro obě léčiva až 10,8x s maximálním účinkem 
pro 6C acyl. Žádný vzrůst v permeabilitě nebyl zaznamenán při použití analogů s 2C a 12C 
acylem a u ceramidu NS. Vztahy mezi délkou acylového řetězce ceramidu a jeho schopností 
rozrušit kožní bariéru vykazují značnou podobnost s chováním krátkých ceramidů ve 
sfingomyelin-fosfolipidových membránách. Krátké analogy se tedy vždy nechovají jako 
přirozené ceramidy a jejich experimentální využití musí být opodstatněné. 
Předpokládá se, že exogenně podané ceramidy mohou procházet přes stratum corneum a 
vstupovat do živých epidermálních vrstev, ve kterých dochází k jejich vychytávání a 
metabolizaci v keratinocytech. Tato hypotéza je založena na studii, ve které autoři použili 
fluorescenčně značený krátký ceramid NBD-C6-Cer. Jak je popsáno v kapitole 4, krátké 
ceramidy a zvláště C6 derivát se nechovají jako identické kožní sfingolipidy s dlouhým 
řetězcem a spíše snižují bariérové vlastnosti kůže. Kapitola 5 je zaměřená na srovnání 
penetrace C6, C12 a C24  fluorescenčně značených ceramidů a pseudoceramidu 14S24 do 
živé lidské epidermis. Fluorescenční lipidy byly syntetizovány ze sfingosinu či esteru L-
serinu a omega-NBD-značených kyselin. Kyselina 24-NBD-lignocerová byla syntetizována 
z dodekan-1,12-diolu. Značený ceramid byl aplikován ve dvou koncentracích na živou 
lidskou kůži po dvě, respektive po dvanáct hodin. Pouze krátký NBD-C6-ceramid pronikl do 
živé epidermis. Penetrace NBD-C12-ceramidu a obou NBD-C24-lipidů byla omezena na 
svrchní vrstvy stratum corneum jak u nepoškozené kůže, tak i u kůže podrobené částečné 
extrakci lipidů acetonem. Tyto výsledky potvrzují, že chování exogenních ceramidů závisí na 
délce acylového řetězce; přirozený fluorescenčně značený ceramid s dlouhým řetězcem a jeho 
analoga zůstávají lokalizována ve stratum corneum a nepronikají do živé epidermis.  
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1. Transdermal drug delivery 
 
On initial inspection, the skin is an unlikely route for systemic drug administration. 
Indeed, large number of potentially valuable drugs can not alone be used for topical 
administration because they can not cross the skin barrier and reach the site of action in 
sufficient quantity. Since transdermal drug delivery offers many advantages over conventional 
routes of application including avoidance of first pass effect, stable blood levels, easy 
application and higher compliance of the patient, there is a continuing interest in attempting to 
circumvent this barrier and unfavorable physico-chemical properties of applied drugs. The 
drugs administered across the skin presently include clonidine, fentanyl, lidocaine, nicotine, 
nitroglycerin, estradiol, ethinyl estradiol, norelgestromin, norethindrone, oxybutinin, 
scopolamine, and testosterone. Among the requirements for these easy-to-deliver drugs 
belong a small daily dose, molecular weight lower than 500 g.mol
-1
, low melting point and 
balanced lipophilicity. If the daily dose exceeds 10 mg, then the transdermal delivery might 
be complicated, more convenient are doses lower than 5mg [1]. A number of various methods 
have been developed to open the transdermal route to the therapeutics which do not fulfill 
above mentioned demands, including permeation enhancers, ultrasound, iontophoresis, 
electroporation, magnetophoresis, photoacustic waves, microneedles, targeted follicular 
absorption, liposomes and other vesicles, eutectic systems, supersaturated systems, ion pairs 
etc. [1, 2]. 
 
DRUG TRANSPORT ROUTES THROUGH THE HUMAN SKIN 
 
Human skin selectively and effectively inhibits penetration of xenobiotics to the body.  
Transdermal absorption into the systemic circulation includes the permeation across the horny 
layer, viable epidermis and the upper dermal layers. The rate-limiting step in absorption of the 
compound into systemic circulation is the permeation through the stratum corneum (SC). The 
viable epidermis functions as a major barrier only for permeation of extremely lipophilic 
compounds. 
There are three possible routes to reach the 
viable tissue: via sebaceous glands in hair 
follicles, through eccrine sweat ducts or 
across continuous SC. Since the skin 
appendages occupy only 0.1% of the total 
human skin surface, the contribution of this 
route was primarily considered to be small 
and important only for limited number of 
charged substances or substances with high 
molecular weight. Recently it was shown, 
that follicular penetration may be an 
important pathway for the penetration of 
topically administered compounds [3, 4]. 
The transepidermal route can be divided 
into transcellular route through the 
corneocytes and intercellular pathway (Fig 1 
- [5]). The more direct route is transcellular. Since the lipid phase is continuous throughout 
 
 
Fig 1. Transepidermal penetration pathway . 
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the SC, the drug has to overcome both the lipophilic structures of SC and hydrophilic 
environment of the cytoplasm of dead keratinocytes. It has been shown, that intercellular 
pathway is common for substances with a great polarity spectrum [6, 7]. Relationships 
between the rate of the skin permeation of various compounds and their physicochemical 
properties have been also described [8-10].  
 
TRANSDERMAL PENETRATION ENHANCERS 
 
These chemical compounds are designed to reversibly increase the delivery of drugs in 
therapeutic concentrations into the skin or through the skin into deeper tissues and systemic 
circulation. Ideally, these compounds should be pharmacologically inert, non-toxic, non-
irritating, non-allergic, compatible with the drug and excipients, odorless, tasteless, 
inexpensive, have good solvent properties, their effect should be immediate, predictable and 
reversible and they should be chemically and physically stable [11]. Although, there is no 
single compound possessing all the required properties, many enhancers exhibit most of these 
attributes and they have been clinically tested or are already commercially available.  
 
Mechanism of the action of penetration enhancers 
 
The mechanisms of action of enhancers are varied and can range from direct influence on 
the skin barrier to the modification of the formulation. According to Barry‘s lipid-protein 
partitioning concept, the direct mode of action of transdermal enhancers is based on lipid 
interaction, protein modification, and partition changes within the SC [12]. Thus the enhancer 
can: 
a) Act on the SC intracellular keratin, denature it or modify its conformation causing 
swelling and increased hydration. 
b) Affect the desmosomes that maintain the cohesion between corneocytes. 
c) Modify the intercellular lipid domains. The interaction with the polar region of the 
lipidic lamellae is characteristic for small molecules, e.g. water or ethanol. These 
substances are expected to interfere with hydrogen bonding that provides tight packing 
of lipid bilayers. The hydrophobic region is the site of action of amphiphilic enhancers 
possessing similar structural features like natural ceramides. These compounds are 
likely to be inserted into the lamellae, with their polar head in the polar region and the 
hydrophobic part between the hydrophobic chains of SC lipids. This may induce 
disturbance of the lipid packing, lateral fluidization of the lamellae and decrease of the 
skin barrier resistance [13]. Some enhancers, e.g. oleic acid are likely to be 
heterogeneously concentrated within domains and act as more permeable pores for 
polar substances [14]. Some solvents may act via lipid extraction [15, 16]. 
d) Alter the solvent nature of the SC and thus modify partitioning of the drug or the 
cosolvent into the tissue. 
12 
 
In addition, penetration enhancer can act indirectly by: 
a) Modification of thermodynamic activity of the vehicle. 
b) Solubilisation of the permeant in the donor, especially if the solubility of the drug is 
low. 
 
Overview of the enhancers regarding their chemical structure 
 
Penetration enhancers represent a heterogeneous group of chemical compounds. 
Regarding the basic structural features they may be divided into several classes. 
Water is the most natural enhancer. The hydration of the SC is associated with swelling 
of the corneocytes and an increase in the water content of the inter-corneocyte lipid bilayers. 
These phenomena appear to facilitate xenobiotic delivery across the tissue. 
Alcohols may influence the transdermal penetration by several mechanisms depending on 
alkyl chain length. The lower molecular weight alkanols appear to enhance the solubility of 
drugs in the matrix of SC [17]. The more hydrophobic alcohols may contribute by disruption 
of SC through the extraction of biochemicals [18]. 
Activity of polyols, and propylene glycol in particular, are thought to result from 
solvatation of α-keratin within the SC [2]. Propylene glycol can also modify the solubility in 
of the drug in the delivery vehicle and work as a cosolvent [19]. The penetration is probably 
enhanced by a solvent drag effect. Propylene glycol also displays a synergic effect when 
combined with other permeation enhancers that act on the lipid barrier.  
Fatty acids have been used to improve transdermal delivery of wide variety of drugs, e.g. 
estradiol, progesterone, acyclovir, 5-fluorouracil etc. [11], indicating that these enhancers may 
be used for wide variety of both hydrophilic and lipophilic permeants. Based on experiments 
of Aungst the most potent are saturated fatty acids with carbon chain length of C10 – C12 [20, 
21]. In contrast, unsaturated fatty acids have the optimum activity at C18. Oleic acid, in 
relatively low concentration, has been shown to be effective for many drugs, and can work 
synergistically when delivered from vehicles such as PG.  
Esters such as ethyl acetate are relatively small hydrogen bonding species that may 
enhance permeation by penetrating into the SC and increasing the lipid fluidity by disruption 
of lipid packing [22]. Moreover, the aliphatic esters may influence partitioning between 
vehicle and skin by solubilization effects [23]. 
DMSO is dipolar, aprotic solvent with excellent dissolving power. The mechanism of 
action is combination of denaturation of intercellular structural proteins of SC, disturbing of 
SC barrier lipids and their extraction [24]. Unfortunately, DMSO is skin irritating in 
concentrations over 60% required for penetration enhancement. A group of iminosulfurans, 
based on DMSO structure was designed to be more lipophilic and effective at lower 
concentrations (Fig. 2) [25]. This should result in lower skin irritation. 
Urea promotes transdermal permeation by facilitating hydration of the SC and formation 
of hydrophilic diffusion channels within the barrier [26]. The keratolytic properties of urea 
and its derivatives is other reason for the modest permeation enhancement achieved by use of 
these compounds. However, application of these substances (Fig. 3) [27] as permeation 
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enhancers is limited by their inadequate chemical stability, the proteolytic properties and the 
skin irritating effects [28]. 
 
 
 
 
Fig. 2. S,S-Dimethyl-N-(4-bromobenzoyl) 
iminosulfurane. 
 
 
 
 
 
Fig. 3. 1-Dodecyl-3-methythiourea. 
 
Derivatives of ω-amino acids include a number of potent enhancers of transdermal 
penetration. Pyrrolidones are able to promote the penetration of both hydrophilic drugs as 
well as of lipophilic substances. N-methyl-2-pyrrolidone and 5-oxo-pyrrolidin-2-carboxylic 
acid are the most widely used enhancers of this group. Derivatives of 1-alkyl-2-piperidone 
promoted the flux of 5-fluorouracil, caffeine, indomethacin, triamcinolon, acetonide and 
ibuprofen. Michniak prepared a series of alkyl 2-(oxopiperidyl)acetates (Fig. 4) with higher 
activity for enhancement of hydrocortisone than Azone (Fig. 5), which is the most important 
derivative of 2-azepanons [29]. Azone is a first compound specifically designed as a 
transdermal permeation enhancer. It is a very good solvent and possesses overall enhancing 
activities for a quantity of lipophilic therapeutics, thus being often used as a standard for other 
sorption accelerants. Nevertheless, it is inconvenient for clinical use due to its irritation 
potential [30]. Derivatives of alkyl-N,N-disubstituted amino alkanoates are other effective 
representatives of this group [31]. 
 
 
 
 
Fig. 4. Dodecyl 2-(2-oxopiperidin-1-yl)acetate. 
 
 
 
 
Fig. 5. 1-Dodecylazepan-2-one. 
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An α-amino acid derivative, DDAIP (dodecyl 2-(dimethylamino)propanoate), is a 
therapeutically used permeation enhancer which interacts both with lipid-rich bilayers and 
keratine-rich layers. The enhancer appears to open new penetration routes and increase the 
ohmic resistence, capacity properties and fractal dimension of the skin [32]. A series of α-
amino acid based enhancers was synthesized by Fisher and Vavrova (Fig. 6) [33, 34]. 
Carbamates, in particular tramskarbam 12 (Fig. 7), have been reported as excellent 
penetration enhancers for numerous drugs with wide range of physico-chemical properties 
with low toxicity and no dermal irritability [35, 36]. The activity is most likely attributed to 
the structure of the polar head of these compounds, which can be decomposed easily in the 
mildly acidic environment of the skin. The released carbon dioxide probably interferes with 
SC lipid packing thus opening the penetration route for the permeant. 
 
 
 
Fig. 6. Dodecyl 2-dodecanamidoacetate. 
 
 
 
 
Fig. 7. Transkarbam 12. 
 
Surfactants are frequently used as emulsifiers in formulations for dermal application. 
They have the potential to cause protein denaturation or extraction, enzyme inactivation, 
swelling of tissue and extraction of lipid components. Normally, cationic surfactants are more 
effective than anionic and nonionic compounds. However, nonionic compounds are used 
because of low skin irritation potential. 
Terpenes and terpenoids, as highly lipophilic compounds, influence the non-polar 
penetration route. Their effect is linked to a disruption of the lipid packing and to a 
disturbance in the stacking of the bilayers. Terpenes are promising candidates for transdermal 
enhancers due to their low cutaneous irritation in low concentrations (1-5%), low systemic 
toxicity and high activity for both lipophilic and hydrophilic compounds [28].  
Oxazolidinones benefit from their ability to localize increased concentration of the 
permeant into SC or into dermis, which results in low systemic permeation [37]. The 
structural similarity to sphingosine and ceramide like lipids probably causes the lack of 
effective absorption of the enhancer into lower skin layer where irritation is likely to occur. 
Few studies also used phospholipids in non-vesicular form as penetration enhancers. 
There is evidence that phospholipids interact directly with lipid packing of SC. Nevertheless, 
phospholipids can occlude the skin surface, which leads to skin hydration and subsequent 
increase in drug penetration.  
Further and more detailed information on transdermal delivery and penetration enhancers 
can be found in several reviews [24, 28, 38-40].  
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Jakub Novotný, Alexandr Hrabálek, Kateřina Vávrová 
 
ABSTRACT 
 
Ceramides are a complex group of lipids that has gained much attention as cell signaling 
molecules and skin barrier constituents. In the skin, these sphingolipids form a major part of 
the stratum corneum intercellular lipid matrix, which is the barrier for penetration of most 
compounds. The development of such a protective layer was a critical step in the evolution of 
life on a dry land. Moreover, prominent skin diseases such as psoriasis and atopic dermatitis 
are associated with diminished ceramide levels and may be effectively improved by 
exogenous ceramides or their analogues. Since ceramides are not obtained from natural 
sources in pure form, they are of synthetic interest since 1950's. In this review, we describe 
sphingosine syntheses from 1998 until 2008, and the synthetic approaches to the unique 
epidermal ceramides, including the 6-hydroxysphingosine-based ones, the alpha- and omega-
hydroxy forms and the omega-acyloxy species. Moreover, the structural requirements of 
ceramides for a competent skin barrier are discussed, including acyl chain length, trans 
double bond, acyl alpha-hydroxyl, stereochemistry, omega-linoleyloxy species and ceramide 
conformation. 
 
INTRODUCTION 
 
The primary function of the skin is to protect the body from the loss of water and other 
physiologically important components and to prevent or limit the penetration of potential 
toxic compounds, allergens, irritants and microbes. The principal barrier for penetration of 
most compounds resides is the stratum corneum (SC), the uppermost layer of the skin, which 
consists of flattened dead cells, corneocytes, and intercellular lipid lamellae. The intercellular 
lipids are considered as the only continuous domain through the SC to be the most important 
pathway for the diffusion of substances into the body. This lipidic matrix is composed of an 
approximately equimolar mixture of ceramides, cholesterol and free fatty acids. The unusual 
composition of the SC lipids with high ceramide content and, particularly, their exceptional 
organization seems to be essential for maintaining the skin barrier function. This is supported 
by the observation that prominent skin diseases, such as atopic dermatitis and psoriasis, have 
diminished ceramide levels. On the other hand, administration of drugs across the skin is a 
delivery route with great potential; however, only a limited number of drug are able to cross 
the skin barrier to reach therapeutically active plasma levels. For recent reviews on the skin 
barrier formation, physiology and pathology, see [1-6]. 
 
SKIN CERAMIDE STRUCTURES 
 
Ceramides, i.e. N-acylsphingosines, belong to the class of sphingolipids, which are a 
complex group of lipids that gained much attention as cell signaling molecules and skin 
barrier constituents. The role of sphingolipids in cell signaling has been covered in many 
recent reviews, for example [7-10]. Ceramides are among the most hydrophobic lipids in 
membranes, which may explain their abundance in SC. Their solubility in water is negligible. 
Thus, free natural long-chain ceramides cannot exist in solution in biological fluids or in 
cytosol. In addition, they belong to the category of non-swelling amphiphiles [11], implying 
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that they cannot even give rise to micelles or other aggregates in aqueous suspension, as do, 
for example phospholipids and short-chain ceramides [12]. 
 
Table 1. Structure and nomenclature of skin ceramides 
 
 
 
Sphingosine (S) 
1 
 
6-Hydroxy- 
sphingosine (H) 
2 
 
Phyto- 
sphingosine (P) 
3 
 
Dihydro- 
sphingosine (DS) 
4 
 
Lignoceric acid (N) 
5 
Ceramide NS 
(Ceramide 2) 
Ceramide NH 
(Ceramide 8) 
Ceramide NP 
(Ceramide 3) 
Ceramide NDS 
 
 
30-(Linoleyloxy)- 
triacontanoic acid (EO) 
6 
Ceramide EOS 
(Ceramide 1) 
Ceramide EOH 
(Ceramide 4) 
Ceramide EOP 
(Ceramide 9) 
 
 
(R)-2-Hydroxytetracosanoic 
acid (A) 
7 
Ceramide AS 
(Ceramide 5) 
Ceramide AH 
(Ceramide 7) 
Ceramide AP 
(Ceramide 6) 
Ceramide ADS 
 
 
In the human SC, eleven major ceramide subclasses have been identified (Table 1) [13]. 
These compounds consist of a sphingoid base – sphingosine (1) (designated as S), 6-
hydroxysphingosine (2) (H), phytosphingosine (3) (P) or dihydrosphingosine (4) (DS), which 
is N-acylated by a long-chain saturated fatty acid (N, C16-30, mostly lignoceric acid (5)), α-
hydroxy acid (A, C16-30, mostly 2-hydroxylignoceric acid (7)) or ω-hydroxy acid (O, C28-32). 
The ω-hydroxyl is further esterified with linoleic acid (6) (E) or attached to carboxyl side 
chains on the outer surface of the corneocyte to form a monolayer of covalently bound lipids. 
The letters in parentheses refer to the Motta's nomenclature [14]; for example, non-hydroxy 
acyl sphingosine, the most abundant SC ceramide formerly known as ceramide 2, is 
designated ceramide NS, the phytosphingosine acylated with ω-linoleyloxy acid would be 
ceramide EOP, etc. For an extensive overview of the biodiversity of the sphingoid bases, both 
naturally occurring and synthetic, see [15].  
 
 
STRUCTURE-ACTIVITY RELATIONSHIPS IN SKIN CERAMIDES 
 
Although the physiological and pathological role of ceramides in the skin, their 
biosynthesis and physicochemical behavior has been widely investigated, little is known 
about their structure-activity relationships. In order for the epidermal lipid barrier to protect 
the body from external insult and internal water loss, the lipids of the SC must be highly 
ordered. At the same time, the lipid matrix must remain plastic enough to withstand the stress 
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and shear forces routinely encountered by the skin [16]. It is generally accepted, that the 
relatively small polar head of ceramides in contrast to phospholipids, their ability to create an 
extensive hydrogen bonding network, their exceptionally long saturated chains allowing for 
strong hydrophobic attraction and the heterogeneity in their structure are the basic 
prerequisites of a competent skin barrier. The available data are summarized in the following 
sections. 
 
ω-Acyloxy- and ω-hydroxy ceramides 
 
The linoleate and ω-hydroxyacid-containing ceramides are the most unusual of the SC 
ceramides Ceramide EOS was proved to influence dominantly the formation of the long 
periodicity phase and lateral lipid packing [17], which is essential for skin barrier function. It 
has been postulated that the ω-hydroxyacyl portion of the ceramide EOS completely spans a 
bilayer while the linoleate tail inserts into an adjacent bilayer, thus riveting the two together at 
a molecular level. In essential fatty acid deficiency, oleate replaces linoleate in ceramide EOS, 
and this is accompanied by a decreased barrier function [18]. While it seems likely that 
ceramide EOP and EOH have similar role, there are presently no data on this point. The only 
exception is an X-ray diffraction study on the phase behavior of synthetic lipid mixtures 
containing ceramide EOS and EOP. It was shown that complete substitution of ceramide EOS 
with EOP reduces the formation of the long periodicity phase and results in phase separation 
of ceramide EOP [19]. This may well be connected with smaller polar head of sphingosine 
ceramides allowing for a tighter chain packing, see below. 
During the formation of the skin lipid barrier, linoleate is removed from a part of EO-type 
ceramides and recycled and the resulting ω-hydroxy ceramide becomes ester-linked through 
the ω-hydroxyl group to carboxyl side groups at the corneocyte surface [20-22]. These 
covalently bound ceramides may function as a template that provides for orientation of the 
initially extruded lamellar granule contents [23] and this lipid envelope is sometimes regarded 
as the least permeable part of the skin barrier [24]. Further details on covalently bound SC 
lipids can be found in [25, 26]. 
Recently, it has been found that the loss of very long-chain fatty acids (C28 and more) and 
ω-acyloxyceramides in the skin was incompatible with survival in desiccating environment 
leading to neonatal death [27]. 
 
Acyl chain length 
 
In order to increase their aqueous solubility in various experiments, native long-chain 
ceramides are often replaced by synthetic derivatives with short-chain fatty acids like acetyl- 
or hexanoylsphingosine. However, many substantial differences between naturally occurring 
long-chain ceramides and their short-chain analogues were described recently (for a review, 
see Goñi and Alonso [28] and van Blitterswijk [29] and references therein). In the skin 
ceramides, the acyl chain length was found to be crucial for their barrier properties [30]. 
Ceramides with C4-8 acyl chain were able to increase skin permeability for two model drugs 
up to 10.8 times with maximum effect at C6 acyl. No increase in permeability was found for 
ceramide analogues with C2 and C12 acyl and ceramide NS. Those relationship between 
ceramide acyl chain length and its ability to perturb skin barrier showed striking similarity to 
the behavior of short-chain ceramides in sphingomyelin/phospholipid membranes [31-34] and 
confirmed that short-chain ceramides do not act as natural ceramides. Thus, their use as 
experimental tools should be cautious.  
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Moreover, examples of the effects of the chain length on the skin permeability of fatty 
acids and other amphiphiles may be found in transdermal permeation enhancers, i.e. 
compounds that promote transdermal drug delivery by decreasing skin barrier resistance. The 
most promising enhancers are believed to interact with SC ceramides; thus, their structure-
activity relationships may be relevant to those of ceramides. For a review, see [35]. 
 
C4 trans double bond 
 
The C4 trans double bond seems to be essential in most ceramide biological actions [36-
38]. Moreover, the importance of the allylic alcohol moiety in ceramide-induced apoptosis 
and anticancer drugs has been widely discussed by Radin [39, 40]. In the skin, the 
significance of the C4 trans double bond has not been established to date. Due to 
physiological occurrence of sphingoid bases lacking this structural feature in human SC, i.e. 
phytosphingosine and dihydrosphingosine; it may not seem important. Moreover 
pseudoceramides without this double bond effectively repair skin barrier disrupted by various 
insults, for example L-serine ester 14S24 [41, 42]. However, the C4 trans double bond was 
found to promote tight water association through internal hydrogen bonding and closer 
packing of ceramides in interfaces relative to comparable dihydroceramides. Moreover, the 
sphingosine-based ceramides exhibited dipole potentials as much as 150-250 mV higher that 
the saturated species [43]. Conformational characterization of ceramides by NMR pointed to a 
network of cooperative hydrogen bonds that involves the NH and OH groups as well as two 
molecules of water. This structural motif was distorted when the trans double bond was 
absent [44]. This could contribute to ceramide phase behavior in membranes and may also be 
relevant to their SC packing.  
Ceramides containing C4 cis double bond form different internal hydrogen bonding 
network, they insert more easily than the trans isomers in lipid monolayers, but they are less 
effective in inducing flip-flop motion (unpublished results, in [12]). Recently, long-chain 
dicarboxylic acids with cis double bond in their headgroup have been shown to increase intact 
skin permeability while their trans isomers were less active [45]. 
From the comparison of the sphingosine and phytosphingosine ceramides, Rerek 
concluded that the driving force for molecular self-assembly in the sphingosine-based 
ceramides is the orthorhombic chain packing, while in the phytosphingosines it appears to be 
headgroup hydrogen bonding [46]. The finding that phytoceramides pack less tightly than the 
corresponding ceramides is consistent with the monolayer study of Lofgren and Pascher [47]. 
Moreover, the lesser importance of hydrogen bonding in comparison to chain length of 
sphingosine-based ceramides for their barrier properties was shown by Novotný [30]. Thus, 
these two types of ceramides act by different mechanisms: the sphingosine ceramides form 
separate domains while ceramides NP and AP help join the mosaic domains together through 
H-bond connection. Acting together, a structure that is relatively water impermeable, yet 
flexible can result in agreement with the domain mosaic model of the skin barrier [48]. 
However, the role of 6-hydroxysphingosine and dihydrosphingosine remains unresolved. 
 
-Hydroxyl 
 
It has been demonstrated that model SC lipid systems have quite different physical 
properties depending on whether they contain ceramide NS or AS [16, 49]. While both 
ceramide species were packed in highly ordered crystalline phases at physiological 
temperatures, the interactions of the headgroups were different. A transverse organization via 
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hydrogen bonding between ceramide NS molecules, which collapsed with the melting of the 
chains, was described. In contrast, strong lateral hydrogen bonding was maintained between 
headgroups of ceramide AS even after conformational disordering of the chains. Similar 
differences in hydrogen bonding between ceramide NP and AP were also described 
implicating that the water permeability barrier is smaller for ceramide AP compared to 
ceramide NP [50]. It seems that the additional hydroxyl, either in phytosphingosine or next to 
amide carbonyl, prevents tight association of the lipid chains via hydrophobic interactions but 
allows for more extensive hydrogen bonding between the headgroups. 
 
Stereochemistry 
 
Despite their structural diversity, sphingoid bases share a common D-erythro (2S,3R) 
amino alcohol moiety. This stereochemistry of sphingosine, isolated first in 1884 [51], was 
established in 1950's (reviewed in [52]). Phytosphingosine was first isolated from mushroom 
Amanita muscaria in 1911 [53] and its configuration was assigned as D-ribo or 2S,3S,4R. The 
6-hydroxysphingosine, which seem to be unique to the epidermis, was identified first in 1994 
[54] and its stereochemistry was assigned to 2S,3R,6R in 2005 [55].  
The importance of ceramide stereochemistry in the skin is not known at present. Lofgren 
and Pascher [47] showed that acyl α-hydroxyl group in natural R configuration [56] promoted 
the condensation of ceramide monolayers to a close packed crystalline state with a small 
molecular area whereas the reverse effect was observed for a hydroxyl in unnatural S 
configuration. Stereoselective interaction of ephedrine enantiomers with ceramide AS 
monolayer was shown [57]; however, further studies with permeation of chiral drugs (see [58, 
59] and references therein) and chiral permeation enhancers [59, 60] did not confirm these 
findings. 
 
Ceramide conformation 
 
Two conformations of the ceramide molecule were described: a hairpin conformation, i.e. 
with the two chains pointing in the same direction and a splayed chain (or extended) 
conformation, i.e. with the chains pointing in opposite direction [61]. During the preliminary 
stages of skin barrier morphogenesis the ceramide precursors, glucosylceramides, should be in 
the hairpin conformation [62].  During the formation of the SC lipid matrix, however, a 
transition of the ceramides from hairpin to extended conformation is possible. The existence 
of the fully extended conformation of ceramide AP in a model SC lipid system was shown by 
Kiselev [63]. This conformation seems to be advantageous since it allows higher cohesion of 
the lamellae interconnected by the ceramide chains and the absence of water-swelling 
hydrophilic interfaces [64]. Interestingly, the extended ceramide conformation has also been 
proposed as one of the mechanisms how ceramide in plasma membranes interact with proteins 
[65]. 
 
 
SYNTHESIS OF SKIN CERAMIDES 
 
The key step in ceramide synthesis is the preparation of the sphingoid base. Ceramides 
are then prepared by conventional acylation including the use of succinimidyl esters, p-
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nitrophenyl esters, carbodiimide coupling, acyl halogenides and anhydrides. The major 
synthetic problems are associated with surfactant-like properties of amphiphilic intermediates 
or low solubility at low temperatures. Moreover, the allylic hydroxyl moiety of sphingosine is 
prone to epimerization. The preparation of ceramides of the EO and A type is more 
complicated due to difficult handling of its poorly soluble parts and introduction of another 
chiral centre, respectively.  
In this review, we will focus on the syntheses of ceramides that were not covered by 
earlier reports with special attention to epidermal ceramides, including the 6-
hydroxysphingosine-based ones, the α- and ω-hydroxy forms and the ω-acyloxy species. The 
procedures for the synthesis of the most abundant sphingoid base, sphingosine, will be 
reported since 1998; the earlier publications were summarized by Koskinen [52] and Devant 
[66]. Likewise, the synthesis of phytosphingosine [67] and dihydrosphingosine (sphinganine) 
[68] has been carefully reviewed recently.  
 
Synthesis of sphingoid bases of naturally occurring skin ceramides 
 
Synthesis of sphingosine 
 
Since sphingosine is not readily obtained from natural sources in homogeneous form, 
great effort has been devoted to development of a simple and low cost synthetic method, 
starting with the first racemic one in 1954 [69]. Due to the presence of two stereogenic centers 
and trans double bond in the target molecule, several synthetic strategies based on chiral 
starting compounds (in particular serine, carbohydrates or tartaric acid) or asymmetric 
reactions have been used. When chiral substrates are used as starting material, the 
characteristic trans double bond is often generated by Wittig reaction, Julia olefination, 
Horner-Wadsworth-Emmons reaction or by alkynylation of the chiral substrate and 
subsequent selective reduction of triple bond. Recently, methods using olefin cross-metathesis 
have been described, see below. Other syntheses have employed asymmetric introduction of 
the chiral centres, including Sharpless asymmetric epoxidation, asymmetric aldol or other 
stereoselective reactions. Additionally, strategies based on Diels-Alder reaction, 
iodolactonization, enzymatic approach etc. have been reported. 
From the earlier methods reviewed by Koskinen [52] and Devant [66] we would like to 
mention several representative ones, which are widely applied in sphingosine synthesis for 
sphingolipid studies. Two characteristic methods using carbohydrate approach are the 
syntheses published by Schmidt and Zimmermann [70] and Kiso [71]. The sphingosine 
synthesis relying on the Sharpless asymmetric epoxidation are well illustrated in the work of 
Julina [72]. Method of Nicolaou relies on the aldol reaction of boron enolate of N-
acyloxazolidinone with hexadecenal to construct the sphingosine carbon skeleton. The 
methods of Garner [73] and Herold [74] are based on alkynylation of protected serinal known 
as Garner aldehyde [75].  
In comparison with the methods published between 1991 and 1997, asymmetric 
syntheses are the most abundant, followed by the preparations from serine. Monosaccharides 
as precursors of sphingosine partially lost their attraction for synthetic chemists but 
phytosphingosine became a frequent starting material. The recent syntheses are described here 
in chronological order. 
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In 1998, Kobayashi reported synthesis of sphingosine and its derivatives including 
sphingofungines B and F using heterocycles as chiral ligands and auxiliaries  via 1,3-dioxane 
(12) as a key intermediate (Scheme 1) [76]. Trimethylsilylpropynal (8) and (Z)-2-benzyloxy-
1-phenoxy-1-trimethylsiloxyethen (9) were used as starting compouns for tin(II) triflate and 
(R)-methyl-2-[(N-1-naphtylamino)methyl]pyrrolidone catalyzed asymmetric aldol reaction 
(syn/anti = 97/3, 91% ee for syn). Resulting phenyl ester (10) was reduced with DIBAL to 
give diol, which was protected as acetonide (11). Sphingosine and its derivatives were then 
prepared from (11) according to standard transformations. The removal of trimethylsilyl 
group was followed by alkylation and removal of benzyl group by lithium in liquid ammonia. 
Azide group was introduced by Sn2 process by successive treatment of alcohol by triflic 
anhydride/pyridine and sodium azide. The removal of acetal and reduction of azido group 
yielded 2-amino-1,3-hydroxy alkyne (15) as a second key intermediate for preparation of D-
erythro-sphingosine (1), cis-sphingosine and dihydrosphingosine by various reduction 
procedures. D-erythro-sphingosine was prepared in 10 steps and 19% overall yield. 
 
 
 
Scheme 1. Reagents and conditions: (i) Sn(OTf)2/SnO/(R)-methyl-2-[(N-1-naphtylamino)methyl]pyrrolidone/ 
propionitrile; (ii) DIBAL; (iii) DMP/TsOH; (iv) Bn4NF; (v) BuLi/C13H27Br; (vi) Li/liq. NH3; (vii) 
Tf2O/pyridine/NaN3; (viii) AcOH-H2O; (ix) Ph3P/H2O-pyridine; (x) Red-Al. 
 
Synthesis D-erythro-sphingosine, L-threo-sphingosine and sphinganine diastereomers 
from commercially available N-Boc-L-serine methyl ester (16) via its biological intermediate 
3-ketosphinganine (20) as a key synthetic intermediate was published in the same year 
(Scheme 2) [77]. The strategy sets the stereochemistry of the allylic hydroxyl in the last stage 
of the synthesis and allows attachment of diverse tails as triflate electrophiles derived from 
alcohols. The starting compound was protected by cyclization with DMP. Conversion to β-
ketoester (17) with CDI and lithium allyl acetate followed a standard procedure published by 
Harris [78]. The subsequent alkylation of (17) with sodium hydride and 1-tetradecyl triflate 
allowed for using milder conditions than the procedure employing 1-bromotetradecane, 
HMPE and sodium iodide, and minimized the chances of epimerization. Deallylation and 
decarboxylation achieved with Pd(PPh3)4 and morpholine yielded the desired oxazolidinone 
derivative (18). The utilization of Pd[0] enabled to use mild and neutral conditions for the 
removal of allylic group and following decarboxylation. This was a significant improvement 
over the previous method using  t-butyl ester  [79]. Treatment of the 3-ketosphinganine with 
NaHMDS followed by TMSCl gave TMS-enol ether, which was oxidized with Pd(OAc)2 to 
unsaturated ketone (20). The crude (20) was reduced with NaBH4/CeCl3 to D-erythro-
sphingosine derivative (21). CeCl3 suppressed conjugate reduction, which occurred in its 
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absence. The straightforward deprotection of sphingosine was achieved with 1M HCl. The 
synthesis proceeded in approximately 26% overall yield in six steps with a good stereocontrol 
(>91% de, >95% ee).  
 
 
 
Scheme 2. Reagents and conditions: (i) DMP/TsOH; (ii) LiOH; (iii) a) CDI, (b) lithium allyl acetate; (iv) NaH/1-
tetradecyl triflate; (v) Pd(Ph3)4/morpholine; (vi) a) NaHMDS, b) TMSCl; (vii) Pd(OAc)2/CHCN3; (viii) 
NaBH4/CeCl3; (ix) 1M HCl. * - in two steps. 
 
An alternative approach using sulfoxide as a chiral auxiliary in the reduction of β-
ketosulfoxide precursor in the syntheses of D-erythro and L-threo-sphingosine was published 
by Khiar (Scheme 3) [80]. β-Ketosulfoxide (23) was prepared by the condensation of 
protected L-serine methyl ester with (R)-(+)-methyl-4-tolyl sulfoxide carbanion (22) [81]. The 
key step in this synthetic sequence was the quantitative DIBAL reduction of compound (23) 
to β-hydroxysulfoxide (24) as a single isomer. Interestingly, the addition of one equivalent of 
ZnCl2 to the reaction caused the change in the spatial arrangement of C3 hydroxyl, giving 
thus epimer of (24) also quantitatively as a single isomer. Protection of the secondary alcohol 
with MOMCl in the presence of NaH yielding (25) and subsequent one-pot Pummerer 
rearrangement using trifluoroacetic anhydride and NaBH4 reduction led to optically pure 
primary alcohol (26). Its oxidation was followed by the Schlosser modification of Wittig 
olefination using tetradecyltriphenylphosphonium bromide, which afforded the protected 
sphingosine (28) as the only isomer. The deprotection with aqueous acetic and aqueous TFA 
resulted in the desired sphingosine. The synthesis gave D-erythro-sphingosine in nine steps 
from protected serine and may be used for preparation of other three sphingosine 
stereoisomers, depending on the starting material and the conditions of β-ketosulfoxide 
reduction. Unfortunately, the authors did not publish the yields of the Wittig olefination.  
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Scheme 3. Reagents and conditions: (i) Condensation; (ii) DIBAL; (iii) NaH/MOMCl; (iv) a) 
(CF3CO)2O/Collidine, b) NaBH4/H2O; (v) (COCl)2/ Et3N; (vi) H31C14PPh3Br/PhLi/LiBr; (vii) a) AcOH/H2O, b) 
TFA/H2O. 
 
Hertweck and Boland introduced a synthetic strategy based on α-chloroallylation of 
Garner aldehyde (29), followed by base mediated cyclization of the originating chlorohydrine 
(30) and reaction of the resulting vinyloxirane (31) with an organocuprate (Scheme 4) [82]. 
Serinal (29) was treated with γ-(Z)-chloroallylboranes prepared in situ from DIpc2BOME, 
allylchloride and lithium dicyclohexylamide. Since the chloroallylation is largely substrate 
controlled, the 9-OMe-9-BBN can be used as an inexpensive alternative to the pinene-based 
borane with only slightly decreased diastereo- and E/Z selectivity. Nevertheless, the 
recrystallization of halohydrines (or epoxides obtained by their cyclization) afforded 
isomerically pure material. The treatment of halohydrine (30) with DBU furnished 
vinyloxirane (30) under mild conditions and without isomerization. The allylation/epoxidation 
sequence can be conducted as one pot procedure. Copper assisted Sn2 alkylation of the 
epoxide was achieved by its simple addition into the solution of organocuprate prepared in 
situ from CuCN and carbon nucleophile (RLi, RMgCl) with exclusive formation of trans-
double bond (32). Sphingosine (1) can be received from (32) by hydrolysis with 1M HCl/THF 
or aqueous TFA. 
 
 
 
Scheme 4. Reagents and conditions: (i) a) 
l
IpcBOMe/LiN(
c
Hex)2/n-BuLi, b) 8-hydroxyquinoline or 
NaHCO3/H2O2; (ii) DBU; (iii) BrC12H25/t-BuLi/CuCN; (iv) acidic hydrolysis. 
 
Johnson presented a total synthesis of the L-threo-isomer of sphingosine and formal 
synthesis of the other three isomers employing a chemoenzymatic approach [83]. The general 
strategy was based on the use of enantiocomplementary hydroxynitrile lyases to yield an 
enantiomeric pair of starting compounds. This method yields L-threo-sphingosine in 14 steps 
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in 12% overall yield. The sequence employing hydroxynitrile lyase from Prunus amygdalus 
should allow the preparation of D-erythro-sphingosine as well.  
 
He reported asymmetric synthesis of ceramide and sphingosine analogues from 
pentadecyne via cyclic thionocarbonate intermediate (36) (Scheme 5) [84]. Their strategy 
involved three key reactions including asymmetric dihydroxylation of an (E)-α,β-unsaturated 
ester (34) as the chiral induction stage, regioselective induction of the azido group at the α-
position with inversion via cyclic thionocarbonate intermediate, and selective reduction of the 
ester. Substrate for asymmetric dihydroxylation was prepared by Horner-Wadsworth-Emmons 
reaction via coupling of hexadec-2-ynal with a phosphonate reagent. To the authors 
disappointment the optimized Sharpless conditions for dihydroxylation of enyne ester have 
brought the product very slowly and in a low yield, probably due to the electron deficient 
double bond placed between triple bond and ester function. Nevertheless, they were able to 
overcome the problem by addition of more osmium reagent (K2OsO4.2H2O) and chiral ligand 
((DHDQ)2-PHAL or (DHQ)2-PHAL) to the commercial AD-mix-β/α and thus receive (35) in 
high yield and 98% ee. Diastereoselective α-azidation of the diol ester via a cyclic sulfate was 
unsuccessful due to parallel oxidation of the triple bond. Direct regioselective Mitsunobu 
monoazidation also furnished unwanted β-azido ester. Finally, α-azido ester (37) was 
prepared via cyclic thionocarbonate intermediate by reaction with thiophosgene in the 
presence of DMAP. The ring opening of the crude was achieved by NaN3. Although the 
monoazidation (36) was achieved in high yield, only poor degree of regioselectivity (α/β 
2.4:1) was encountered. The simultaneous reduction of ester and azido group together with 
triple bond was performed using LiAlH4. The final product was obtained in five steps and 
25% overall yield. 
 
 
 
Scheme 5. Reagents and conditions: (i) n-BuLi/1-formylpiperidine; (ii) (i-PrO)2P(O)CH2CO2Et/LiBr/Et3N; (iii) 
AD mix β, CH3SO2NH2; (iv) Cl2CS/pyridine/DMAP; (v) NaN3/PPTS; (vi) LiAlH4. 
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Chiral β-lactam (38) obtained from D-(-)-tartaric acid [85], was used as a basic building block 
for the synthesis of sphingosine and phytosphingosine in the work of Nakamura (Scheme 6) 
[86]. First, the ester group was reduced to alcohol and protected as triisopropylsilyl ether. The 
lactam nitrogen was protected by di-t-butyl dicarbonate to yield compound (40). The 
alkylation of the lactam (40) with carbanion of n-tetradecyl-p-toluensulfone yielded a mixture 
of diastereomers of (41). Elimination of p-toluensulfonyl moiety with lithium naphthalenide 
and subsequent deprotonation and sulfonylation with N-phenyltrifluoromethanesulfonimide 
afforded Z-enoltriflate (42) exclusively. The reductive elimination of triflate group by formic 
acid and Et3N using palladium catalyst and the successive deprotection of the remaining silyl 
groups by tetrabutylammonium fluoride yielded in E-olefin (43). The Boc-derivative can be 
easily converted into sphingosine by deprotection according to known methods. The authors 
claim approximately 35% yield in six steps. However, the practical use of this synthesis is 
hampered by the use of commercially unavailable starting material. 
 
 
 
Scheme 6. Reagents and conditions: (i) NaBH4/EtOH; (ii) a) TIPSCl/imidazole, b) (Boc)2O/Et3N/DMAP; (iii) p-
Tol-SO2-C13H27/n-BuLi; (iv) lithium naphthalenide; (v) KN(SiMe3)2/(CF3SO2)2NPh; (vi) a) HCOOH/ 
Pd(OAc)2(PPh3)2/Et3N, b) n-Bu4NF. 
 
The total sphingosine synthesis from D-galactose via an azidosphingosine using Wittig 
olefination, and determination of its optical purity by new method using Mosher‘s acid was 
presented by Duclos [87]. The synthesis is rather a combination of previously published 
sequences, e.g. [70, 71], but it resolves their discrepancies in synthetic procedures and 
characterizations. 
 
Milne reported synthesis of sphingosine from D-xylose via 1,2-metallate rearrangement 
of higher order cuprate (Scheme 7) [88]. The crucial α-lithiated glycal intermediate (46) may 
be prepared by two different ways. The shorter one used 1-thio-β-D-xylopyranoside, 
protected as its tris(t-butyldimethylsilyl) ether (44), which was oxidized to the corresponding 
sulfoxide. β-Elimination of TBSOLi with LDA gave stable α-phenylsulfinyl glycal (45). Its 
reaction with t-BuLi resulted in phenylsulfinyl-lithium exchange and generation of α-lithiated 
glycal (46). The reaction of the glycal with CuBr.SMe2 and n-tridecyllithium caused a 1,2-
metallate rearrangement of higher order cuprate (47) connected with inversion of 
configuration and O-C-O silicon shuttle. The 1,3-diol (49) was protected as its benzylidene 
acetal derivative and the remaining O-TBS group was cleaved with Bu4NF to yield compound 
(50). The C-TBS group was transferred back to oxygen by Brooks rearrangement and 
resulting mixture of alcohol and its O-TBS ether was treated with Bu4NF again, giving the 
alcohol (51) only. Mitsunobu reaction with diphenylphosphoryl azide afforded inverted azide 
(52), which was reduced with zinc and ammonium chloride to give sphingosine. The synthesis 
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is very interesting from a chemical point of view but it consists of 12 steps and gives 
sphingosine in a poor overall yield (9-12% from D-xylose). 
 
 
 
Scheme 7. Reagents and conditions: (i) H2O2/(NH4)2MoO4; (ii) LDA; (iii) t-BuLi; (iv) 
C13H27Li/CuBr.SMe2/Et2O-SMe2; (v) H2O; (vi) PhCH(OMe)2/p-TsOH; (vii) Bu4NF; (viii) NaH/15-crown-5; (ix) 
Bu4NF; (x) diphenylphosphoryl azide/DIAD/Ph3P; (xi) p-TsOH; (xii) Zn/NH4Cl. * - from (47). 
 
Lee described convenient, stereoselective synthesis of all four diastereoisomers of 
sphingosine from L-serine methyl ester (Scheme 8) [89]. Protected L-serine methylester (53) 
was quantitatively converted to β-ketophosphonate (54) by treatment with excess lithium 
dimethyl methylphosphonate. The Horner-Wadsworth-Emmons olefination with 
tetradecylaldehyde under Masamune conditions provided the corresponding enone (55), 
which was deprotected to give 3-ketosphingosine hydrochloride (56). The chelation-
controlled reduction of free amino enone, presumably via a cyclic Felkin-Anh transition state, 
gave D-erytro-sphingosine in satisfactory 90% de. Sphingosine was obtained by this practical 
synthetic route in 51% overall yield in six steps. Similar procedure using serine-derived β-
ketophosphonates was also described previously by Koskinen [52].  
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Scheme 8. Reagents and conditions: (i) TBSCl/Et3N; (ii) TrCl/Et3N; (iii) LiCH2PO(OMe)2; (iv) 
C13H27CHO/DBU/LiCl; (v) 2M HCl; (vi) Zn(BH4)2. 
 
The experience with the preparation of syn- and anti-β-amino alcohols accessible through 
electrophile-promoted intramolecular amidation of allylic and homoallylic 
trichloroacetimidates was used by Kang for the establishing of D-erythro-sphingosine and D-
ribo-phytosphingosine synthetic route [90] (Scheme 9). The disilylation of the starting triol 
(57) was followed by chemoselective monodesilylation and monoimidate formation in the 
presence of Cl3CCN, sodium hydride and n-Bu4NF. Iodoamidation of the resulting silyloxy 
homoallylic imidate by IBr afforded dihydro-1,3-oxazine (58). The eliminative reduction of 
the iodohydrine functionality, hydrolysis of the alkene and protection of the amino group 
furnished dihydroxycarbamate (59). The ozonolysis of the olefinic bond, formation of 1,3-
dioxane and subsequent Swern oxidation of primary hydroxyl group provided a substrate for 
the attachment of the aliphatic chain by Julia olefination. Unfortunately, the alkene (61) was 
formed with rather poor stereoselectivity as 2.8:1 mixture of trans- and cis-isomer. D-erythro-
sphingosine (1) was received from trans-alkene after its chromatographic isolation and acidic 
hydrolysis of the benzylidene ring. The procedure provides sphingosine in 21% overall yield. 
 
 
 
Scheme 9. Reagents and conditions: (i) TIPSOTf/Et3N; (ii) a) Cl3CCN/NaH, b) n-Bu4NF; (iii) IBr/K2CO3; (iv) a) 
(CF3CO)2O/Et3N, b) NaI; (v) 6N HCl; (vi) Boc2O/K2CO3; (vii) a) O3, b) NaBH4; (viii) p-TsOH/PhCHO; (ix) 
Swern oxid.; (x) 1-phenyl-5-(tetradecylsulfonyl)-1H-tetrazole/ KHMDS; (xi) CF3COOH. 
 
Olofsson and Somfai published an asymmetric, divergent route from a common starting 
material, vinyl epoxide, toward all possible regio- and stereoisomers of sphingosine (Scheme 
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10) [91]. The starting dienol was prepared from 1-tetradecanol by modified Horner-Emmons 
reaction and reduction of crude ester (62) with DIBAL, and protected as its benzyl ether (63). 
Though Shi‘s epoxidation on protected dienols proceeds on the most electron-rich double 
bond, 2,3- (64) and 4,5-epoxides were formed in equimolar ratios, probably due to the lipid 
chain shielding of 4,5-double bond. As the vinyl epoxides are unstable on silica, their mixture 
was subjected to stereoselective ring opening (>20:1) in the presence of ammonium 
hydroxide. Because only the 2,3 isomer reacts under the described reaction conditions, 
resulting anti-amino alcohol (65) and unreacted epoxide isomer were separated on silica. The 
authors continued the synthesis by regioselective ring opening of N-H vinylaziridine (66), 
which was obtained from anti-amino alcohol (65) by ring closure under Mitsunobu 
conditions. The crude aziridine was treated with TFA and amino alcohol (67) was obtained 
with high diastereo- and regioselectivity (>20:1). Sphingosine was obtained by removal of the 
benzyl group with sodium in liquid ammonia in less than 16% overall yield. 
 
 
 
Scheme 10. Reagents and conditions: (i) a) IBX, b) triethyl phosphonocrotonate/LiOH; (ii) DIBAL; (iii) 
BnBr/NaH/Bu4NI; (iv) Shi‗s reagent/Oxone; (v) NH4OH/THF; (vi) DIAD/PhP3; (vii) TFA; (viii) Na/NH3. * - 
from 1-tetradecanol. ** - two steps. 
 
An elegant and short three-step synthesis of sphingosine and C10 sphingosine from 
protected L-serine methyl ester (68) involving β-ketosulfoxide or sulfone intermediates was 
published recently (Scheme 11) [92]. Alkyl phenyl sulfoxide was prepared in high yield by 
the reaction of thiophenol with n-alkyl bromides and subsequent treatment of the resulting 
sulfide with MCPBA. Nucleophilic addition of the sulfoxide anion to the L-serine ester (68) 
afforded sulfoxide intermediate (69). Its overnight heating in tetrachloromethane gave the 
desired enone (70). A lower yield of the long-chain derivative in comparison with the short-
chain one was observed. The requisite configuration at C(3) was reached by diastereoselective 
reduction of (70 by NaBH4 with addition of CeCl3. Regrettably, the authors did not report 
diastereoselective excess of this reaction. Hydrolysis of alcohol (71) provided D-erythro-
sphingosine in three steps and 26% overall yield from the starting ester. Another method of 
sphingosine synthesis described in the same article was based on sulfone derivatives of L-
serine [92]. Since the reaction of pentadecyl phenyl sulfone with L-serine ester (68) produced 
low yields, the sulfone intermediate (75) was acquired by reaction with aldehyde (73) and 
subsequent oxidation of secondary hydroxyl. The intermediate β-ketosulfon (75) can also be 
received from ester (68) by reaction with methyl phenyl sulfone and alkylation with tetradecyl 
iodide. Desulfonylation of (75) was done by aluminum amalgam. The ketone (76) was 
selectively reduced to enone (70) according to Hoffman [77]. The synthesis was finished as 
described above. 
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Scheme 11. Reagents and conditions: (i) LDA/PhS(O)C14H29; (ii) CCl4; (iii) NaBH4/CeCl3; (iv) 1M HCl; (v) 
MeSO2Ph/n-BuLi; (vi) DBU/C14H29I; (vii) C15H31SO2Ph/n-BuLi; (viii) PCC; (ix) Al(Hg); (x) see scheme 2 [77]. 
* - from (68). 
 
Phytosphingosine, as a relatively inexpensive and commercially available sphingoid base 
with both sphingosine chiral centers established, was used for synthesis of sphingosine in 
2002 [93]. The authors utilized the introduction of the requisite E-alkene moiety by two 
different ways. First strategy dealt with transformation of protected 4-oxo derivative with a 
high degree of stereoselectivity (Scheme 12), as showed previously by Nakamura [86]. 
Commencing with phytosphingosine (3), amino group and 1,3 hydroxy groups had to be 
protected. The amino group was protected by treatment with di-t-butyl dicarbonate. In order 
to avoid an inseparable mixture caused by protection of 1 and 3 hydroxyl with benzylidene 
group, the regioselective protection was accomplished by silylation with di-t-butyl silyl 
ditriflate. The oxidation of protected phytosphingosine derivative (78) to 4-ketone (79) and its 
in situ conversion into enolate was followed by sulfonylation with N-phenyl-
bis(trifluoromethanesulfonimide) furnishing Z-enol triflate (80). The regiospecific reductive 
elimination of the enol triflate function, desilylation and acidolysis of N-Boc moiety led to 
sphingosine in 58% overall yield.  
Second approach was based upon the procedure published by Wild [94], which envisaged 
the conversion of protected 2-azido-4-nitrophenylsulfonate derivative into azidosphingosine 
(Scheme 13). Phytosphingosine was subjected to Wong‘s diazo transfer to furnish azido 
derivative (83), which was silylated to protect 1,3-hydroxy groups. Disappointingly, the 
nitrophenylsulfonylation under Schmid‘s conditions led to intractable mixture of products. In 
contrast, nosylation with in situ prepared mixed anhydride provided nitrophenylsulfonyl 
derivative in a high yield. However, the elimination of the product led to (85) in 
unsatisfactory yield. Surprisingly, the triflation of alcohol (84) with triflic anhydride in the 
presence of pyridine gave directly the E-olefin (85), instead of expected triflate ester. The 
following Staudinger reduction and desilylation afforded sphingosine in 58% overall yield.
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Scheme 12. Reagents and conditions: (i) 
Boc2O/Et3N; (ii) (t-Bu)2Si(OTf)2/pyridine; (iii) 
(Ac)2O; (iv) KHMDS/N-phenyl-
bis(trifluoromethanesulfonimide);  
(v) Pd(OAc)2(PhP3)2/HCOOH/Et3N; (vi) n-
Bu4NF/AcOH; (vii) TFA. 
 
 
Scheme 13. Reagens and conditions: (i) 
TfN3/K2CO3/CuSO4; (ii) (t-Bu)2Si(OTf)2/pyridine; 
(iii) Tf2O/ pyridine; (iv) Me3P; (v) n-Bu4NF/AcOH. 
 
The same authors succeeded in the development of even more economical approach 
based on phytosphingosine as a starting material, trying to avoid the use of expensive 
chemicals (Scheme 14) [95]. 1,2-aminoalcohol moiety of phytosphingosine was protected in 
one step as 2-phenyl-1,3-oxazoline derivative (87) with ethyl benzimidate hydrochloride. The 
key events of the procedure were the stereospecific transformation of the vicinal diol into 
oxirane derivative (89) followed by regio- and stereoselective transformation of the epoxide 
into allylic hydroxyl functionality of sphingosine. After the failure of the oxirane formation 
by the methods reviewed by Kolb and Sharpless [96] (decomposition of the starting material) 
and Szejas phase transfer epoxidation [97] (inseparable diastereomeric mixture), the 
conversion of (87) into (89) was finally achieved by tosylation of vicinal diol and treatment 
with potassium t-butoxide in methanol. The regioselective eliminative opening of oxirane 
using TMSI and DBN led to a high yield formation of E-allyl silyl ether (90). Acidic 
deprotection of trimethylsilyl and phenyloxazoline protecting groups followed by base 
hydrolysis of in situ formed 1-O-benzoate sphingosine furnished (1). It is worth to note that 
this two pot multigram synthesis can be accomplished under mild conditions and with a 
minimal number of column chromatography purifications in an overall yield of 70%.  
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Scheme 14. Reagents and conditions: (i) ethyl benzimidate hydrochloride; (ii) TsCl/pyridineDMAP; (iii) t-
BuOK; (iv) TMSI/DBN; (v) a) 2N HCl, b) NaOH/MeOH. 
 
Raghavan and Rajender described a procedure using β-hydroxy-γ,δ-unsaturated sulfoxide 
for the synthesis of L-erythro-sphingosine [98]. The stereochemistry of the polar head was 
established by transformation of the double bond into bromohydrine which utilizes the 
sulfinyl moiety as an intramolecular nucleophile. The sequence continues with conversion of 
bromodiol into epoxide and its regio- and stereoselective opening to azidodiol according to 
Sharpless protocol. The aliphatic chain was introduced by the Pummerer ene reaction. The 
authors claim the preparation to be flexible and permit the synthesis of D-erythro-sphingosine 
by following an identical reaction sequence. The synthesis is relatively inovative, but 
complicated with rather low overall yield and with commercially unavailable starting 
material.  
 
The first synthesis employing E-selective cross metathesis for the formation of double 
bond and connection of aliphatic chain appeared in 2004 (Scheme 15) [99]. The polar head 
spatial arrangement was introduced via a stereoselective epoxide opening. Dienol (91) was 
transformed by Sharpless epoxidation and base induced Payne rearrangement to vinyl epoxide 
(92) (>99% ee) [100]. To circumvent the preferential ring opening at the allylic position, the 
alcohol was converted to benzyl carbamate (93). Carbamate, as a nitrogen nucleophile, 
provided regioselective attack at C2 position in the presence of NaHMDS causing 
intramolecular ring opening and thus giving oxazolidinone (94). Protected sphingosine 
derivative (95) was synthesized in 17:1 E/Z selectivity by coupling allylic alcohol with 1-
pentadecene using Grubbs‘ phosphine-free ruthenium catalyst C. The benzyl group was 
removed with sodium in liquid ammonia and resulting oxazolidinone was then hydrolyzed 
with KOH to afford (1). Sphingosine was obtained in 51% overall yield over five steps from 
(92). The introduction of the aliphatic chain in the later phase of the synthesis enables to avoid 
problems with surfactant like properties of amphiphilic intermediates e.g. aggregation of the 
material on silica during the purification or low solubility at low temperatures. Another 
advantage lies in the low formation of byproducts during the cross metathesis process and the 
possibility to introduce different aliphatic chains. Unfortunately, the commercially available 
catalysts are relatively costly. 
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Scheme 15. Reagents and conditions: (i) Ref [100]; (ii) BnNCO/Et3N; (iii) NaHMDS; (iv) 1-pentadecene/ 
Grubbs‘ catalyst C; (v) Na/NH3; (vi) 1M KOH. 
 
Rai and Basu described the preparation of glycosphingolipids and differentially protected 
building blocks starting with diethyl tartrate and mesylate diol (Scheme 16), respectively 
[101, 102]. Assembling of the E-double bond provided intermediates of natural ceramides. 
Mesylate diol (96), requisite for the latter, improved synthesis, was prepared in five steps 
without chromatographic purification following a patented procedure [103]. The primary 
alcohol was protected as silyl ether. Protection of the secondary alcohol was followed by 
azide displacement of the sulfonate to receive (98). Because its cross-metathesis suffered from 
low yields and undesirable side reactions, probably due to the interaction of the phosphine 
ligands with the azide group and/or metal-mediated nitrene process, the azido group was 
reduced to amine and protected as an Fmoc carbamate. The orthogonally protected alkene 
(99) was obtained in 21% yield from the diol (96). Reaction of (99) with 1-pentadecene 
catalyzed by Grubbs‘ catalyst A delivered protected sphingosine (100) as a precursor for the 
synthesis of glycosphingolipids. 
 
 
 
Scheme 16. Reagents and conditions: (i) t-BuPh2SiCl/imidazole; (ii) p-MeO-benzyl 
trichloroacetimidate/La(OTf)3; (iii) a) NaN3/Bu4NCl, b) TBDPSCl/imidazole; (iv) Zn/NH4Cl; (v) Fmoc-
Cl/Hunig‘s base; (vi) Grubbs‘ cat. A/1-pentadecene. 
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The synthesis of sphingosine by the sequence including Horner-Wadsworth-Emmons 
olefination and copper-mediated Grignard coupling was described by Lu (Scheme 17) [104]. 
Pentylidene-protected D-threitol derivative (101) was used as a starting material due to its 
lower acid sensitivity than the corresponding isopropylidene acetal. Its oxidation to aldehyde 
(102) was followed by formation of double bond with diisopropyl 
(ethoxycarbonylmethyl)phosphonate and conversion of the resulting ester (103) to allylic 
acetate (105) via alcohol (104). Regioselective coupling of (105) with dodecylmagnesium 
bromide afforded intermediate (107) exclusively. The conversion of secondary hydroxyl 
group to an azido group after deprotection was achieved with DIAD, triphenylphosphine and 
trimethylsilylazide. Resulting O-silyl ether was hydrolyzed by tetrabutylammonium fluoride. 
The reduction of azide (108) was accomplished by Staudinger reaction and benzyl group was 
removed by Birch reduction to give (1) in nine steps and 17% yield from (101). 
 
 
 
Scheme 17. Reagents and conditions: (i) PCC/NaOAc; (ii) (i-PrO)2P(O)CH2CO2Et/Et3N/LiBr; (iii) DIBAL; (iv) 
AcCl/i-Pr2NEt; (v) C12H25MgBr/Li2CuCl4; (vi) 5% H2SO4; (vii) a) PPh3/DIAD/TMSN3, b) n-Bu4NF; (viii) 
PPh3/H2O; (ix) Na/NH3. 
 
Disadee and Ishikawa utilized alkenyl aziridines as key intermediates in the preparation 
of D-erythro-sphingosine (Scheme 18) [105]. Treatment of (S,S)-guanidinium salt (109) with 
(E)-hexadec-2-enal in the presence of TMG yielded in the formation of cis- and trans-isomers 
with a good combined yield and enantioselectivity. The ring opening of trans-isomer (111) 
and methanolysis of acetyl derivative (113) produced allylic alcohol (114) (Scheme 17). The 
protection of hydroxyl as a silyl ether was followed by reduction of carboxyl group with 
lithium aluminium hydride. (116) was converted to oxazolidinone (117) and the subsequent 
debenzylation was carried out under Birch conditions affording N-deprotected oxazolidinone 
as a substrate for further removal of TIPS function and alkaline hydrolysis. Sphingosine was 
thus received in eight steps and 62% overall yield starting with trans-aziridine (111). 
Similarly, cis-aziridine derivative (112) was used for the synthesis of sphingosine with 
aziridine ring opening as a crucial step (Scheme not shown). The required configuration of 
sphingosine was achieved by inversion of stereochemistry at C3 and the desired product was 
obtained in 27% overall yield in eight steps from (112).  
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Scheme 18. Reagents and conditions: (i) TMG/THF; (ii) SiO2/CHCl3; (iii) AcOH; (iv) KOH/THF/MeOH; (v) 
TIPSOTf/Et3N/CH2Cl2; (vi) LiAlH4/THF; (vii)CDI/CH2Cl2; (viii) Li/liq. NH3/Et2O; (ix) n-Bu4NF/THF; (x) 2M 
NaOH/EtOH. 
 
Another sequence exploiting olefin cross metathesis used a D-glucose-derived building 
block as the source of chirality for the synthesis of D-erythro- and D-threo-
sphingosine(Scheme 19) [106]. The requisite azido-carbohydrate (119) was synthesized 
according to Gruner [107]. Despite the supposed failure of cross-metathesis olefination due to 
the presence of azide functionality, the authors succeeded in coupling of the sugar derivative 
and pentadecene in the presence of Grubbs‘ catalyst B. The cross-coupled product (120) was 
treated with TFA to afford an anomeric mixture of hemiacetal (121) that on sodium periodate 
cleavage and subsequent reduction afforded D-erythro-sphingosine. This strategy provides the 
product in nine steps and 52% overall yield from D-glucose. 
 
 
 
Scheme 19. Reagents and conditions: (i) Ref: [106]; (ii) 1-pentadecene/Grubbs‘ catalyst B; (iii) TFA/H2O; (iv) 
NaIO4; (v) LiAlH4. * - multistep procedure. ** - three steps. 
 
A nucleophilic addition of 2-silyloxy silylketene acetal (123) to N-benzyl-2,3-O-
isopropylidene-D-glyceraldehyde nitron (122) (Mannich type reaction) gave adducts, which 
may be further converted into suitable orthogonally protected enantiomeric D- and L-erythro-
sphingosines (Scheme 20) [108]. Nitron was chosen because it is an excellent equivalent of 
several chiral units, containing both amino- and oxygen functionalities. Furthermore, its 
activity can be modulated by the use of different Lewis acids due to the presence of reactive 
oxygen atom. Both the nitron and silyl ketene acetal are readily available [109, 110]. Several 
Lewis acids were evaluated in this work, with Zn(OTf)2 furnishing the best 
diastereoselectivity and yields of O-silylhydroxylamine (124). Its hydrolysis provided free 
hydroxylamine (125), which was transformed into N-Boc protected ester (126). Reduction to 
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aldehyde (127) and Schlosser modification of the Wittig condensation with 
tetradecenylphosphorane afforded alkene (128). The dioxolane ring was transformed to 
orthogonally protected sphingosine (130) which was treated with Bu4NF and TFA to give D-
erythro-sphingosine (1). The synthesis was accomplished in 28% overall yield from the 
starting nitron. 
 
 
 
Scheme 20. Reagents and conditions: (i) Zn(OTf)2; (ii) citric acid; (iii) H2/Pd(OH)2-C/Boc2O; (iv) DIBAL; (v) 
C14H28PPh3; (vi) p-TsOH; (vii) a) NaIO4, b) NaBH4; (viii) n-Bu4NF; (ix) TFA. * - two steps. 
 
A synthesis of sphingosine from phytosphingosine (3) via a cyclic sulfate intermediate 
(132) (Scheme 21) [111] offers a complementary transformation to the eliminative epoxide 
opening used for the introduction of E-allylic alcohol. The authors presented two synthetic 
pathways and claimed avoiding some drawbacks of the previous methods [86] (Schemes 12 
and 13), including the use of rather expensive reagents, low temperature manipulations and 
unwanted side products. Their approach started with the protection of amino function as azide 
and primary hydroxyl group as silyl ether. The treatment of silylated 3,4-vicinal diol (131) 
with thionyl chloride in the presence of triethylamine followed by oxidation with ruthenium 
chloride provided cyclic sulfate (132). The next step included one-pot opening of the sulfate 
by iodide and dehydrohalogenation with DBU, which furnished the desired E-allylic alcohol 
(134) as the only isomer. The silyl group was removed with Bu4NF and azido group was 
reduced to amine by NaBH4 in 2-propanol. Alternatively, the primary hydroxyl group can be 
blocked as a trityl ether. Tritylated azido sphingosine obtained by the procedure described 
above is than hydrolyzed with HCl to azidosphingosine and reduced to sphingosine. This 
preparative route affords D-erythro-sphingosine in approximately 60% overall yield. 
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Scheme 21. Reagents and conditions: (i) TfN3/K2CO3/CuSO4; (ii) TBDPSCl/Et3N/DMAP; (iii) a) SOCl2/Et3N, b) 
RuCl3.3H2O/NaIO4; (iv) a) Bu4NI/DBU, b) H2SO4; (v) n-Bu4NF; (vi) NaBH4. 
 
An asymmetric synthesis of sphingosine and phytosphingosine isomers from 
commercially available Z-4-benzyloxybut-2-en-1-ol via a common oxazolidine derivative for 
the preparation was published by Righi (Scheme 22) [112]. The chiral epoxide (135), obtained 
by Sharpless asymmetric epoxidation was regioselectively opened to give bromohydrine 
(136). The one pot sequence of azidation, reduction of azide to amine group, Boc protection 
of amino group and formation of oxazolidine gave ester (139). The key intermediate for the 
synthesis of sphingoid bases was prepared from (139) by reduction of ester group to hydroxyl, 
its subsequent silylation and transformation of benzyl-protected group to aldehyde (142). The 
aldehyde (142) was transformed to D-erythro-sphingosine by an already reported sequence of 
olefination, izomerization and deprotection [113]. In spite of the versatility of the presented 
synthesis regarding the preparation of stereoisomers of both bases, the synthesis is somewhat 
complicated. The isomerization of double bond in the synthesis of sphingosine proceeds in 
70/30 E/Z selectivity; being thus more useful for parallel preparation of cis- and trans-
isomers. The overall yield for preparation of D-erythro-sphingosine is 24%. 
 
 
 
Scheme 22. Reagents and conditions: (i) Amberlyst 15/NaBr; (ii) NaN3; (iii) H2/Pd/Boc2O; (iv) 2,2-DMP/p-
TsOH; (v) DIBAL; (vi) NaBH4; (vii) TBDPSCl/Et3N/DMAP; (viii) H2/Pd; (ix) Py/SO3; (x) C14H29PPh3Br/n-
BuLi; (xi) hν/Ph2S2; (xii) TFA. * from epoxide (131). 
 
Preparation of sphingosine, sphingomyelin, ceramide, sphingosine 1-phosphate and 
functionalized sphingosine derivatives from L-serine by cross-metathesis olefination were 
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reported by Yamamoto. (Scheme 23) [114]. The Boc protection of serine was followed by 
Weinreb amide formation and the protection of the primary hydroxyl group by TBSCl without 
column chromatography. The reaction with vinylmagnesium bromide provided vinyl ketone 
(144). Then, the carbonyl was selectively reduced with lithium tri-t-butoxyaluminohydride 
and primary hydroxyl deprotected to yield (146). Cross-metathesis and following deprotection 
of (147) produced D-erythro-sphingosine (1) in 37% overall yield. Similar synthesis via 
Weinreb amide was also described by Pham. [115]. 
 
 
 
Scheme 23. Reagents and conditions: (i) a) Boc2O/Et3N, b) Me(MeO)NH.HCl/NMM, c) TBSCl/imidazole; (ii) 
vinylmagnesium bromide; (iii) LiAl(O-tBu)3H; (iv) 2M HCl/MeOH; (v) 1-pentadecene/ Grubbs‘ catalyst B; (vi) 
TFA. * - three steps. 
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A novel approach for the synthesis of sphingosine was reported by Yang and Liebeskind 
(Scheme 24) [116]. The sequence started with N-Boc-L-serine and the key steps were 
palladium catalyzed, copper(I)-mediated, non-basic coupling of the thiophenyl ester of N-
Boc-O-TBS L-serine (150) with E-1-pentadecenyl boronic acid and highly diastereoselective 
reduction of the resulting peptidyl ketone. Thiophenyl ester (149) was prepared by common 
dehydration conditions using DCC and DMAP. The primary hydroxyl group was than 
protected as O-silylether employing N-methyl morpholine as a base. Boronic acid requisite for 
the cross-coupling was obtained by hydroboration of 1-pentadecyne with HBBr2.SMe2 
followed by hydrolysis on ice-water. Its reaction with protected thiophenyl ester (150) 
delivered ketone (151) with no E/Z isomerization. Racemization-free asymmetric reduction of 
enone by LiAl(t-BuO)3H generated alcohol (152). The synthesis was ended up by desilylation 
and N-deprotection. Sphingosine was received in 71% overall yield from N-Boc-L-serine in 
six steps. The synthesis is characterized by high enantio- and diastereoselectivity (ee>99%, de 
up to 99%). 
 
 
 
Scheme 24. Reagents and conditions: (i) PhSH/DCC/HOBt; (ii) TBSCl/NMM/DMAP; 
(iii)Pd2(dba)3/P(OEt)3/CuTC/C13H27CH=CHB(OH)2; (iv) LiAl(t-BuO)3H; (v) 1M HCl; (vi) TFA. 
 
 
Synthesis of 6-hydroxysphingosine 
 
Because 6-hydroxysphingosine occurs mainly in human skin (as a structural part of 
ceramide EOH, AH, NH and protein-bound ceramide OH) and it does not play an important 
role in cell processes, there was not so much attention paid to its synthesis up to date. Since 
1994 and 1999, when Downing reported the isolation of several new ceramides containing 
this base [54, 117], only three methods for its preparation were reported. All of them are 
based on the coupling of lithiated propargylic ethers and L-serine-derived Garner aldehyde. 
Because the spatial arrangement at C2 and C3 is introduced via L-serine derivative, the main 
task envisaged by the authors was the enantioselective preparation of the propargylic alcohol 
synthon. It is worth to mention that the 6R configuration of 6-hydroxysphingosine skin 
ceramides was determined by Masuda and Mori in 2005 [55].  
 
Chun applied two different synthetic approaches to obtain both enantiomers of the 
intermediate (155) [118]. The asymmetric reduction of α,β-ynones neither with lithium 
aluminum hydride in the presence of Darvon alcohol nor with B-(3-pinanyl)-9-
borabicyclo[3.3.1]nonane proved to give the desired product in satisfactory enantioselectivity. 
The alternative method consisted of base-mediated double elimination of 4-(chloromethyl)-
1,3-dioxolane (157) (Scheme 25). Diol ester (154) was prepared by Horner-Wadsworth-
Emmons reaction of tridecanal with ethyl 2-(diisopropoxyphosphoryl)acetate  and asymmetric 
dihydroxylation of resulting α,β-unsaturated ester (153) with AD-mix-β (96% ee). Protection 
of vicinal hydroxy groups and reduction of ester with DIBAL furnished alcohol (156), which 
was converted to chloride (157) under Mitsunobu conditions. (R)-pentadec-1-yn-3-ol (158) 
was obtained in high enantioselectivity (96% ee) by treatment of chloride (157) with butyl 
lithium and HMPA. Its silylation and coupling with Garner aldehyde provided the protected 
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6-hydroxysphingosine (160). The removal of TBS group, Birch reduction of triple bond, 
acidic hydrolysis of oxazolidine cycle and subsequent acylation gave ceramide analogue 
without the separation of 6-hydroxysphingosine intermediate. To authors disappointment this 
method provided the ceramide in 42% yield only from (161). The changed sequence of the 
reactions (acidic hydrolysis of the oxazolidine, acylation and Birch reduction) gave N-
octanoyl 6-hydroxysphingosine in good 73% yield from (161). 
 
 
 
Scheme 25. Reagents and conditions: (i) (i-PrO)2P(O)CH2CO2Et/Et3N/LiBr; (ii) AD-mix-β/MeSO2NH2; (iii) 
DMP/p-TsOH; (iv) DIBAL; (v) NCS/PhP3; (vi) n-BuLi/HMPA; (vii) TBSCl/imidazole; (viii) Garner aldehyde/ 
n-BuLi; (ix) n-Bu4NF. *- two steps. 
 
Yadav used Sharpless asymmetric epoxidation of E-allyl alcohol and subsequent 
elimination of 2,3-epoxy chloride as the key reactions for the preparation of the propargyl 
alcohol intermediate (167) (Scheme 26) [119]. Reaction of propargyl alcohol (162) with 
dodecyl bromide gave pentadecynol (163), which was treated with LiAlH4 to provide E-
allylic alcohol (164). Its Sharpless asymmetric epoxidation using titanium tetraisopropoxide, 
(-)-DET and TBHP yielded epoxy alcohol (165), which was converted to epoxy chloride 
(166). The triple bond was introduced by treatment of 2,3-epoxy chloride (166) with LiNH2 in 
liquid ammonia. The protection of secondary hydroxyl functionality was followed by 
coupling with Garner aldehyde. The removal of Boc, acetonide and TBS protecting groups 
was achieved by treatment with 1M HCl/THF. The final reduction of triple bond with LiAlH4 
led to 6-hydroxysphingosine (2). 
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Scheme 26. Reagents and conditions: (i) C12H25Br/LiNH2/NH3; (ii) LiAlH4; (iii) (-)-DET/Ti(O-i-Pr)4/TBHP; (iv) 
PPh3/CCl4/NaHCO3; (v) LiNH2/NH3; (vi) TBSCl/imidazole; (vii) Garner aldehyde/ n-BuLi/HMPA; (viii) 1M 
HCl; (ix) LiAlH4. 
 
Masuda and Mori used similar reaction of Garner aldehyde and protected (R)-pentadec-1-
yn-3-ol for the preparation of skin ceramides derived from 6-hydroxysphingosine (Scheme 
27) [55, 120].  Treatment of tridecanal with lithium trimethylsilylacetylide furnished racemic 
alkynol (170). Asymmetric acetylation of the latter with vinyl acetate in the presence of lipase 
PS on Celite and subsequent HPLC separation afforded acetylated (R)-enantiomer (171) in 
49% yield and 99% ee, while (S)-enantiomer of (170) was recovered. Intermediate (171) was 
converted to acetylenic alcohol (172) and the secondary hydroxyl functionality was protected 
as silyl ether (173). Silylation improved diastereoselectivity of the coupling with Garner 
aldehyde. 
 
 
 
Scheme 27. Reagents and conditions: (i) lithium trimethylsilylacetylide/n-BuLi; (ii) lipase PS on Celite/vinyl 
acetate; (iii) K2CO3/MeOH; (iv) TBSCl/imidazole. 
 
Synthesis of acid part of skin ceramides 
 
Synthesis of ω-acyloxy fatty acid (EO) 
 
The procedure for the preparation of skin-identical cerebroside containing ceramide EOS 
was published by Matsuda and Mori in 1991 [121] (Scheme 28). The synthesis of the 30-
(linoleyloxy)triacontanoic acid segment started from pentadecan-15-olide (174). Its 
methanolysis and oxidation with PCC gave aldehyde (176). The second bifunctional 
intermediate (179) required for the subsequent Wittig coupling was obtained by treatment of 
(175) with TBDPSCl, reduction of the resulting ester and halogenation with 
tetrabromomethane and triphenylphosphine. Wittig reaction of aldehyde (176) and ylide 
derived from the bromide (179) provided a mixture of geometrical isomers (180). Their 
hydrogenation followed by ester hydrolysis, activation of the carboxyl with p-nitrophenyl 
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trifluoroacetate and mild desilylation achieved with Et2O-BF3 yielded the ω-hydroxy ester 
(184). Acylation of (184) with linoleyl chloride afforded the desired p-nitrophenyl 30-
(linoleyloxy)triacontanoate (185) in 59% yield based on (181). 
 
 
 
Scheme 28. Reagents and conditions: (i) p-TsOH/MeOH; (ii) PCC/powdered molecular sieves 4Å; (iii) 
TBDPSOCl/imidazole; (iv) LiAlH4; (v) CBr4/PhP3; (vi) PhP3/n-BuLi; (vii) Pd-C/H2; (viii) KOH/EtOH; (ix) 
CF3COOC6H5NO2-p/pyridine; (x) Et2O-BF3; (xi) linoleoyl chloride/pyridine. 
 
Another preparation of ceramide EOS and ceramide EOS-derived cerebroside was 
described by Müller and Schmidt (Scheme 29) [122]. The synthetic sequence involved three 
coupling steps to obtain 30-hydroxytriacontanoic acid (199), including the reaction of 11-
bromoundecan-1-ol (186) with diethyl malonate to introduce the carboxylic function, 
coupling of Grignard compound obtained from (193) and chloromagnesium salt of (190) with 
Li2CuCl4 catalysis to yield (194), and Wittig reaction to connect the building blocks A and B 
(188 and 195) (Scheme 29). The activation of linoleic acid with 2-chloro-1-pyridinium iodide 
was necessary for esterification with almost insoluble saturated ω-hydroxy acid. N-acylation 
of sphingosine with resulting O-acyl fatty (200) acid in the presence of EEDQ furnished 
ceramide EOS in 60% yield. 
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Scheme 29. Reagents and conditions: (i) a) diethyl malonate/NaOEt, b) HBr/CH3COOH/H2SO4; (ii) PPh3; (iii) 
HBr; (iv) DHP/H
+
; (v) Mg/CH3MgCl /Li2CuCl4; (vi) PCC; (vii) a) NaN(SiMe3)2, b) CH2N2; (viii) Pd-C/H2; (ix) 
H
+
; (x) NaOH; (xi) linoleic acid/CMPI/ (C4H9)3N/pyridine. 
 
 
Synthesis of α-hydroxy fatty acid (A) 
 
α-Hydroxytetracosanoic acid was synthesized as an intermediate for the preparation of 
cerebrosides based on ceramide AS by Koike (Scheme 30) [123]. The ethyl (S)-2-
acetoxytetracosanoate, necessary for the synthesis, was obtained by Horn and Pretorius 
procedure from (S)-(-)-malic acid [124]. The silylated α-hydroxytetracosanoic acid (206) was 
prepared from (202) in four steps including the inversion of configuration according to Eguchi 
and Mitsunobu [125]. The hydrolysis of the resulting benzoate (203), silylation of secondary 
hydroxyl and deprotection of the carboxylic group gave compound (206) in a good 
stereoselectivity. 
An enzymatic approach was published in 2005 (Scheme 31) [55]. Tetracosanoic acid 
(207) reacted with bromine in the presence of phosphorus. The resulting racemic 2-bromo 
acid (208) was treated with aqueous sodium hydroxide to give (±)-2-hydroxy acid (209). Its 
enzymatic kinetic resolution was achieved with lipase PS and vinyl acetate to give (S)-acetoxy 
acid (211). The natural (R)-2-hydroxy acid (210) was recovered, its hydroxyl group protected 
and used for the preparation of ceramide AH. 
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Scheme 30. Reagents and conditions: (i) 
MeONa/MeOH/Amberlyst 15; (ii) 
Ph3P/DIAD/benzoic acid; (iii) 
MeONa/MeOH/Amberlyst 15; (iv) 
TBDPSCl/imidazole; (v) NaOH/MeOH/Amberlyst 
15. 
 
 
Scheme 31. Reagents and conditions: (i) Br2/P; (ii) 
NaOH/H2O; (iii) lipase PS/vinyl acetate/BHT; (iv) 
Ac2O/pyridine. * - yield for (R)-hydroxy acid.
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CONCLUSION 
 
Synthesis of ceramides and their analogues in pure form is essential for elucidation of 
their biological functions and structure-activity relationships, which are still poorly 
understood. In the last decade, significant progress has been achieved in both the synthetic 
methodologies and the functional elucidation of epidermal ceramides. Since the last review in 
1998 [52], many interesting syntheses of sphingosine emerged. Asymmetric syntheses 
together with the preparations from L-serine are the most abundant while monosaccharides 
have partially lost their attractiveness as starting material. Synthesis using serine-derived β-
ketophosphonates (Scheme 8) is convenient and high yielding with satisfactory selectivity. 
The use of phytosphingosine as a relatively inexpensive starting material has been explored 
since 2002 (Schemes 12-14 and 21). These procedures are economical, suitable for large-scale 
preparations, but somewhat less versatile for the synthesis of ceramide analogues. It is worth 
to mention that a process to identify microorganisms that are capable of converting exogenous 
phytosphingosine to sphingosine was patented in 2007 [126]. First in 2004, olefin cross 
metathesis was used for the formation of double bond and attachment of the lipophilic chain. 
These syntheses are versatile, high yielding and highly stereoselective, e.g. Schemes 19 and 
23. Another high yielding, scalable and highly stereoselective synthesis used thiol ester-
boronic acid cross-coupling (Scheme 24). Nevertheless, the early synthesis using alkynylation 
of Garner aldehyde [73, 74] is still very common for the preparation of sphingosine and its 
analogues for biological studies.  
In addition, methods for the preparation of the unique epidermal ceramides and their 
structural fragments including 6-hydroxysphingosine, α-hydroxy- and ω-hydroxy- and ω-
linoleyloxy acids are described in this paper.  
The current data on the structure-activity relationships of ceramides in the skin barrier are 
summarized in this review. Although these data are not conclusive and many may be model 
system-dependent, it seems that the exceptionally long hydrophobic chains, hydrogen bonding 
ability and the presence of the ω-linoleyloxy- and protein-bound ceramides are the basic 
prerequisites for a competent skin barrier. In general, the most important feature seems to be 
the structural heterogeneity of the epidermal lipids. Particularly interesting is the suggestion 
about the complementary mechanisms of lamellar self-assembly of sphingosine and 
phytosphingosine based ceramides [46]. 
For a deeper understanding of the role of the individual ceramide species and their 
structural moieties in the skin, and in order to design better ceramide analogues for the 
treatment of skin diseases and better permeation enhancers for transdermal drug delivery, 
further studies are needed. Synthetic lipid models are an excellent tool to investigate the 
behavior of the individual ceramides on a molecular level (reviewed recently in [127]). 
However, it should be confirmed by permeability studies that the changes in ceramide 
packing/chain order/hydrogen bonding strength, etc. observed by physicochemical methods 
result in the suggested changes in skin barrier function. Indeed, a direct effect of exogenous 
short-chain ceramides on skin permeability for two model drugs was described recently [30].  
When regarding the SC lipid models as tools to study the role of SC ceramides, the model 
recently described by Bouwstra‘s group [128-132] seems to be well suited for such 
experiments since the lipid lamellae reconstituted on a filter support may be used for both the 
physicochemical characterization and permeation studies. Alteration of the lipid content of 
this or similar model or replacement of selected species by their synthetic analogues may be a 
reasonably simplified tool to obtain information on the function of this unique class of lipids.  
In conclusion, although impressive progress has been made in elucidating the role of 
ceramides in the skin barrier, the essential information is still missing. Possibly, lessons could 
be learned from the studies on the behavior of ceramides in phospholipid/sphingomyelin 
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membranes and those on the structure-activity relationships of transdermal permeation 
enhancers. 
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ABBREVIATIONS 
 
BHT butylated hydroxy toluene 
Boc t-butyloxycarbonyl 
CDI 1,1'-carbonyldiimidazole 
CMPI 2-chloro-1-methyl-pyridinium iodide 
CuTC copper(I) thiophene-2-carboxylate 
DBN 1,5-diazabicyclo[5.4.0]undec-5-ene 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC dicyclohexylcarbodiimide 
de diastereomeric excess 
DET diethyltryptamine 
DHP dihydropyrane 
DIAD diisopropyl azodicarboxylate 
DIBAL diisobutylaluminium hydride 
DMAP 4-dimethylaminopyridine 
DMSO dimethylsulfoxide 
DMP 2,2-dimethoxypropane 
EDCl 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
ee enantiomeric excess 
EEDQ ethyl 1,2-dihydro-2-ethoxyquinoline-1-carboxylate 
Fmoc 9-fluorenylmethyl 
HMPA hexamethylphosphoramide 
IBX 2-iodoxybenzoic acid 
Ipc2BOMe B-methoxydiisopinocampheylborane 
KHMDS potassium bis(trimethylsilyl)amide 
MCPBA 3-chloroperoxybenzoic acid 
9-MeO-9-BBN 9-methoxy-9-Borabicyclo[3.3.1]nonane 
MOM methoxymethyl 
Ms mesylate 
NaHMDS bistrimethylsilyl amide 
NCS N-chlorosuccinimide 
NMM N-methylmaleimide 
Oxone potassium peroxomonosulfate 
PCC pyridinium chlorochromate 
Pd2(bda)3 tris(dibenzylideneacetone)dipalladium(0)) 
PMB p-methoxybenzyl 
PPTS pyridinium 4-toluensulfonate 
SC stratum corneum 
TBDPS t-butyldiphenylsilyl 
TBHP t-butyl hydroperoxide 
TBS t-butyldimethylsilyl 
Tf trifluoromethylsulfonyl 
TFA trifluoroacetic acid 
TIPS triisopropylsilyl 
TMG 1,1,3,3-tetramethyl guanidine 
TMS trimethylsilyl 
Tr trityl  
TsOH toluensulfonic acid 
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ABSTRACT 
 
Purpose. Series of N,N-dimethylamino acid esters was synthesized to study their transdermal 
permeation-enhancing potency, biodegradability and reversibility of action. Effects of 
chirality, linking chain length and polyfluorination were investigated. 
Methods. In vitro activities were evaluated using porcine skin and four model drugs – 
theophylline, hydrocortisone, adefovir and indomethacin. Biodegradability was determined 
using porcine esterase, reversibility was measured using electrical resistance. 
Results. No differences in activity were found between (R), (S) and racemic dodecyl 2-
(dimethylamino)propanoate (DDAIP). Substitution of hydrocarbon tail by fluorocarbon one 
resulted in loss of activity. Replacement of branched linking chain between nitrogen and ester 
of DDAIP by linear one markedly improved penetration-enhancing activity with optimum in 
4-6C acid derivatives. Dodecyl 6-(dimethylamino)hexanoate (DDAK) was more potent than 
clinically used skin absorption enhancer DDAIP for theophylline (enhancement ratio of 
DDAK and DDAIP was 17.3 and 5.9, respectively), hydrocortisone (43.2 and 11.5) and 
adefovir (13.6 and 2.8), while DDAIP was better enhancer for indomethacin (8.7 and 22.8). 
DDAK was rapidly metabolized by porcine esterase, and displayed low acute toxicity. 
Electrical resistance of DDAK-treated skin barrier promptly recovered to control values. 
Conclusion. DDAK, highly effective, broad-spectrum, biodegradable and reversible 
transdermal permeation enhancer, is promising candidate for future research.  
 
INTRODUCTION 
 
Transdermal drug delivery offers many advantages compared to the conventional routes 
of application including avoidance of the first pass effect, stable blood levels, easy application 
and higher compliance of the patient [1, 2]. However, physicochemical properties of the 
majority of clinically used drugs do not allow them to overcome the skin barrier, which is 
represented mainly by the uppermost epidermal layer, the stratum corneum (SC). One of the 
possibilities to temporarily decrease the skin barrier resistance is the use of permeation 
enhancers [3-5]. These compounds promote the permeation of topically applied drugs through 
SC to achieve the therapeutic concentrations necessary for local or systemic effect. Although 
hundreds of permeation enhancers have been identified to date, no ideal compound possessing 
high activity and low toxicity has been found, and the structure-activity relationships are still 
poorly understood.  
Amino acid derivatives belong to the most promising groups of permeation enhancers. 
Dodecyl 2-(dimethylamino)propanoate (DDAIP, NexACT
®
, Figure 1), based on the amino 
acid alanine, is a clinically used biodegradable transdermal permeation enhancer [6]. It is 
effective in promoting the transdermal permeation of several types of drugs by mechanisms 
including disordering the lipid organization [7-9], keratin interaction [10] and drug 
complexation [11]. Moreover, DDAIP and its hydrochloride salt have low toxicity, are rapidly 
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metabolized by esterases, and are well tolerated on skin [12]. For a review on dimethylamino 
acid-based enhancers, see Ref. [10].  
Being an alanine derivative, DDAIP bears a chiral centre within its polar head. Since the 
SC lipids, in particular the polar head groups of ceramides, represent a chiral environment, the 
interaction between DDAIP and skin lipids [7] may be of a stereoselective nature. For a 
review on chirality in skin permeation, see [5] and [13]. Previously, no difference in 
enhancing effect of (R), (S) and racemic 6-aminohexanoic acid 2-octyl ester was found [14]. 
However, those compounds are relatively weak enhancers with the chiral centre in the 
hydrophobic chain, not in the polar head, which is expected to interact with the chiral polar 
heads of ceramides. Therefore, we focused on DDAIP as a model chiral enhancer to evaluate 
the hypothesis that the enhancer action may be dependent on its configuration. 
DDAIP is an amphiphilic substance possessing a bulky polar head and a 12C alkyl 
chain. The structure-activity relationships of enhancer hydrophobic chain(s) are well 
documented with the optimum usually at around 10-12 carbons in saturated chains [15, 16]. 
Nevertheless, there is no study concerned with the effect of polyfluorination of an enhancer. 
Fluorocarbon chains in general have exceptional chemical and biological inertness, unique 
hydro and lipophobicity, have greater cross-sectional area, are stiffer, and fluorocarbon 
surfactants are more surface-active than their hydrocarbon analogues [17, 18]. Highly 
fluorinated materials have potential as pulmonary, topical and ophthalmological drug delivery 
systems [19]. All of these properties may influence the enhancer behavior in the skin barrier. 
Another structural feature of DDAIP is that the dimethylamino group is positioned on 
the α-carbon resulting in a sterically demanding polar head group. We have previously 
described dodecyl 6-(dimethylamino)hexanoate (DDAK, Figure 1) being even more active 
enhancer than DDAIP for theophylline [20] and adefovir [21, 22]. DDAK was designed by 
combining the 5-carbon linking group between the ionizable nitrogen and the enzymatically 
labile ester group of Transkarbam 12, a highly potent non-toxic permeation enhancer [21, 23], 
and the N,N-dimethylamino polar head from DDAIP. Based on these findings, we aimed to 
compare DDAIP and DDAK in a greater detail, particularly the linking chain structure. 
The purpose of this study was to synthesize a series of DDAIP analogues to study the 
effects of chirality, polyfluorination and linking chain length on their transdermal permeation-
enhancing potency. We aimed to evaluate their activity using four model drugs with distinct 
physicochemical properties, determine the biodegradability of the most potent compound by 
porcine esterase, and confirm the reversibility of its action by transdermal electrical resistance 
measurement. 
 
 
MATERIALS AND METHODS 
 
Chemicals and instrumentation  
 
All chemicals were purchased from Sigma-Aldrich (Schnelldorf, Germany). Silica gel 
60 (230-400 mesh) for column chromatography and TLC plates (silica gel 60 F254, aluminum 
back) were obtained from Merck (Darmstadt, Germany). The structure and purity of the 
synthesized compounds were confirmed by FTIR (Nicolet Impact 400 spectrophotometer) and 
1
H and 
13
C NMR spectra (Varian Mercury-Vx BB 300 instrument, operating at 300 MHz for 
1
H, 75 MHz for 
13
C) and optically active compounds were characterized by their optical 
rotation (ADP Bellingham and Stanley Polarimeter; 1.0 dm cell). The melting points were 
measured with a Kofler apparatus, and are uncorrected. 
 
Synthesis 
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General procedure for the preparation of the bromocarboxylic acid esters (2a, 2c-2g). 
9.8 mmol of a bromo acid, 9.8 mmol of an alcohol and 0.12 g (0.98 mmol) of 4-
dimethylaminopyridine (DMAP) in 20 ml of ethyl acetate was cooled to 0°C and 2.22 g (10.8 
mmol) of dicyclohexylcarbodiimide (DCC) in 15 ml of ethyl acetate was added. The reaction 
was allowed to reach room temperature, and then was stirred overnight. The unreacted DCC 
was removed by addition of a droplet of acetic acid. The resulting dicyclohexylurea was 
filtered off and washed with small amount of ethyl acetate. After a water/diethyl ether 
extraction work up, the pure product was obtained as a colorless liquid by column 
chromatography using ethyl acetate/hexane elution system. 
 
Dodecyl 2-bromopropanoate (2a). Yield = 87%. 
1
H NMR (300 MHz, CHCl3): δ 4.36 (q; 
J=6.9 Hz; 1H), 4.09-4.22 (m; 2H), 1.82 (d; J=6.9; 3H), 1.61-1.71 (m; 2H), 1.26-1.38 (m; 
18H), 0.88 (t; J=6.6 Hz; 3H); 
13
C NMR (75 MHz, CHCl3): δ 170.3, 66.1, 40.3, 31.9, 29.6, 
29.5, 29.3, 29.2, 28.4, 25.7, 22.7, 21.7, 14.1; IR (ATR): νmax 2922, 2853, 1739, 1219, 1157 
cm
-1
. 
 
Dodecyl 4-bromobutanoate (2c). Yield = 72%. 
1
H NMR (300 MHz, CHCl3): δ 4.07 (t, J 
= 6.7 Hz, 2H), 3.46 (t, J = 6.5 Hz, 2H), 2.49 (t, J = 7.2 Hz, 2H), 2.12-2.21 (m, 2H), 1.57-1.67 
(m, 2H), 1.25-1.41 (m; 18H), 0.87 (t, J = 6.7 Hz; 3H); 
13
C NMR (75 MHz, CHCl3): δ 170.3, 
65.2, 37.8, 31.9, 29.6, 29.5, 29.4, 29.3, 29.2, 28.5, 25.8, 22.7, 21.7, 14.1; IR (ATR): νmax 
2922, 2853, 1734, 1198, 1170 cm
-1
. 
 
Dodecyl 5-bromopentanoate (2d). Yield = 84%. 
1
H NMR (300 MHz, CHCl3): δ 4.06 (t, 
J = 6.7 Hz, 2H), 3.41 (t, J = 6.5 Hz, 2H), 2.33 (t, J = 7.5 Hz, 2H), 1.74-1.94 (m, 4H), 1.56-
1.69 (m, 2H), 1.25-1.41 (m; 18H), 0.87 (t, J = 6.7 Hz; 3H); 
13
C NMR (75 MHz, CHCl3): δ 
173.2, 64.6, 33.3, 33.0, 31.0, 29.6, 29.5, 29.3, 29.2, 28.6, 25.9, 23.5, 22.7, 14.1; IR (ATR): 
νmax 2922, 2853, 1731, 1458, 1253, 1170 cm
-1
.  
 
Dodecyl 6-bromohexanoate (2e). Yield = 83%. 
1
H NMR (300 MHz, CHCl3): δ 4.05 (t; 
J=6.7 Hz; 2H), 3.40 (t; J=6.7 Hz; 2H), 2.31 (t; J=7.4 Hz; 2H), 1.83-1.92 (m; 2H), 1.56-1.70 
(m; 4H), 1.42-1.52 (m; 2H), 1.25-1.30 (m; 18H), 0.87 (t; J=6.7 Hz; 3H); 
13
C NMR (75 MHz, 
CHCl3): δ 173.5, 64.5, 34.1, 33.4, 32.4, 31.9, 29.6, 29.5, 29.3, 29.2, 28.6, 27.6, 25.9, 24.1, 
22.7, 14.1; IR (ATR): νmax 2923, 2853, 1734, 1463, 1253, 1173 cm
-1
. 
 
Dodecyl 8-bromooctanoate (2f). Yield = 56%. 
1
H NMR (300 MHz, CHCl3): δ 4.05 (t; 
J=6.9 Hz; 2H), 3.40 (t; J=6.9 Hz; 2H), 2.29 (t; J=7.5 Hz; 2H), 1.80-1.90 (m; 2H), 1.56-1.67 
(m; 4H), 1.26-1.48 (m; 24H), 0.88 (t; J=6.6 Hz; 3H); 
13
C NMR (75 MHz, CHCl3): δ 173.9, 
64.5, 34.3, 33.9, 32.7, 31.9, 29.6, 29.3, 29.2, 28.9, 28.6, 28.4, 27.9, 25.9, 24.9, 22.7, 14.1; IR 
(ATR): νmax 2923, 2853, 1735, 1465, 1458, 1235, 1173 cm
-1
. 
 
1H,1H,2H,2H-Perfluorodecyl 2-bromopropanoate (2g). Yield = 88%. 
1
H NMR (300 
MHz, CHCl3): δ 4.48 (t; J=6.4 Hz; 2H), 4.37 (q; J=6.9 Hz; 1H), 2.60-2.44 (m; 2H), 1.83 (d; 
J=7.0 Hz; 3H); 
13
C NMR (75 MHz, CHCl3): δ 169.8, 57.7, 39.3, 30.6, 30.3, 30.1, 21.4; IR 
(ATR): νmax 2982, 2930, 1748, 1449,  1206, 1152 cm
-1
. 
 
Dodecyl 3-bromopropanoate (2b). 1.50 g (9.8 mmol) of 3-bromopropanoic acid was 
refluxed with 5 ml of thionyl chloride for two hours. Thionyl chloride was evaporated under 
vacuum, the residue dissolved in 5 ml of chloroform and added to the solution of 1.83 g (9.8 
mmol) of dodecanol in 8 ml of chloroform. The mixture was kept under reflux for six hours. 
The product was purified on silica with hexane/ethyl acetate. Yield = 66%. 
1
H NMR (300 
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MHz, CHCl3): δ 4.12 (t; J = 6.7 Hz; 2H), 3.58 (t; J = 6.9 Hz; 2H), 2.91  (t; J = 6.9  Hz; 2H), 
1.58-1.68 (m; 2H), 1.26-1.44 (m; 16H), 0.88 (t; J = 6.7 Hz; 3H); 
13
C NMR (75 MHz, CHCl3): 
δ 172.6, 64.8, 32.7, 32.5, 31.9, 29.6, 29.5, 29.3, 29.2, 28.6, 27.8, 25.9, 22.7, 14.1; IR (ATR): 
νmax 2922, 2853, 1737, 1466, 1234, 1172 cm
-1
. 
 
General procedure for the preparation of N,N-dimethylaminoalkanoates (3a-3g). 4.67 
mmol of the bromo ester 2a-2g was dissolved in 10 ml of tetrahydrofurane (THF). 11 ml of 
2.0M dimethylamine solution in THF was added by syringe and the mixture was stirred for 24 
h at room temperature. The suspension was filtered and the filtrate was concentrated under 
vacuum. Compounds 3a, 3e, 3f and 3g were purified on silica column using hexane/ethyl 
acetate – ethyl acetate. The other compounds (3b-d) were dissolved in 50 ml of dry diethyl 
ether and gently bubbled with hydrogen chloride. White crystals of an ammonium salt 
appeared immediately and the mixture was bubbled with nitrogen to remove the unreacted 
hydrogen chloride. The solid was filtered off and recrystallized from chloroform/diethyl ether. 
The crystals were suspended in diethyl ether, corresponding amount of 5% solution of 
hydrogen carbonate was added and the free base was extracted. The organic phase was 
separated, treated with saturated solution of KBr, dried over sodium sulfate and concentrated 
in vacuum yielding colorless oily liquid. 
 
Dodecyl 2-(dimethylamino)propanoate (3a, DDAIP). Yield = 96%. 
1
H NMR (300 
MHz, CHCl3): δ 4.08-4.13 (m; 2H), 3.18-3.25 (q; J=7.0 Hz; 1H), 2.34 (s; 6H), 1.59-1.69 (m; 
2H), 1.25-1.29 (m; 21H), 0.87 (t; J=6.9 Hz; 3H); 
13
C NMR (75 MHz, CHCl3): δ 173.3, 64.5, 
62.9, 41.8, 31.9, 29.6, 29.5, 29.3, 29.2, 28.7, 25.9, 22.7, 15.1, 14.1; IR (ATR): νmax 2923, 
2853, 1731, 1454, 1167 cm
-1
. 
 
Dodecyl 3-(dimethylamino)propanoate (3b). Yield = 86%. 
1
H NMR (300 MHz, 
CHCl3): δ 4.06 (t; J=6.9 Hz; 2H), 2.61 (t; J=7.2 Hz; 2H), 2.47 (t; J=6.9 Hz; 2H), 2.24 (s; 6H), 
1.56-1.65 (m; 2H), 1.25-1.35 (m; 18H), 0.87 (t; J=6.9 Hz; 3H); 
13
C NMR (75 MHz, CHCl3): δ 
172.6, 64.6, 54.7, 45.2, 32.9, 31.9, 29.6, 29.5, 29.3, 29.2, 28.6, 25.9, 22.7, 14.1; IR (ATR): 
νmax 2923, 2853, 1736, 1461, 1168 cm
-1
. 
 
Dodecyl 4-(dimethylamino)butanoate (3c). Yield = 71%. 
1
H NMR (300 MHz, CHCl3): 
δ 4.05 (t; J=6.9 Hz; 2H), 2.26-2.36 (m; 4H), 2.22 (s; 6H), 1.74-1.84 (m; 2H), 1.56-1.65 (m; 
2H), 1.25-1.35 (m; 18H), 0.88 (t; J=6.9 Hz; 3H); 
13
C NMR (75 MHz, CHCl3): δ 173.6, 64.5, 
58.5, 45.3, 32.1, 31.9, 29.6, 29.5, 29.3, 29.2, 28.6, 25.9, 22.9, 22.6, 14.1; IR (ATR): νmax 
2923, 2853, 1736, 1461, 1181 cm
-1
. 
 
Dodecyl 5-(dimethylamino)pentanoate (3d). Yield = 60%. 
1
H NMR (300 MHz, CHCl3): 
δ 4.04 (t; J=6.9 Hz; 2H), 2.31(t; J=7.2 Hz; 2H), 2.25 (t; J=7.2 Hz; 2H), 2.20 (s; 6H), 1.55-1.56 
(m; 4H), 1.43-1.53 (m; 2H), 1.25-1.36 (m; 18H), 0.87 (t; J=6.9 Hz; 3H); 
13
C NMR (75 MHz, 
CHCl3): δ 173.7, 64.5, 59.3, 45.5, 34.2, 31.9, 29.6, 29.5, 29.3, 29.2, 28.6, 27.2, 25.9, 22.8, 
22.7, 14.1; IR (ATR): νmax 2923, 2853, 1736, 1459, 1174 cm
-1
. 
 
Dodecyl 6-(dimethylamino)hexanoate (3e, DDAK). Yield = 80%. 
1
H NMR (300 MHz, 
CHCl3): δ 4.04 (t; J=6.9 Hz; 2H), 2.29 (t; J=7.5 Hz; 2H), 2.23 (t; J=7.5 Hz; 2H), 2.20 (s; 6H), 
1.55-1.68 (m; 4H), 1.42-1.52 (m; 2H), 1.25-1.37 (m; 20H), 0.87 (t; J=6.9 Hz; 3H); 
13
C NMR 
(75 MHz, CHCl3): δ 173.8, 64.4, 59.6, 45.5, 34.3, 31.9, 29.6, 29.5, 29.3, 29.2, 28.6, 27.4, 
27.0, 25.9, 24.9, 22.7, 14.1; IR (ATR): νmax 2923, 2853, 1736, 1459, 1170 cm
-1
. 
 
63 
 
Dodecyl 8-(dimethylamino)octanoate (3f). Yield = 87%. 
1
H NMR (300 MHz, CHCl3): δ 
4.05 (t; J=6.9 Hz; 2H), 2.28 (t; J=7.5 Hz; 2H), 2.22 (t; J=7.2 Hz; 2H), 2.20 (s; 6H), 1.56-1.66 
(m; 4H), 1.39-1.49 (m; 2H), 1.25-1.31 (m; 24H), 0.87 (t; J=6.9 Hz; 3H); 
13
C NMR (75 MHz, 
CHCl3): δ 173.9, 64.4, 59.9, 45.5, 34.4, 31.9, 29.6, 29.5, 29.3, 29.2, 29.1, 28.6, 27.7, 27.3, 
25.9, 25.0, 22.7; 14.1; IR (ATR): νmax 2924, 2853, 1736, 1459, 1168 cm
-1
. 
 
1H,1H,2H,2H-Perfluorodecyl 2-(dimethylamino)propanoate (3g). Yield = 86%. 
1
H 
NMR (300 MHz, CHCl3): δ 4.42 (t; J=6.4 Hz; 2H), 3.26 (q; J=7.0 Hz; 1H), 2.41-2.58 (m; 
2H), 2.34 (s; 6H), 1.29 (d; J=7.0 Hz; 3H); 
13
C NMR (75 MHz, CHCl3): δ 172.8, 62.7, 56.2, 
41.6, 30.9, 30.6, 30.3, 14.7; IR (ATR): νmax 2985, 2945, 2873, 2834, 2787, 1735, 1458 cm
-1
. 
 
Preparation of DDAIP enantiomers.  
2-(tert-butoxycarbonylamino)propanoic acid (4h, 4i). 1.47 g (6.74 mmol) of di-tert-
butyl dicarbonate in 6 ml of dioxane was added to an ice cold solution of 0.5 g (5.61 mmol) of 
L- or D-alanine in 10 ml of 1M sodium hydroxide. The reaction was stirred for 0.5 h at 5 °C 
and subsequently for 3.5 h at room temperature. The mixture was concentrated to half of its 
volume on rotary evaporator, cooled to 0 °C, and acidified to pH 2-3 by slow addition of 1N 
KHSO4. Product was extracted with ethyl acetate, dried over Na2SO4 and concentrated under 
vacuum providing white crystalline solid with melting point of 81-82°C. (R)-isomer (4h). 
Yield = 90 %. (S)-isomer (4i). Yield = 93 %. 
1
H NMR (300 MHz, CHCl3): δ 5.05 (d; J=5.7 
Hz; 1H), 4.34 (m; 1H), 1.45 (s; 9H), 1.43 (s; 3H); 
13
C NMR (75 MHz, CHCl3): δ 177.9, 
155.4, 80.3, 49.1, 28.3, 18.3.  
 
Dodecyl 2-(tert-butoxycarbonylamino)propanoate (5h, 5i). 1.00 g (5.29 mmol) of the 
protected acid 4h or 4i, 0.99 g (5.29 mmol) of dodecanol and 0.065 g (0.53 mmol) of DMAP 
was dissolved in 10 ml of ethyl acetate. The mixture was cooled to 0 °C and 1.20 g (5.82 
mmol) of DCC in 10 ml of ethyl acetate was added. The mixture was allowed to warm to 
room temperature and stirred for additional 24h. Subsequently, the reaction was quenched by 
addition of a droplet of acetic acid and filtered. The filtrate was concentrated under vacuum, 
and purified on silica column using hexane/ethyl acetate 19:1. (R)-isomer (5h). Yield = 65 %. 
[α]D
22.7°C
 = 2.77° (1.0, CHCl3), (S)-isomer (5i). Yield = 68 %. [α]D
22.9°C
 = -2.84° (1.0, CHCl3). 
1
H NMR (300 MHz, CHCl3): δ 5.05 (d; J=5.7 Hz; 1H), 4.29 (m; 1H), 4.9-4.15 (m; 2H), 1.63 
(m; 2H), 1.44 (s; 9H), 1.37 (d; J=7.2 Hz; 3H), 1.25-1.32 (m; 18H), 0.87 (t; J=6.7 Hz; 3H); 
13
C 
NMR (75 MHz, CHCl3): δ 173.4, 155.1, 79.7, 65.5, 49.2, 31.9, 29.6, 29.5, 29.3, 29.2, 28.5, 
28.3, 25.8, 22.7, 18.8, 14.1. 
 
Dodecyl 2-aminopropanoate. 5 ml of trifluoroacetic acid (TFA)/dichlomethane (1:1 v/v) 
mixture was added to 0.5 g (1.40 mmol) of the N-protected ester (5h, 5i). TLC 
(butanol/water/acetic acid 4:1:1, Rf = 0.79) indicated a full deprotection of the amino group in 
30 min. The solvent was evaporated in vacuum, oily residue dissolved in 20 ml of 
dichloromethane, cooled on ice and neutralized with 25 ml of ice cold 2% solution of sodium 
bicarbonate. The aqueous phase was extracted with additional 2×20 ml of dichloromethane. 
The organic phase was dried over sodium sulfate, concentrated and used without further 
purification. 
 
Dodecyl 2-(dimethylamino)propanoate (6h, 6i). 0.35 g (1.35 mmol) of dodecyl 2-
aminopropanoate was dissolved in 20 ml of dry dichloromethane and 214 µl of 35% 
formaldehyde solution was added. Then, 1.14 g (5.38 mmol) of sodium triacetoxyborohydride 
[24] was added and the mixture was stirred for two hours at room temperature. The reaction 
was cooled to 0 °C and extracted with 0.25M sodium bicarbonate. The products were 
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obtained after separation on silica using hexane/ethyl acetate 4:1 as a colorless liquid. (R)-
isomer (6h). Yield = 82 %. [α]D
22°C
 = 12.5° (1.0, CHCl3), (S)-isomer (6i). Yield = 82 %. 
[α]D
22°C
 = -12.8° (1.0, CHCl3). The spectra were in accordance with racemic DDAIP (3a). 
 
Donor samples 
 
The composition of the donor samples is listed in Table I. The enhancers were added in 
1% concentration (w/v). The suspension was stirred for 5 min at 50°C and then allowed to 
equilibrate at 37°C for 24h before the application on the skin. All the donor samples were 
saturated with the pertinent model drug at these concentrations. 
For the determination of the effect of the studied enhancers on the solubility of the 
model drugs in the donor vehicle, the samples, either with or without the enhancer, were 
prepared in triplicate as described above. The samples were centrifuged at 10,000g for 5 min, 
the supernatant was withdrawn, diluted with the pertinent mobile phase and the concentration 
of the drug was determined by HPLC.  
 
Table I. The properties of the model drugs and the composition of the donor samples used for 
the permeation experiments. 
Model drug 
Physicochemical properties  Donor sample 
MW  
(g/mol) 
mp  
(°C) 
logP
 
pKa
  Drug amount 
(%) 
Vehicle 
Solubility 
(mg/ml) 
Theophylline 180 273
a
 -0.02
a 
1.5, 8.6
b
  5 60% PG 28±3 
Hydrocortisone 362 220
a
 1.61
a 
-  2 60% PG 8.3±0.6 
Adefovir 273 301
c 
-2.06
b 
1.2, 4.2, 6.8
d 
 2 PB pH 4.8 70±7 
Indomethacin 358 158
a
 4.27
a 
4.5
a 
 2 60% PG 0.9±0.1 
a
Data retrieved from SRC PhysProp database (www.syrres.com). 
b
Calculated using ACD/Labs Software V8.14 for Solaris 
c
Taken from Ref. [25] 
d
Taken from Ref. [26] 
PG = propylene glycol, PB = phosphate buffer 
 
 
Skin 
 
For the in vitro experiments, porcine skin was selected due to it is availability and 
permeability similar to the human skin [27-29]. Porcine ears were purchased from a local 
slaughterhouse. To ensure integrity of the skin barrier, ears were removed post-sacrifice 
before the carcass was exposed to the high-temperature cleaning procedure. Full-thickness 
dorsal skin was excised by blunt dissection, and hairs were carefully trimmed. The skin was 
then immersed in 0.03% sodium azide solution in saline for 5 min for preservation. The skin 
fragments were stored at -20°C up to two months. 
 
Permeation experiments 
 
The skin permeability was evaluated using modified Franz diffusion cells with an 
available diffusion area of 1 cm
2
 and acceptor volume of approximately 17 ml. The porcine 
skin was slowly thawed, cut into pieces of 2x2 cm, mounted into the diffusion cells dermal 
side down and sealed with silicone grease. The acceptor compartment was filled with PBS at 
pH 7.4 with 0.03% of sodium azide as a preservative and the volume of the acceptor phase 
was measured and included into the calculation.  The Franz diffusion cells with mounted skin 
samples were placed in a thermostated water bath with a constant temperature of 32 °C 
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equipped with a multi-place magnetic stirrer. After equilibration period of 1 h, 200 µl (i.e. an 
infinite dose) of the donor sample was applied to the SC side of the skin and covered with a 
glass slide. The acceptor phase was stirred at 32 °C throughout the experiment. Sink 
conditions were maintained for all the drugs. Samples of the acceptor phase (0.6 ml) were 
withdrawn at predetermined time intervals during 48 h (52 h in the case of hydrocortisone) 
and replaced with fresh buffer solution. The permeation experiment with hydrocortisone had 
to be prolonged to reach the pseudo steady-state. The cumulative amount of the drug 
permeated across the skin, corrected for the acceptor phase replacement was plotted against 
time, and the steady state flux was calculated from the linear region of the plot. Enhancement 
ratio (ER) was calculated as a ratio of the flux with and without the enhancer. 
At the end of the permeation experiment, the diffusion cells were dismounted; the skin 
surface washed with 0.5 ml of ethanol and 0.5 ml of water and blotted dry. The exposed area 
of 1 cm
2
 was punched out and weighted. The skin sample was then extracted with 5 ml of the 
appropriate mobile phase (or PBS at pH 7.4 for adefovir) for 48 h. The recovery was 98±2 % 
for theophylline, 101±7 % for indomethacin, 93±1 % for hydrocortisone and 97±2 % for 
adefovir [30]. The concentration of the drug in the extract was determined by HPLC. 
 
Enzymatic hydrolysis of DDAK 
 
DDAK (10 mg, 0.03 mmol) was dissolved in 10 ml of acetonitrile. 100 µl of this stock 
solution was added to 0.2 IU porcine esterase in 9.9 ml of PBS at pH 7.4 and the solution was 
incubated at 32°C. The samples of 0.1 ml were withdrawn in predetermined intervals during 
120 min and 0.1 ml of acetonitrile was added to deactivate the enzyme. The sample was 
diluted with 1.8 ml of acetonitrile/ water (4:1) and assayed on HPLC/MS. Since this analytical 
method describes only the decomposition of DDAK, the presence of the expected hydrolysis 
product dodecanol was confirmed by TLC on silica gel using chloroform/methanol 9:1. The 
Rf values for dodecanol and DDAK were 0.82 and 0.25, respectively. The negative control 
containing DDAK without the esterase was prepared likewise.  
 
HPLC conditions 
 
The model drugs were determined by isocratic reversed-phase HPLC using LC-20AD 
pump, SIL-20AC autosampler and SPD-20A UV/VIS detector (Shimadzu, Kyoto, Japan). The 
data were analyzed using CSW v. 1.7 for Windows integrating software (Data Apex, Prague, 
Czech Republic). 
Separation of theophylline was achieved on LiChroCART 250-4 column (LiChrospher 
100 RP-18, 5 µm, Merck) at 35°C using methanol/0.1M NaH2PO4 4:6 (v/v) as a mobile 
phase. A flow rate of 1.2 ml/min was employed and the effluent was measured at 272 nm. The 
retention time of theophylline was 2.9±0.1 min. 
Indomethacin samples were analyzed on LiChroCART 250-4 column (LiChrospher 100 
RP-18, 5 µm, Merck) using a mobile phase containing acetonitrile/water/acetic acid 90:60:5 
(v/v/v) at a flow rate of 1.5 ml/min at 40°C. UV absorption was monitored at 270 nm and the 
retention time was 3.9±0.1min. 
Hydrocortisone was determined on LiChroCART 250-4 column (LiChrospher 100 RP-
18, 5 µm, Merck) at 40°C using methanol/water/THF 60:40:1 (v/v/v). The flow rate was 
adjusted at 1.2 ml/min, absorption was measured at 252nm. The retention time of 
hydrocortisone was 4.2±0.1min. 
Adefovir samples were analyzed  on LiChroCART 250-4 column (Purospher STAR, 
RP-18e, 5 µm, Merck) with LiChroCART 4-4 guard column containing the same sorbent at 
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40°C. The mobile phase consisted of 10mM KH2PO4 and 2mM Bu4NHSO4 at pH 6.0 with 7% 
of acetonitrile at a flow rate of 1.5 ml/min. The detector wavelength was set at 260 nm [30].  
HPLC-MS analysis of DDAK was performed using a chromatographic system LC 20A 
Prominence (Shimadzu, Kyoto, Japan) coupled with LCQ Max advantage mass spectrometer 
(Thermo Finnigan, San Jose, U.S.A.) with ESI source and an ion trap analyzer. The data were 
processed using Xcalibur software (Thermo Finnigan, San Jose, U.S.A.). DDAK was 
determined on Luna, phenyl-hexyl column (150 x 30 mm, 5 µm, Phenomenex, 
Aschaffenburg, Germany) at 40 °C using a mixture of 0.01% HCOOH and acetonitrile 
(30:70; v/v) as a mobile phase. A flow rate of 0.3 ml/min and an injection volume of 2 µl 
were used. The determination was made in selected ion monitoring mode on [M+H]
+
 at m/z 
328 for DDAK and m/z 356 for internal standard (dodecyl 8-dimethylaminooctanoate (3f)). 
The retention times of DDAK and the internal standard were 2.4±0.1 min and 2.7±0.1 min, 
respectively.  
 
Reversibility of DDAK action 
 
The reversibility of the skin barrier function after DDAK treatment was studied by measuring 
the transdermal electrical resistance using an LCR meter 4080 (Conrad electronic, Hirschau, 
Germany, measuring range 20 Ω – 10 MΩ, error at kΩ values < 0.5%, measuring frequency 
120 kHz). The skin samples were mounted into the Franz diffusion cells, the acceptor 
compartments were filled with PBS at pH 7.4 and the cells were equilibrated at 32°C for 0.5 h 
as described above. 0.5 ml of PBS was introduced into a donor compartment and the baseline 
skin resistance (kΩ/cm2) was measured by stainless steel electrodes inserted into the donor 
and acceptor compartment. The buffer solution was removed from the donor compartment by 
a cotton swab, and 150 µl of the donor sample containing 1% (w/v) of DDAK in 60% 
propylene glycol (PG) was applied. The control cells received 150 µl of 60% PG without the 
enhancer. The donor samples were removed after two hours and the skin surface was washed 
with 0.5 ml of distilled water and gently blotted dry. The resistance was measured at 
predetermined time intervals during 8 h. 
 
Data analysis 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks with Dunn‘s or Student-
Newman-Keuls post test method was used for the statistical analysis. The skin electrical 
resistances were compared using t-test or Mann-Whitney Rank Sum Test (SigmaStat for 
Windows version 3.0.1). Data are presented as means ± SEM and the number of replicates is 
given in the pertinent figure. 
 
 
RESULTS 
 
Synthesis 
 
The N,N-dimethylamino acid esters were prepared via carbodiimide coupling of a 
bromo acid and dodecanol or 1H,1H,2H,2H-perfluoro-1-decanol, except for dodecyl 3-
bromopropanoate 2b, which was synthesized from an acyl chloride, followed by a 
nucleophilic substitution of bromine with dimethylamine (Fig. 1). This synthetic pathway via 
the bromo esters was more convenient and provided better yields with easy purification of the 
products in comparison with our previous work starting from dimethylamino acid [20]. 
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Solution of dimethylamine in THF provided similar yields but was easier to handle than liquid 
dimethylamine [6].  
The above procedure could not be applied to the synthesis of (R)- and (S)-DDAIP 
because the substitution occurs at the chiral centre. Hence, reductive dimethylation of alanine 
dodecyl ester using sodium triacetoxyborohydride and formaldehyde was applied (Fig. 2) 
[24]. 
 
 
 
 
 
Fig. 1. Synthesis of N,N-dimethylamino acid esters. 
Reagents and conditions: (i) dodecanol or 
1H,1H,2H,2H-perfluoro-1-
decanol/DCC/DMAP/ethyl acetate /0°C; (ii) 1. 
SOCl2, reflux; 2. dodecanol/ CHCl3, reflux; (iii) 
(CH3)2NH/THF. 
 
 
 
 
Fig. 2. Synthesis of DDAIP enantiomers. Reagents 
and conditions: (i) (Boc)2O/1M NaOH/dioxane; (ii) 
C12H25OH/DCC/DMAP/ethyl acetate/0°C; (iii) 1. 
TFA/CH2Cl2 (1:1); 2. Na[(CH3CO)3BH]/35% 
HCHO/CH2Cl2. 
 
Permeation experiments 
 
The effect of the linking chain length on the enhancing activity of the prepared 
compounds was evaluated using theophylline as the model drug. The basic physicochemical 
characteristics of this drug are listed in Table I. The theophylline flux through the porcine skin 
without an enhancer was 2.4±2.5 µg/cm2/h, and the skin concentration was 436 µg/g. All of 
the synthesized dimethylamino acid dodecyl esters significantly increased the theophylline 
permeation (Fig. 3). DDAIP enhanced the theophylline flux 5.9 times to 13.9 µg/cm2/h with 
no significant difference between the (R) and (S)-enantiomers and the racemate. Its straight-
chain isomer 3b, i.e. 3-(dimethylamino)propionate, displayed significantly higher activity 
than DDAIP with enhancement ratio (ER) of 15.0. The highest activity was observed in 
aminobutanoic (3c), aminopentanoic (3d) and aminohexanoic acid (DDAK) derivatives, i.e. 
those with 3 to 5-carbon linking chain between the tertiary nitrogen and ester carbonyl. These 
enhancers allowed for reaching theophylline flux values up to 42.2±14.3 µg/cm2/h, with the 
corresponding ER being 17.8, i.e. approximately 3 times higher activity than DDAIP. Further 
prolongation of the linking chain to 7 carbons in 3f resulted in diminished theophylline 
permeation. Interestingly, replacement of a hydrocarbon chain in DDAIP by a polyfluorinated 
one in 3g led to a complete loss of its permeation-enhancing activity. 
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When considering the effects of the enhancers on the theophylline skin concentration, 
neither racemic DDAIP nor its enantiomers showed any effect. On the other hand, DDAK 
significantly increased theophylline skin concentration to 1149±278 µg/g (Fig. 3). The 
solubility of the theophylline in the donor medium was 27.9±3.3 mg/ml, and was not 
significantly affected by any of the tested compounds.  
 
 
Fig. 3. Effects of the N,N-dimethylamino acid esters on theophylline (TH) flux through (left) and its 
concentration in the porcine skin (right). Means ± SEM, n = 8-11 (3 donors). * indicates significant difference 
against control (p < 0.05), + indicates significant difference against DDAIP (p < 0.05). 
 
DDAIP – both the racemate and the enantiomers – and DDAK were further compared 
using hydrocortisone, indomethacin and adefovir as the model drugs covering a wide range of 
physicochemical properties (Table I). 
The flux of hydrocortisone without an enhancer was 0.11±0.07 µg/cm2/h, and DDAIP 
increased it 11.5 times to 1.27 µg/cm2/h. The corresponding skin concentration was 168±39 
µg/g. Again, no significant difference was found between the (R) and (S)-enantiomers and the 
racemic DDAIP. DDAK proved to be a more potent enhancer than DDAIP for hydrocortisone 
with the flux of 4.78 µg/cm2/h (ER = 43.2) and the skin concentration of 484±96 µg/g (Fig. 
4). The solubility of hydrocortisone in the donor vehicle was 8.3±0.6 mg/ml, and it was not 
significantly affected by any of the enhancers. 
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Fig. 4. Effects of the N,N-dimethylamino acid esters on hydrocortisone (HC) flux through (left) and its 
concentration in the porcine skin (right). Means ± SEM, n = 6 (2 donors). * indicates significant difference 
against control (p < 0.05), + indicates significant difference against DDAIP (p < 0.05). 
 
The flux of adefovir through the porcine skin was 1.4±0.6 µg/cm2/h, and the skin 
concentration was 219 µg/g. DDAIP increased the adefovir flux approximately three times, 
but had no effect on the amount retained in the skin. No stereoselectivity in DDAIP action 
was observed.  The addition of DDAK into the donor sample resulted in significantly higher 
adefovir flux (ER = 13.6) and skin concentration (714 µg/g) in comparison with DDAIP. The 
permeability characteristics of the racemic DDAIP and DDAK measured under the same 
conditions were taken from our previous work [21, 22], and were included in Fig. 5 for 
comparison. The solubility of adefovir in the donor vehicle was 70±7 mg/ml, and was not 
significantly changed by any of the enhancers. 
 
Fig. 5. Effects of the N,N-dimethylamino acid esters on adefovir (PMEA) flux through (left) and its 
concentration in the porcine skin (right). Means ± SEM, n = 4-11 (2-4 donors). * indicates significant difference 
against control (p < 0.05). 
 
 
On the other hand, DDAIP (ER = 22.8) was more effective than DDAK (ER = 8.7) in 
enhancing the permeation of indomethacin through the porcine skin. Similar results were 
obtained for the indomethacin skin concentration. The donor sample with DDAIP and DDAK 
produced indomethacin skin concentration of 1012±173 µg/g and 482±166 µg/g, respectively 
(Fig. 6). The solubility of indomethacin in the donor media significantly increased from 
0.9±0.1 mg/ml in the control sample to 3.4±0.2 mg/ml and 11.6±1.2 mg/ml in the samples 
with DDAIP and DDAK, respectively. 
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Fig. 6. Effects of the N,N-dimethylamino acid esters on indomethacin (IND) flux through (left) and its 
concentration in the porcine skin (right). Means ± SEM, n = 7 (2 donors). * indicates significant 
difference against control (p < 0.05). 
Enzymatic hydrolysis of DDAK 
 
DDAK was hydrolyzed in the presence of porcine esterase - the degradation followed a 
first order kinetics with the estimated half time T1/2 of approximately 17.2 min (Fig. 7). The 
negative control without the enzyme showed that the compound was stable toward chemical 
hydrolysis. 
 
 
 
 
 
Fig. 7. In vitro hydrolysis of DDAK in the presence 
of porcine esterase (first order reaction, T1/2 = 17.2 
min). Means ± SEM, n = 5. Insert: plot of ln of 
DDAK concentration against time.
Fig. 8. In vitro transdermal electrical resistance of 
DDAK-treated and control skin as a function of 
time. The arrows indicate the application and 
removal of the donor samples. * indicates 
significant difference against control. Means ± 
SEM, n = 4 (2 donors). 
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Reversibility of DDAK action 
 
The baseline transdermal electrical resistance was 9.1 - 14.6 kΩ/cm2. The resistance 
decreased to 35 % (4.8 kΩ/cm2) and 81 % (8.9 kΩ/cm2, significant difference at p < 0.05) of 
the initial value after 2-h application of DDAK and control sample, respectively (Fig. 8). The 
resistance of the control (PG-treated sample) continued to slowly decrease until it reached 
approximately 5.5 kΩ/cm2. The DDAK-treated skin resistance further dropped to 20 % (2.7 
kΩ/cm2) at 3 h, i.e. 1 h after the sample removal. Then, the resistance started to increase 
continually up to values of the control samples. At 6 h, i.e. 4 h after the removal of the donor 
samples, no significant difference between DDAK and control was observed.  
 
 
DISCUSSION 
 
Chirality of DDAIP 
 
The purpose of this study was to investigate the structure-activity relationships in a 
group of dimethylamino acid transdermal permeation enhancers. The parent compound of this 
series, DDAIP, is a chiral compound. Since DDAIP increases the skin permeability by 
interacting with the skin barrier lipids [7], which represent a chiral environment, its enhancing 
activity may be of a stereoselective nature. The results from this study, however, did not show 
any significant difference between (R), (S) and racemic DDAIP in increasing either the flux or 
skin concentration of any of the four model drugs. This is in accordance with our previous 
study with 2-octyl 6-aminohexanoate as an enhancer with the chiral centre located in the 
hydrophobic chain [14]. Thus, the interaction of DDAIP with the skin lipids and/or the 
consequent barrier permeabilization is not dependent on the exact spatial orientation of its 
polar head.  
 
Polyfluorination of DDAIP tail 
 
In order to explore the impact of polyfluorination on the behavior of permeation 
enhancers, fluorocarbon DDAIP analogue 3g was synthesized, and its effect on the skin 
transport of theophylline was evaluated. However, this compound was completely inactive. It 
should be noted that the chain length in 3g was 2C-shorter than that in DDAIP - 
1H,1H,2H,2H-perfluoro-1-decanol was used for the synthesis because it was commercially 
available. However, such shortening of the chain could not be responsible for the observed 
change as the decyl derivatives are usually equally or more active than their dodecyl 
counterparts [5, 15]. Thus, the loss of enhancing activity can be attributed to the presence of a 
fluorocarbon instead of a comparable hydrocarbon chain. 
This effect of chain fluorination may be explained either by insufficient penetration of 
3g into the SC lipid bilayers, or its inability to disrupt the barrier lipid packing. The former 
explanation is probably not feasible since polyfluorinated compounds have been found to 
cross the skin barrier. For example, in vitro dermal absorption of 8-2 fluorotelomer alcohol, 
i.e. 1H,1H,2H,2H-perfluoro-1-decanol (the same alcohol as incorporated in 3g molecule in 
this study), from a 0.5% methylcellulose vehicle and ethanol was approximately 7 and 30%, 
respectively, for human skin (DuPont-6997 unpublished, in [31]). Moreover, perfluorinated 
poison ivy allergens were elicitors of allergic contact dermatitis in pentadecylcatechol-
sensitized mice [32].  
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The latter possible explanation, i.e. that polyfluorinated DDAIP did not disrupt the skin 
barrier lipid lamellae, may be connected with different behavior of a fluorocarbon chain. It 
was suggested that phospholipid membrane permeability after replacing a part of the 
hydrocarbon tail for a fluorinated one resulted from a compromise between a) increased 
packing disorder due to weaker lateral interaction and augmented steric repulsions and b) 
increased order related to increased hydrophobicity of the fluorocarbon chains. In short C4F9 
fluorinated tails, both effects appeared to be balanced while with longer C8F17 chains the 
hydrophobic interactions predominated, resulting in enhanced membrane ordering and rigidity 
[17]. This may provide a reasonable explanation of the inability of 3g to perturb the tight SC 
lipid packing.  
 
Linking chain structure 
 
DDAK is a DDAIP analogue with longer linking chain between the tertiary nitrogen 
and ester bond. Its exceptional transdermal permeation-enhancing activity was identified 
using theophylline [20] and adefovir [21, 22], where it was even more active than DDAIP. To 
compare these two structurally similar enhancers in a greater detail, their effects on the 
permeation of four model permeants having different physicochemical properties were 
studied. 
First, the effect of the linking chain structure between the dimethylamino group and 
ester carbonyl was investigated using theophylline as a model drug. DDAIP is an alanine 
derivative bearing the basic nitrogen on the α-carbon together with a methyl group, i.e. its 
linking chain could be regarded as ―branched‖. Its isomer 3b having linear ethylene linking 
chain, i.e. a β-alanine derivative, showed significantly higher activity, suggesting a negative 
effect of the linking chain branching on the activity of DDAIP.  
The effect of branching on the enhancing properties of various compounds was 
discussed in several articles. Aungst described similar enhancement produced by 5C-14C 
branched and unbranched fatty acids [33]. Likewise, no significant difference in permeation-
enhancing ability of fatty alcohols and acids [34] and carbamates [35] with terminal methyl 
branching with the only exception of 12C acid was observed by Klimentova. However, 
similar ethyl-branched alcohols and acids showed significantly higher activity [34]. On the 
other hand, Chantasart described a decrease in the intrinsic enhancing potency with a higher 
degree of branching [36]. Hrabálek suggested that the relatively small degree of branching in 
the hydrophobic chain of 6-aminohexanoic acid esters did not prevent them from interacting 
with the lipid components of SC. However, a higher degree of branching, cyclization of the 
chain, and presence of an aromatic ring resulted in a loss of activity [37]. The results from this 
study with DDAIP and 3b seem to support the latter studies that branching close to the polar 
head has negative effect on the enhancing activity. 
With prolonging the linking chain between the nitrogen and ester carbonyl, the potency 
of the enhancers increased first, and then remained comparable in 3c, 3d and DDAK, i.e. in 
derivatives of butanoic, pentanoic and hexanoic acid, and decreased in octanoic acid-based 
enhancer 3f. Neither of these enhancers changed the solubility, i.e. the thermodynamic 
activity of the model drug in the vehicle. The difference between DDAK and DDAIP can be 
explained by diverse interaction within the SC lipid bilayers. DDAK is a substance with the 
same hydrogen bonding activity as DDAIP, but more lipophilic and with a flexible linking 
chain, which could adopt an optimal conformation and probably interact more readily with SC 
components.  
 
DDAK versus DDAIP 
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The activity of DDAK and DDAIP was further studied using hydrocortisone, adefovir 
and indomethacin (Table I) to find whether DDAK was able to facilitate absorption of a 
broader spectrum of drugs. This enhancer was more potent than DDAIP in increasing both the 
flux and skin concentration of hydrocortisone and adefovir confirming the results with 
theophylline. Neither DDAIP nor DDAK changed the solubility of these drugs in the donor 
vehicle, i.e. their thermodynamic activity. Thus, the reported enhancement ratios reflect a 
direct increase in the skin permeability.  
On the other hand, the enhancing effect of DDAIP on the permeation of indomethacin 
was 2.6 times higher than that of DDAK. The enhancing potency of DDAIP towards 
indomethacin permeation was previously explained by a complex formation via hydrogen 
bonding between the carboxyl group of indomethacin and the tertiary amine of the enhancer 
[11]. This is consistent with 3.8 times increased solubility of the drug in the donor vehicle 
observed in this work. On the other hand, DDAK possesses similar dimethylamino group 
capable of interacting with indomethacin. Indeed, the solubility of indomethacin in 60% PG 
increased 10 times after the addition of DDAK. However, its ability to enhance indomethacin 
permeation through the skin was lower than that of DDAIP. In order to study the nature of the 
interaction, NMR and IR spectra of indomethacin, DDAIP, DDAK and their equimolar 
mixtures were recorded. 
13
C-NMR spectra showed larger upfield shifts of the carbons next to 
nitrogen in DDAK-indomethacin complex than in the DDAIP one, consistent with the shifts 
of protonated DDAK. Similar changes were observed in the 
1
H-NMR and IR spectra. Thus, 
DDAK was likely protonated by indomethacin. This may be explained by different basicity of 
the two enhancers: DDAK is a stronger base that DDAIP due to better steric availability and 
higher electron density of the nitrogen lone pair and is therefore capable of (partly) 
dissociating indomethacin, i.e. a carboxylic acid. However, the formation of an ion pair in the 
donor vehicle may be decreased due to its high dielectric constant and the two ionic species 
are likely solvated. This may explain the lower activity of DDAK towards indomethacin.  
 
Biodegradability of DDAK 
 
DDAK was designed as a biodegradable permeation enhancer. Similar to DDAIP, it 
contains ester bond and may thus be hydrolyzed by skin esterases. To determine DDAK 
biodegradability, we used the same porcine esterase method as was applied previously to 
DDAIP [6], tranexamic acid-based enhancers [16] and Transkarbam 12 [23]. However, the 
conditions for HPLC determination of DDAIP described by Büyütimkin et al. [6] were not 
applicable to DDAK analysis due to its low UV absorption, which limited the sensitivity of 
the assay. The enhancer concentration was thus determined using HPLC/MS. The results 
demonstrated that DDAK was rapidly hydrolyzed by porcine esterase with T1/2 = 17.2  min. 
This is in a good agreement with DDAIP showing half life of 18.5 min [6]. The longer half 
life of DDAIP may be explained by steric hindrance of the ester group by the adjacent methyl. 
As esterases are present in the human epidermis [38, 39], the hydrolysis is likely to occur in 
vivo as well, preventing any possible harmful action of this compound on living cells. 
Moreover, pilot oral toxicity tests in mice and rats showed that all animals survived a DDAK 
dose of 2 g/kg without any signs of toxicity (BioTest Ltd, Konárovice, Czech Republic). 
 
Reversibility of DDAK action 
 
Electrical resistance is a simple, quick and robust method for measuring the skin barrier 
integrity [40]. In this study, we used this method for evaluation of the reversibility of DDAK 
action. The results confirmed that a) DDAK acts by direct decrease of the skin barrier 
resistance as suggested previously [22], b) the action of this enhancer on the skin is temporary 
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and c) the barrier changes induced by DDAK are reversible. The reversibility is probably 
connected with rapid clearance of DDAK from the SC with subsequent hydrolysis of this 
compound by epidermal esterases. The rapid reversibility may also explain the previously 
found difference in activity of this enhancer in the co-application and pretreatment protocol 
[22].  
 
 
CONCLUSION 
 
In this study, the transdermal permeation-enhancing potency of a series of N,N-
dimethylamino acid esters was studied. No stereoselectivity in action of DDAIP was found. 
Polyfluorination of a hydrophobic chain of DDAIP resulted in a complete loss of activity. 
Replacement of a ―branched‖ linking chain between nitrogen and ester of DDAIP by a linear 
one markedly improved the enhancing activity with optimum linking chain length found in 4-
6C acid derivatives. DDAK was more potent enhancer than DDAIP for theophylline, 
hydrocortisone and adefovir, while DDAIP was better enhancer for indomethacin. DDAK was 
rapidly metabolized by porcine esterase, displayed low acute toxicity and reversible action. 
These results suggest that DDAK, a highly effective biodegradable transdermal permeation 
enhancer for a broad spectrum of drugs, is a promising candidate for future research.  
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ABSTRACT 
Stratum corneum ceramides are major determinants of skin barrier function. Although 
their physiological and pathological role has been widely investigated, to date no structure-
activity relationships have been established. In this study, a series of short-chain ceramide 
analogues with polar head structure identical to ceramide NS, sphingosine length of 12 
carbons and acyl chain length from 2 to 12 carbons was synthesized. Their effect on skin 
permeability was evaluated using porcine skin and two model drugs, theophylline and 
indomethacin, and compared to that of a physiological ceramide NS. The results showed that 
ceramide chain length was crucial for their barrier properties. Ceramides with 4-8C acyl chain 
were able to increase skin permeability for both drugs up to 10.8 times with maximum effect 
at 6C acyl. No increase in permeability was found for ceramide analogues with 2C and 12C 
acyl and ceramide NS. The same relationships were obtained for skin concentrations of the 
model drugs. The relationship between ceramide acyl chain length and its ability to perturb 
skin barrier showed striking similarity to the behavior of short-chain ceramides in 
sphingomyelin/phospholipid membranes and confirmed that short-chain ceramides do not act 
as natural ceramides and their use as experimental tools should be cautious. 
 
 
INTRODUCTION 
 
 The primary function of the skin is to protect the body from the loss of water and other 
physiologically important components and to prevent or limit the penetration of potential 
toxic compounds, allergens, irritants and microbes. The principal barrier for penetration of 
most compounds resides is the stratum corneum (SC), the uppermost layer of the skin, which 
consists of flattened dead cells, corneocytes, and intercellular lipid lamellae. The intercellular 
lipids are considered, as the only continuous domain through SC, to be the most important 
pathway for the diffusion of substances into the body. This lipidic matrix is composed of an 
approximately equimolar mixture of ceramides, cholesterol and free fatty acids. The unusual 
composition of the SC lipids with the high ceramide content and, particularly, their 
exceptional organization seems to be essential for maintaining the skin barrier function. This 
is supported by the observation that prominent skin diseases, such as atopic dermatitis and 
psoriasis, have diminished ceramide levels. For recent reviews on the skin ceramides, see 
Wertz [1], Bouwstra et al. [2, 3], Wartewig et al. [4], Kessner et al. [5] and Holleran et al. [6]. 
 In the human SC, nine major ceramide subclasses have been identified [7]. These 
compounds belong to the class of sphingolipids and consist of a sphingoid base - sphingosine, 
phytosphingosine or 6-hydroxysphingosine, which is N-acylated by a long-chain saturated 
fatty acid, α-hydroxy acid (both with approximately 24C) or ω-hydroxy acid (30C and more). 
The ω-hydroxyl is further esterified with linoleic acid.  
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 Although the physiological and pathological role of ceramides in the skin, their 
biosynthesis and physicochemical behavior has been widely investigated, to date no structure-
activity relationships have been established. It is generally accepted that the relatively small 
polar head of ceramides, their ability to create an extensive hydrogen bonding network, their 
exceptionally long saturated chains allowing for strong hydrophobic attraction and the 
heterogeneity in their structure are the basic prerequisites of a competent skin barrier. 
Particularly, ceramide 1 (EOS) was proved to influence dominantly the formation of the long 
periodicity phase and lateral lipid packing [8]. Nevertheless, no systematic study has been 
done to investigate the importance of the individual structural features of ceramides for their 
diffusion resistance. 
 In this study, we have focused on the role of acyl chain length of skin ceramides. This 
structural modification has been widely discussed in studies concerning the role of ceramides 
in cell signaling. Short-chain analogues, particularly N-acetylsphingosine (C2 ceramide), have 
been extensively used as agonists when ceramide effects had to be elicited. However, many 
substantial differences between naturally occurring long-chain ceramides and their short-chain 
analogues were described recently (for a review, see Goñi and Alonso [9] and van Blitterswijk 
et al. [10] and references therein).  
 No such data are available for the ceramide action in the skin. Although short-chain 
fluorescent ceramide analogue was used to study ceramide behavior in the skin after topical 
application [11], it is questionable whether this result may be reproduced using natural 
ceramide. We have previously studied ceramide analogues based on simple L-serine esters. 
Compound 14S24, having the same chain length as ceramide NS, was able to repair both 
porcine [12] and human skin barrier disrupted by various model insults [13]. On the other 
hand, compound 12S12, having the same polar head but shorter chains, acted as a permeation 
enhancer [14]. Moreover, many potent permeation enhancers, i.e. compounds increasing skin 
permeability, bear one common structural feature, which is a chain of 10-12C [15]. These 
compounds can incorporate into the SC lipid lamellae and fluidize them, thereby promoting 
drug flux through the skin [16]. Similar example can be found in fatty acids. While the long-
chain fatty acids are important components of the SC lipid mixture, the shorter ones act as 
permeation enhancers [15, 17-19]. Thus, we hypothesize, that short-chain ceramides may not 
have the same barrier properties as their long-chain natural counterparts. 
 The aim of this study was to synthesize a series of short-chain analogues of ceramide 
NS and to evaluate their effects on the skin permeability of two model drugs in vitro. 
 
 
MATERIALS AND METHODS 
 
 Chemicals and instrumentation 
 All chemicals were purchased from Sigma-Aldrich (Schnelldorf, Germany). Silica gel 
60 (230-400 mesh) for column chromatography, TLC plates (silica gel 60 F254, aluminium 
back) and HPLC columns were obtained from Merck (Darmstadt, Germany). 
 The structure and purity of the compounds synthesized were confirmed by FTIR 
(Nicolet Impact 400 spectrophotometer) and 
1
H and 
13
C NMR spectra (Varian Mercury-Vx 
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BB 300 instrument, operating at 300 MHz for 
1
H, 75 MHz for 
13
C). The melting points were 
measured with a Kofler apparatus and are uncorrected. 
 
 Synthesis 
 (S)-3-hydroxy-1-methoxy-1-oxopropan-2-aminium chloride (1). Thionyl chloride (9 
ml, 0.12 mol) was added dropwise to anhydrous methanol (120 ml) to keep the internal 
temperature below -15°C. The solution was stirred at -20°C for 0.5 h and then L-serine (5 g, 
47.5 mmol) was added. The mixture was maintained at -20°C for additional 0.5 h and then 
stirred at room temperature overnight. The solvent was removed under reduced pressure and 
the crude was recrystallized from methanol/diethyl ether. White crystals of the product were 
dried over KOH. Yield = 90%. M.p. = 161-163°C, the spectra were in accordance with Ref. 
[20].  
 
 (S)-methyl 2-(tert-butoxycarbonylamino)-3-hydroxypropanoate (2). The methyl ester 
(1) (33.6 g, 0.22 mol) was dissolved in dry chloroform (400 ml) and triethylamine (TEA, 72 
ml, 0.98 mol) was added. The reaction was cooled to -5°C and solution of di-tert-butyl 
dicarbonate (Boc2O, 56.6 g, 0.26 mol) in dioxane (200 ml) was slowly added. The mixture 
was stirred at -5°C for 0.5 h, warmed up to room temperature (RT) and stirred overnight. 
Subsequently, the reaction was treated with 1M KHSO4 (100 ml) and 5% NaHCO3 (100 ml). 
The polar phases were washed with chloroform (2x 100ml) and the combined organic layers 
were dried over Na2SO4, filtered and concentrated in vacuum. The product was used without 
further purification. 
 
 (S)-3-tert-butyl 4-methyl 2,2-dimethyloxazolidine-3,4-dicarboxylate (3). The solution 
of protected L-serine (2) (10.9 g, 49.9 mmol), 2,2-dimethoxypropane (DMP, 12.2 ml, 99.8 
mmol) and p-toluenesulfonic acid monohydrate (TsOH.H2O, 0.13 g, 0.68 mmol) in toluene 
(140 ml) was refluxed for 0.5 h, then the solvent was distilled at 61°C until 10 ml of azeotrope 
was collected and the temperature was dropping. Additional DMP (2.9 ml, 0.10 mol) was 
added, the mixture refluxed for additional 0.5 h and the solvent was distilled off again (5 ml 
collected). The cooled reaction was partitioned between saturated NaHCO3 solution (200 ml) 
and diethyl ether (2x450ml). The combined organic layers were washed with brine (100 ml), 
dried over Na2SO4 and concentrated in vacuum. The crude was purified on silica, using ethyl 
acetate/hexane (1:14 to 1:9) to give a colorless oily product. Yield = 89%. The spectra were in 
accordance with Refs. [21, 22]. 
  
(S)-tert-butyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate (4). The oxazolidine (3) 
(20 g, 77.1 mmol) was dissolved in dry toluene (170 ml) and cooled to -78°C under nitrogen. 
1.0 M solution of diisobutylaluminium hydride (DIBAL-H) in toluene (130 ml, 0.13 mol) was 
slowly added to keep the temperature under -65°C. The reaction mixture was stirred for 2 h at 
– 78°C under nitrogen until the TLC analysis (hexane/ethyl acetate 4:1) shown the reaction to 
be complete. The reaction was quenched by slow addition of -20°C methanol (30 ml) to 
maintain the reaction temperature under -65°C. The resulting white emulsion was poured into 
stirred ice-cold 1M HCl (500 ml) and extracted with ethyl acetate (3x500ml). The combined 
organic layers were washed with saturated KBr solution (350 ml), dried over Na2SO4, filtered 
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and concentrated under vacuum. The product was separated on silica column (ethyl 
acetate/hexane 1:4) as an oily liquid. Yield = 76%. The spectra were in accordance with Refs. 
[21, 22]. 
 
 (R)-tert-butyl 4-((S)-1-hydroxydec-2-ynyl)-2,2-dimethyloxazolidine-3-carboxylate 
(5b). 1.6M solution of butyl lithium (BuLi) in hexane (1.9 ml, 3.04 mmol) was added to -
78°C solution of 1-nonyne (0.57 ml, 3.47 mmol) in dry THF (30 ml) and stirred for 1 h under 
nitrogen. Subsequently, hexamethylphosphoramide (HMPA, 0.9 ml, 5.16 mmol) and the 
aldehyde (4) (0.59 g, 2.58 mmol) in THF (15 ml) was added and the reaction stirred for 
additional 2 h at -78°C. Saturated solution of NH4Cl (20 ml) was added to the resulting 
mixture; the reaction was warmed to RT, diluted with water and extracted with diethyl ether 
(3x100 ml). After drying and concentration of the organic phase under vacuum, the crude was 
purified by flash column chromatography (ethyl acetate/hexane 9:1), giving a colorless oily 
product in 76% yield. The spectra were in accordance with van Overmeire et al. [23].  
(R)-tert-butyl 4-((S)-1-hydroxyhexadec-2-ynyl)-2,2-dimethyloxazolidine-3-carboxylate 
(5a) was synthesized likewise, the spectra were in accordance with Garner et al. [24]. 
 
(2S,3R,4E)-2-aminododec-4-ene-1,3-diol (6b, C12 sphingosine). Lithium (0.39 g, 56 
mmol) was treated with methanol, diethyl ether and hexane, cut into small pieces and 
dissolved in -78°C ethyl amine (70 ml) under nitrogen atmosphere (about 3 h, indicated by 
deep blue colour of the solution). The alkyne (5b) (2 g, 5.66 mmol) in THF (70 ml) was added 
dropwise, the reaction mixture was stirred at –78°C for 2 h, and then quenched by addition of 
solid NH4Cl (2.3 g). Ethyl amine was blown out by a stream of nitrogen; the resulting mixture 
was concentrated under vacuum and partitioned between water (100 ml) and diethyl ether 
(3x150). The organic phase was dried over Na2SO4, filtered and concentrated under vacuum. 
The crude was dissolved in dioxane/1M HCl (1:1) and refluxed under nitrogen atmosphere for 
1 h. The formation of the sphingosine analogue, Rf = 0.71, at the expense of the starting 
material at the solvent front was checked by TLC using n-butanol/acetic acid/water (4:1:1). 
The reaction mixture was concentrated to its half and extracted with diethyl ether/hexane 1:1 
(4x100 ml). The aqueous phase was then alkalized with cold 1M NaOH to pH 10 and 
extracted with dichloromethane (3x200ml). The combined extracts were washed with 
saturated solution of KBr (100 ml), dried over Na2SO4, treated with carbon, filtered and 
concentrated under vacuum. The crude in the form of waxy solid was recrystallized from 
diethyl ether/hexane to give NMR-homogenous product in overall yield of 43%. The spectra 
were in accordance with van Overmeire et al. [23].  
(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol (6a, sphingosine) was prepared from the 
alkyne (5a) likewise, the spectra were in accordance with Garner et al. [24]. 
 
N-((2S,3R,4E)-1,3-dihydroxydodec-4-en-2-yl)acetamide (7b, ceramide 12/2). The 
sphingosine analogue (6b) (160 mg, 0.74 mmol) was dissolved in dry dichloromethane (10 
ml) and 4-dimethylaminopyridine (DMAP, 9 mg, 0.074 mmol), acetic acid (42 µl, 0.74 
mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (WSC, 131 µl, 0.74 mmol) were 
added at 0°C. The reaction was stirred overnight and partitioned between water (30 ml) and 
dichloromethane (2x30 ml). The organic extracts were dried, concentrated and the product 
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was separated on silica with chloroform/methanol 50:1. Yield = 57% of a colorless waxy 
solid. Mp = 37-39°C. 1H NMR (300 MHz, CHCl3): δ 6.44 (d, J = 7.4 Hz, 1H), 5.79 (dt, J = 
15.4, 6.7 Hz, 1H), 5.53 (dd, J = 15.4, 5.6 Hz, 1H), 4.33 (m, 1H), 3.89-3.99 (m, 2H), 3.71 (d, J 
= 10.7 Hz, 1H), 2.51 (br s, 2H), 2.02-2.11 (m; 5H), 1.27-1.37 (m, 10H), 0.88 (t, J = 6.7, 3H). 
13
C NMR (75 MHz, CHCl3): δ 171.2, 133.7, 128.7, 73.7, 61.7, 54.7, 32.2, 31.7, 29.0, 23.1, 
22.5, 14.0. IR (ATR): νmax 3283, 2920, 2852, 1643, 1618, 1554 cm
-1
. 
 
General procedure for the preparation of the succinimidyl esters of carboxylic acids: An 
appropriate aliphatic acid (1.82 mmol), 1-hydroxypyrrolidine-2,5-dione (0.21 g, 1.82 mmol), 
and DMAP (0.02 g, 0.16 mmol) were dissolved in ethyl acetate (2 ml) and cooled to 0°C. 
N,N´-dicyclohexylcarbodiimide (DCC, 0.38 g, 1.84 mmol) in ethyl acetate (1 ml) was added, 
the suspension was slowly warmed to RT and stirred overnight. A droplet of acetic acid was 
used to quench the reaction. The precipitated N,N´-dicyclohexylurea was filtered off and the 
concentrated residue was purified on a silica column with ethyl acetate/hexane. 
 
General procedure for the preparation of the ceramides 7a and 7c-f: The sphingosine 
analogue (6a for the preparation of 7a, or 6b for the preparation of 7c-f) (100 mg, 0.46 mmol) 
and an appropriate succinimidyl ester (0.46 mmol) were dissolved in dry THF (3 ml) and 
stirred at RT overnight. The mixture was concentrated in vacuum and the product separated 
on silica column using chloroform/methanol (50:1) as a mobile phase. 
 
N-((2S,3R,4E)-1,3-dihydroxyoctadec-4-en-2-yl)tetracosanamide (7a, ceramide NS). Yield 
= 89%. M.p. = 94-96°C. 1H NMR (300 MHz, CHCl3): δ 6.24 (d, J = 6.9 Hz, 1H), 5.78 (dt, J = 
15.2, 6.6 Hz, 1H), 5.53 (dd, J = 15.4, 6.5 Hz, 1H), 4.32 (m, 1H), 3.88-3.98 (m, 2H), 3.68-3.7 
(m, 1H), 2.68 (br s, 2H), 2.23 (t, J = 7.5 Hz, 2H), 2.05 (q, J = 6.9 Hz, 2H), 1.56-1.66 (m, 2H), 
1.25-1.37 (m, 62H), 0.87 (t, J = 6.5 Hz, 6H). 
13
C NMR (75 MHz, CHCl3): δ 173.8, 134.3, 
128.8, 74.7, 62.5, 54.5, 36.8, 32.2, 31.9, 29.7, 29.5, 29.4, 29.3, 29.2, 29.1, 25.7, 22.7, 14.1. IR 
(ATR): νmax 3312, 2919, 2849, 1646, 1549 cm
-1
. 
 
N-((2S,3R,4E)-1,3-dihydroxydodec-4-en-2-yl)butyramide (7c, ceramide 12/4). Yield = 
64%. M.p. = 57-58°C. 1H NMR (300 MHz, CHCl3): δ 6.31 (d, J = 7.0 Hz, 1H), 5.78 (dt, J = 
15.5, 6.4 Hz, 1H), 5.52 (dd, J = 15.2, 6.4 Hz, 1H), 4.30 (m, 1H), 3.87-3.96 (m, 2H), 3.69 (dd, 
J = 10.5, 4.7 Hz, 1H), 3.05 (br s, 2H), 2.21 (t, J = 7.0, 2H), 2.05 (q, J = 7.0 Hz, 2H), 1.61-1.73 
(m, 2H), 1.26-1.38 (m, 12H), 0.96 (t, J = 7.2 Hz, 3H), 0.88 (t, J = 6.7 Hz, 3H). 
13
C NMR (75 
MHz, CHCl3): δ 173.8, 134.2, 128.8, 74.5, 62.4, 54.5, 38.8, 32.3, 31.8, 29.1, 22.6, 19.2, 14.1, 
13.7. IR (ATR): νmax 3227, 2921, 2851, 1643, 1623, 1550 cm
-1
. 
 
N-((2S,3R,4E)-1,3-dihydroxydodec-4-en-2-yl)hexanamide (7d, ceramide 12/6). Yield = 
82%. M.p. = 62-65°C. 1H NMR (300 MHz, CHCl3): δ 6.36 (d, J = 7.0 Hz, 1H), 5.78 (dt, J = 
15.2, 6.4 Hz, 1H), 5.52 (dd, J = 15.5, 6.3 Hz, 1H), 4.30 (t, J = 4.2 Hz, 1H), 3.88-3.96 (m, 2H), 
3.69 (dd, J = 8.2, 2.3 Hz, 1H), 2.89 (br s, 2H), 2.23 (t, J = 7.6 Hz, 2H), 2.05 (q, J = 6.9, 2H), 
1.59-1.69 (m, 2H), 1.26-1.36 (m, 14H), 0.85-0.92 (m, 6H). 
13
C NMR (75 MHz, CHCl3): δ 
82 
 
174.0, 134.2, 128.7, 74.5, 62.4, 54.5, 36.8, 32.3, 31.8, 31.4, 29.1, 25.4, 22.6, 22.4, 14.1, 13.9. 
IR (ATR): νmax 3335, 2920, 2851, 1608, 1550 cm
-1
. 
 
N-((2S,3R,4E)-1,3-dihydroxydodec-4-en-2-yl)octanamide (7e, ceramide 12/8). Yield = 
83%. M.p. = 63-64°C. 1H NMR (300 MHz, CHCl3): δ 6.33 (d, J = 7.1 Hz, 1H), 5.77 (dt, J = 
15.4, 6.3 Hz, 1H), 5.51 (dd, J = 15.5, 6.5 Hz, 1H), 4.29 (t, J = 5.6 Hz, 1H), 3.87-3.96 (m, 2H), 
3.69 (dd, J = 10.7, 2.3 Hz, 1H), 2.81 (br s, 2H), 2.22 (t, J = 7.5 Hz, 2H), 2.05 (q, J = 6.7 Hz, 
2H), 1.58-1.68 (m, 2H), 1.26-1.38 (m, 18H), 0.87 (t, J = 6.9 Hz, 6H). 
13
C NMR (75 MHz, 
CHCl3): δ 174.0, 134.2, 128.7, 74.4, 62.4, 54.5, 36.8, 32.3, 31.8, 31.7, 29.2, 29.1, 29.0, 25.7, 
22.6, 14.1, 14.0. IR (ATR): νmax 3349, 3297, 2921, 2851, 1637, 1545 cm
-1
. 
 
N-((2S,3R,4E)-1,3-dihydroxydodec-4-en-2-yl)dodecanamide (7f, ceramide 12/12). Yield 
= 86%. M.p. = 80-82°C. 1H NMR (300 MHz, CHCl3): δ 6.29 (d, J = 7.3 Hz, 1H), 5.78 (dt, J = 
15.6, 6.7 Hz, 1H), 5.52 (dd, J = 15.4, 6.4 Hz, 1H), 4.30 (m, 1H), 3.86-3.96 (m, 2H), 3.66-3.72 
(m, 1H), 2.81 (br s, 2H), 2.22 (t, J = 7.5 Hz, 2H), 2.05 (q, J = 6.9 Hz, 2H), 1.58-1.68 (m, 2H), 
1.25-1.38 (m, 26H), 0.87 (t, J = 6.5 Hz, 6H). 
13
C NMR (75 MHz, CHCl3): δ 174.0, 134.2, 
128.8, 74.6, 62.4, 54.5, 36.8, 32.3, 31.9, 31.8, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 25.7, 22.6, 
14.1. IR (ATR): νmax 3347, 3293, 2918, 2849, 1636, 1546 cm
-1
. 
 
Donor samples 
Donor samples were prepared as 5% w/v suspension of theophylline, and 2% w/v 
suspension of indomethacin, respectively, with 1% w/v of the short-chain ceramide in 
propylene glycol/water 6:4. All the donor samples were saturated with the pertinent model 
drug at these concentrations. The suspension was stirred for 5 min at 50°C and then allowed 
to equilibrate at 37°C for 24h before the application on the skin. The negative control samples 
containing the same amount of the model drug without the ceramide and the positive control 
containing the drug and 1% ceramide NS were prepared likewise.  
For the determination of the effects of the ceramides on the solubility of the drugs in the 
donor solvent, the samples were prepared in triplicate as described above and allowed to 
equilibrate. After 24 h, the suspensions were centrifuged at 10,000g for 5 min; the supernatant 
was withdrawn, diluted with the pertinent mobile phase and analyzed by HPLC. 
 
Skin 
For the initial in vitro experiments, porcine skin was selected because it is easy to obtain 
and its permeability is close to the human skin [25-29]. Porcine ears were purchased from a 
local slaughterhouse. To ensure integrity of the skin barrier, ears were removed post-sacrifice 
before the carcass was exposed to the high-temperature cleaning procedure. Full-thickness 
dorsal skin was excised by blunt dissection and hairs were carefully trimmed. The skin was 
than immersed in 0.05% sodium azide solution in saline for 5 minutes for preservation. The 
skin fragments were stored at -20°C up to two months.  
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Permeation experiments 
The effects of the short-chain ceramides on the skin permeability was evaluated using 
modified Franz diffusion cells [30] with an available diffusion area of 1 cm
2
 and an acceptor 
volume of approximately 17 ml. The skin fragments were slowly thawed immediately before 
use and carefully inspected for any visual damage. They were cut into squares ca 2 x 2 cm, 
mounted into the diffusion cells dermal side down and sealed with silicone grease. The 
acceptor compartment of the cell was filled with phosphate-buffered saline at pH 7.4 with 
0.03% sodium azide as a preservative. The precise volume of the acceptor liquid was 
measured for each cell and included into the calculation. The Franz diffusion cells with 
mounted skin samples were placed in a water bath with a constant temperature of 32°C 
equipped with a multi-place magnetic stirrer. After an equilibration period of 1 h, 150 µl (i.e. 
an infinite dose) of the donor sample was applied to the SC side of the skin and covered with 
a glass slide. The acceptor phase was stirred at 32°C throughout the experiment. Sink 
conditions were maintained. Samples of the acceptor phase (0.6 ml) were withdrawn at 
predetermined time intervals over 48 h and replaced with fresh buffer solution.  
At the end of the permeation experiment (48 h), the diffusion cells were dismounted and 
the skin surface washed with 0.5 ml of ethanol and 0.5 ml of water. The exposed area of 1 
cm
2
 was punched out, blotted dry and weighted. The skin sample was then extracted with 5 
ml of the appropriate mobile phase for 48 h and the concentration was determined by HPLC. 
The extraction efficacy was 98±2% for theophylline and 101±7% for indomethacin, which is 
in accordance with the FDA Guidance for Industry for Bioanalytical Method Validation, 
2001.  
 
HPLC assay conditions 
Theophylline and indomethacin were determined by isocratic reverse-phase HPLC using 
LC-20AD pump, SIL-20AC autosampler and SPD-20A UV/VIS detector (Shimadzu, Kyoto, 
Japan). The data were analyzed using CSW v. 1.7 for Windows integrating software (Data 
Apex, Prague, Czech Republic).  
Reverse phase separation of theophylline was achieved on LiChroCART 250-4 column 
(LiChrospher 100 RP-18, 5 µm, Merck) at 35°C using methanol/0.1M NaH2PO4 4:6 (v/v) as 
the mobile phase at a flow rate of 1.2 ml/min. 10 μl was injected on the column and the 
effluent was measured at 272 nm. The retention time of theophylline was 2.9±0.1 min.  
Indomethacin samples were assayed on a LiChroCART 250-4 column (LiChrospher 100 
RP-18, 5 µm, Merck) using a mobile phase containing acetonitrile/water/acetic acid 90:60:5 
(v/v/v) at a flow rate of 1.5 ml/min. 20 μl was injected on the column, which was maintained 
at 40°C. UV absorption was monitored at a wavelength of 270 nm and the retention time of 
indomethacin was 3.9±0.1 min. 
 
Data analysis 
The cumulative amount of the drug penetrated across the skin, corrected for the acceptor 
phase replacement was plotted against time and the steady state flux was calculated from the 
linear region of the plot. Kruskal-Wallis One Way Analysis of Variance on Ranks with 
Dunn‘s or Student-Newman-Keuls post test method was used for the statistical analysis 
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(SigmaStat for Windows version 3.0.1). Data are presented as means ± SEM and the number 
of replicates is given in the pertinent figure. 
 
 
RESULTS 
  
Synthesis  
The sphingosine analogue was prepared by addition of lithium alkynide to a protected L-
serinal as a chiral building block according to Garner [21] with several synthetic 
modifications, which allowed us to avoid cancerogenic reagents like methyl iodide and 
benzene and afforded better yields. The anti-selectivity of the addition was improved using 
HMPA [23, 31]. For the N-acylation of sphingosine, various means of carboxyl activation 
were evaluated, including N-hydroxysuccinimide, carbodiimides, 4-nitrophenyl esters, 
ethylchloroformate and dimethylsulfamoyl chloride. The best yields and easiest purification 
was achieved with succinimidyl esters of the correspondent carboxylic acids [32], except for 
the ceramide 12/2, which was synthesized via carbodiimide coupling [33]. The synthetic 
scheme and the list of the prepared compounds are shown in figure 1. 
 
 
Fig. 1. Scheme of the preparation of the ceramide analogues. Reagents and conditions: (i) SOCl2/MeOH; (ii) 
Boc2O/dioxane/TEA/CHCl3; (iii) DMP/TsOH.H2O/toluene; (iv) DIBAL-H/toluene; (v) BuLi/1-
alkyne/HMPA/THF; (vi) 1. Li/EtNH2/THF; 2. HCl/dioxan (vii) succinimidyl ester/THF resp. 
AcOH/WSC/DMAP/THF. 
85 
 
 
Effects of the short-chain ceramide analogues on the skin permeation of theophylline 
The effects of the prepared short-chain ceramide analogues on the skin permeability was 
evaluated using porcine skin and two model drugs with distinct physicochemical properties, 
theophylline and indomethacin, and compared to that of a physiological ceramide NS. The 
ceramides 12/4, 12/6 and 12/8, i.e. those with 4-8 carbon acyl chain length, increased the flux 
of theophylline 10.4, 10.8 and 8.7 times, respectively (figure 2). No increase in permeability 
was found for ceramide 12/2 and 12/12 and the natural ceramide NS. A similar profile was 
obtained for the theophylline skin concentration, again with the maximum at around 4-6C 
acyl. The solubility of theophylline in the donor vehicle was 25.8±1.5 mg/ml and was not 
significantly affected by any of the ceramide analogues.  
 
Effects of the short-chain ceramide analogues on the skin permeation of indomethacin 
Almost the same pattern of the skin permeation of the second model drug, indomethacin, 
versus ceramide acyl chain length was observed (figure 3). The ceramide analogue 12/6 with 
hexanoyl chain significantly increased both the flux (7.0 times) and skin concentration (2.6 
times) of this drug. The solubility of indomethacin in the donor vehicle was 1.0±0.2 mg/ml 
and it was not significantly affected by any of the ceramide analogues. 
 
 
Fig. 2. Effects of the ceramide acyl chain length on 
theophylline (TH) flux through (upper panel) and 
its concentration in the porcine skin (lower panel). 
Data are presented as means ± SEM, n = 11-26. * 
indicates significant difference against control (p < 
0.05).
 
Fig. 3. Effects of the ceramide acyl chain length on 
indomethacin (IND) flux through (upper panel) and 
its concentration in the porcine skin (lower panel) 
Data are presented as means ± SEM, n = 5. * 
indicates significant difference against control (p < 
0.05). 
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DISCUSSION 
 
The objective of this work was to synthesize a series of short-chain ceramides and to 
evaluate their effects on the skin barrier properties. The polar head of the prepared analogues 
was identical to ceramide NS, i.e. a non-hydroxy acyl sphingosine, which is the most 
abundant ceramide in the human SC [34]. The length of sphingosine in ceramide is usually 
18C. For the purpose of this initial study, the sphingosine backbone of the prepared ceramide 
analogues was truncated to 12C. The main reason was to pronounce the putative effects of the 
short-chain ceramides on the skin permeability since they may have been relatively small and 
difficult to distinguish due to high variability associated with skin permeation experiments. 
The acyl chain length of the analogues was varied from 2 to 12C. In order to differentiate 
these analogues having 12C sphingosine from those discussed below, they are designated 
ceramide 12/2, 12/4 etc. The former number indicates the sphingosine length and the latter the 
acyl carbon number.  
The effects of the prepared short-chain ceramides on the SC barrier were studied using 
the permeation of two model compounds through the porcine skin. Theophylline and 
indomethacine were selected as the model permeants having different molecular weight (MW 
= 180 and 357 g/mol, respectively), lipophilicity (logP = -0.1 and 3.7, respectively), 
ionization constants (pKa values of theophylline are 1.7 and 8.8 and that of indomethacin is 
4.5) and flux values through the porcine skin (1.4 and 0.26 µg/cm2/h, respectively). Moreover, 
the permeability of theophylline proved to be a good marker of the skin barrier function [12, 
35] with higher sensitivity than transepidermal water loss [13].  
The results showed the importance of the ceramide chain length for the skin barrier 
permeability. Although it was not experimentally possible to selectively replace the natural 
long-chain ceramides in the native SC by the short-chain ones – they were only added to the 
existent skin lipid mixture, the extent of the permeability increase relative to control proved 
the usefulness of this experimental setup. The ceramides 12/4, 12/6 and 12/8, i.e. those with 
4-8C acyl chain, were able to increase the skin permeability for both model permeants with 
maximum at around 6C. No increase in permeability was found for ceramide 12/12, ceramide 
NS and, surprisingly, the ceramide 12/2, i.e. the shortest analogue. The same relationships 
were obtained for the skin concentrations of the model drugs. The inactivity of 12/2 and 12/12 
ceramides proved that the shortening of sphingosine to 12C alone cannot be responsible for 
the increased skin permeability caused by the C4-C8 analogues. 
Several studies suggested that hydrogen bonding plays critical role as a cohesive force in 
lipid membranes [36, 37]. However, the short-chain ceramides prepared in our study 
perturbed the skin barrier although they had the same hydrogen bonding ability as ceramide 
NS. This is in accordance with recent studies demonstrating that sphingosine-based 
ceramides, regardless of chain length, form a network of cooperative hydrogen bonds 
involving the primary and allylic hydroxyl, amide and two molecules of water and not the 
adjacent ceramides [38] and the driving force for molecular assembly of the sphingosine 
ceramides is the formation of the orthorhombic chain packing [39]. Since the hydrophobic 
interactions are caused by the attraction of induced dipoles in the hydrophobic chains, they 
strongly depend on the chain length. Thus, the shorter the chain, the weaker the interaction is 
expected to be, causing an increased permeability of the lipid membrane. Another possible 
explanation is that the insertion of a shorter chain into a long-chain lamella would simply 
produce a free space within the membrane, which would most probably be compensated by an 
increased mobility of the surrounding chains. A similar mechanism has been proposed for the 
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action of the amphiphilic permeation enhancers [15]. A third possibility is that these short-
chain ceramides could form separate phases within the long-chain lipid lamellae, similar to, 
for example, oleic acid [40], creating a more permeable shortcut through the membranes. 
Nevertheless, the above hypotheses may only partly explain the observed relationship 
between the chain length and skin permeability. The permeability increased with decreasing 
chain length up to 6C, but decreased with further shortening of the acyl chain. The shortest 
ceramide analogue 12/2 did not change the skin permeability, at least under these 
experimental conditions. 
The reasons for the difference between ceramide 12/6 and 12/2 are not known at present. 
However, surprisingly similar structure-activity relationships may be found in studies of the 
effects of short-chain ceramides on phospholipid/sphingomyelin membranes. Nybond et al. 
[41] studied the effects of ceramides with 2-14C acyl on the stability of the sphingomyelin-
rich domains and cholesterol displacement in phospholipid/sphingomyelin/cholesterol 
vesicles. The stability of the ordered domains, which may have a relevance to the stability of 
the SC lipids, was increased upon incorporation of sphingosine, C2 ceramide and ceramides 
with an acyl chain of 12C and longer. However, both C4 and C6 ceramides destabilized the 
ordered domains.  
Very similar effects of ceramide analogues on ordered membrane domain (raft) stability 
was reported by Megha et al. [42]. A minimum of 12C acyl chain length was required for 
significant raft stability and C6 and C8 ceramides were more destabilizing than the C2 
analogue. In contrast to Nybond et al. [41], C2 ceramide did not stabilize the ordered 
domains, which may be connected with different lipid chain lengths and concentrations used 
for the bilayer formation. Interestingly, the effects of ceramide acyl chain length were 
qualitatively similar in the absence and presence of cholesterol suggesting that the ability of 
ceramides to stabilize/destabilize ordered lipid domains does not involve a specific ceramide-
sterol interaction. Moreover, from the comparison of ceramide analogues with different polar 
head structure, it was suggested that the ability of lipids to pack tightly is more sensitive to 
small changes in the structure of their hydrophobic segments than small changes in their polar 
headgroups [42]. 
Chiantia et al. [43] demonstrated, using atomic force microscopy and fluorescence 
correlation spectroscopy on sphingomyelin/phospholipid bilayers, that short-chain ceramides 
do not form a separate phase but alter the physical properties of the liquid-ordered domains, 
decreasing their stability and viscosity and perturbing the lipid packing. Interestingly, the 
liquid ordered domain size decreased with decreasing ceramide chain length up to 6C but the 
trend changed in the presence in C2 ceramide. The relative diffusion coefficients for both 
ordered and disordered phase and partition coefficients between these two phases of 
fluorescent dye BodChol increased up to C6 ceramide and then decreased with further 
shortening of the chain. 
Gidwani et al. [44] showed, using fluorescence anisotropy measurement, that C6 
ceramide was 4-5 times more effective than C2 one in decreasing lipid order in plasma 
membranes. In contrast to these, long chain ceramides, such as C16 ceramide are of more 
cylindrical shape and should pack well into liquid ordered membrane.  
The above differences between C2 and C6 ceramide might be explained by the different 
shape of the ceramide molecule after its incorporation into the membrane. Nybond et al. [41] 
presented energy-minimized models of the studied ceramides suggesting that C2 ceramide 
does not require much more space than sphingosine alone and the N-acetyl chain may be well 
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accommodated in the polar region of the bilayer without disruption of the chain packing. The 
4-6C acyl chains were probably not long enough to pack efficiently with the long chain lipids 
and ―wobbled‖ between the hydrophilic and hydrophobic regions, thus perturbing the lipid 
packing in its vicinity. When the acyl chain was 10C or longer it was very likely fully 
embedded in the bilayer, adjacent to the neighboring long chain bases or acyl chains. Since 
lipid packing is an important feature of the SC barrier properties as well, this theory may 
provide a reasonable explanation of our results.  
Another explanation of the lower effect of ceramide 12/2 may be its lower lipophilicity 
compared to longer ceramides and, consequently, lower uptake into the lipophilic SC from a 
relatively hydrophilic vehicle. Similar difference in partitioning was suggested to be 
responsible for the lower cytotoxicity of C2 ceramide compared to C6 one by Shabbits et 
Mayer [45]. However, more studies regarding the molecular aspects of the suggested 
interactions and elucidation of the role of the sphingosine chain length are needed. 
In conclusion, this study showed that the ceramide chain length was crucial for their skin 
barrier properties. The relationship between the ceramide acyl chain length and its ability to 
perturb skin barrier showed striking similarity to the behavior of short-chain ceramides in 
sphingomyelin/phospholipid membranes and confirmed that short-chain ceramides do not act 
as natural ceramides and their use as experimental tools should be cautious.  
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5. Skin Penetration of NBD-Ceramides is Chain Length-Dependent;  
Long-Chain Lipids Do Not Enter Nucleated Human Epidermis 
(submitted) 
 
J. Novotný, K. Pospěchová, A. Hrabálek, R. Čáp, K. Vávrová 
 
ABSTRACT 
 
Topical skin lipid supplementation may provide opportunities for controlling ceramide (Cer) 
deficiency in diseases such as atopic dermatitis or psoriasis. However, the exact mechanisms 
by which exogenous Cer correct the barrier abnormalities are not known. Although exogenous 
short-chain NBD-labeled C6-Cer was shown to rapidly traverse stratum corneum (SC) and to 
be uptaken and metabolized by viable epidermal layers, no such evidence is available for 
long-chain ceramides. Thus, we aimed at comparing skin penetration of fluorescent NBD-
labeled C6, C12, and C24-Cer and pseudoCer 14S24. Fluorescent lipids were synthesized 
from sphingosine or L-serine ester and omega-NBD-labeled hydroxysuccinimide-activated 
acids. 24-NBD-lignoceric acid was prepared from dodecan-1,12-diol using lithium 
tetrachlorocuprate coupling. NBD-Cer at two concentrations, either alone or in equimolar 
mixture with cholesterol and lignoceric acid, were applied on viable human skin for 2 and 12 
h, respectively. Only short-chain NBD-C6-Cer reached viable epidermis; NBD-C12-Cer and 
both NBD-C24 lipids penetrated solely into several upper SC layers of both intact and 
acetone-treated skin. These results show that the skin penetration of exogenous Cer is chain 
length-dependent and that exogenous long-chain NBD-labeled Cer and their analogues do not 
enter viable epidermis. This suggests that short-chain Cer cannot be used as general long-
chain Cer mimics. 
 
 
INTRODUCTION 
 
The principal barrier for penetration of most compounds resides is the stratum corneum (SC), 
the uppermost layer of the skin. SC comprises of flattened anucleated cells, corneocytes, and 
extracellular spaces filled with lipidic matrix, which accumulates during the cell 
differentiation. This lipidic matrix is composed of approximately 50% of ceramides (Cer), 
25% of cholesterol and 10% of long-chain fatty acids. The unusual composition of the SC 
lipids with high Cer content and, particularly, their exceptional organization is believed to be 
the limiting factor for the penetration of topically applied compounds. For recent reviews on 
the skin barrier formation, physiology and pathology, see [1-6]. 
Depletion in total Cer content with alteration in the Cer pattern is a common sign for skin 
disorders with diminished skin barrier function, including atopic dermatitis [7, 8] and 
psoriasis [9]. The formulations containing physiological lipids and, in particular, Cer 
supplementation can improve permeability barrier homeostasis [10-12].  In addition, several 
pseudoCer and Cer analogues were able to recover perturbed skin barrier [13-18]. 
Exogenous Cer have been suggested to act within viable epidermis. Indeed, short-chain 
fluorescent NBD-C6-Cer was found to traverse SC, entering the nucleated epidermal layers 
within two hours [12]. It was uptaken and reprocessed by keratinocytes, entering the lamellar 
bodies [19]. However, no such evidence is available for natural long-chain Cer. Moreover, 
many substantial differences between naturally occurring long-chain Cer and their short-chain 
analogues have been described; for a review, see [20-22] and references therein. The Cer acyl 
chain length was found to be crucial for their barrier properties [23]. Cer with C4-8 acyl chain 
were able to increase skin permeability for two model drugs up to 10.8 times with maximum 
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effect at C6 acyl.  Therefore, we hypothesized that the ability of exogenous Cer to traverse SC 
and enter nucleated epidermal cells may also be chain length-dependent. 
The aim of this study was to synthesize a series of fluorescent Cer analogues with 
different acyl chain length, namely 6, 12 and 24 carbons, and to evaluate their penetration into 
both disrupted and intact human skin. Furthermore, we aimed at comparing the behavior of 
fluorescent Cer and pseudoCer 14S24 in the skin. 
 
 
RESULTS 
 
Synthesis of fluorescent lipids 
For the preparation of the fluorescent long-chain NBD-C24-Cer, 24-aminotetracosanoic 
acid had to be synthesized first (Figure 1). Mono-bromation of dodecan-1,2-diol was achieved 
with HBr under microwave activation with 76% yield and in a short time in comparison with 
a method published previously [24]. The resulting bromo alcohol 1 was oxidized to give acid 
2 [25]. Hydroxyl group of 1 was protected as tetrahydropyranyl ether 3, followed by treatment 
with magnesium to give a Grignard reagent. Coupling of the chloromagnesium salt of 2 with 
the Grignard reagent in the presence of freshly prepared lithium tetrachlorocuprate afforded 
O-tetrahydropyranyl acid 4 in 58% yield [26]. Its hydroxyl was deprotected and the 
carboxylic group was esterified to yield methyl ester 5 in one step procedure using thionyl 
chloride in methanol. The formal one-pot conversion of hydroxyl to primary amino group was 
achieved by combination of Mitsunobu reaction with Staudinger reduction of the azido group 
[27]. The resulting hydrochloride of 24-aminotetracosanoic acid 6 was alkalized and labeled 
with NBD-Cl to yield 7c. The commercially available ω-amino hexanoic and dodecanoic 
acids were labeled in the same manner to yield 7a-b. 
Sphingosine was synthesized by alkynylation of protected L-serinal as described 
previously [23, 28, 29]. Then, it was N-acylated by succinimidyl esters of the NBD acids. 
NBD-labeled pseudoCer 14S24 was prepared by N-acylation of tetradecyl L-serine [15] with 
7c using carbodiimide coupling (Figure 2). 
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Figure 1. Synthesis of NBD-labeled 24-
aminotetracosanoic acid. Reagents and conditions: 
(i) 48% HBr, toluene; (ii) CrO3, acetic acid, H2O, 
acetone; (iii) dihydro-2H-pyran, pyridinium p-
toluensulfonate, CHCl3; (iv) CH2Br2, Mg, CH3MgCl, 
Li2CuCl4, THF; (v) SOCl2, MeOH; (vi) HN3 in 
benzene, PhP3, di-isopropyl azodicarboxylate, 
tetrahydrofurane; (vii) NBD-Cl, NaHCO3, MeOH. 
 
 
 
 
 
 
 
Figure 2. Synthesis of NBD-labeled Cer and 
pseudoCer 14S24. Reagents and conditions: (i) 1. N-
hydroxysuccinimide, dicyclohexylcarbodiimide, 4-
dimethylaminopyridine, CHCl3; 2. sphingosine, 
CHCl3; (ii) L-Serine tetradecyl ester, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide, 4-
dimethylaminopyridine, CHCl3. 
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Penetration of fluorescent Cer through 
human skin  
The first experiment was realized under 
similar conditions as described in [12]. The 
fluorescent Cer were applied as 10 μM 
solutions in propylene glycol/ethanol 7:3 
(v/v) on intact and acetone-treated human 
skin for 2 h. Although ex vivo human skin 
was used, its viability was maintained 
throughout the experiment as assessed by 
2,3,5-triphenyltetrazolium chloride (TTC) 
reduction. The fluorescence of Cer 
derivatives was clearly distinguishable from 
epidermal autofluorescence. NBD-C24-Cer 
and NBD-14S24 stayed in upper SC layers 
while NBD-C6-Cer and NBD-C12-Cer 
diffused deeper into SC. Surprisingly, 
neither long nor short-chain NBD-Cer 
penetrated into nucleated epidermal layers. 
Thus, the exposure was prolonged to 12 
h. Nevertheless, the results were more or 
less the same. In one of five replicates, 
NBD-C6-Cer fluorescence was visible in the 
nucleated epidermis while it reached only 
lower SC in the others. The diffusivity of 
NBD-C12-Cer in SC seemed to be similar; 
however, both 24C acyl-bearing lipids 
persisted in several upper SC layers. At the 
end of this experiment, viability of intact 
and acetone-treated skin was 80±4% and 
63±13%, respectively, compared to freshly 
excised skin.  
 
 
 
 
Figure 3. Penetration of exogenous fluorescent 
Cer with different chain length and pseudoCer 
14S24 into human skin. Cer (green fluorescence) 
were applied on the ex vivo viable human skin in an 
equimolar mixture with cholesterol and lignoceric 
acid in propylene glycol/ethanol 7:3 vehicle at a total 
lipid concentration 1 % for 12h. Histological sections 
are shown using (a) brightfield microscopy with 
H&E staining, (b-f) fluorescence microscopy with 
nuclei of cells (blue) stained with the Hoechst 33258 
dye. (a) and (b) controls, (c) NBD-C6-Cer, (d) NBD-
C12-Cer, (e) NBD-C24-Cer, (f) NBD-14S24. Scale 
bar 50µm. 
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In addition, this experiment was also performed on a non-viable frozen-and-thawed skin 
yielding essentially the same results with slightly deeper SC penetration. In an attempt to 
obtain reproducible penetration of NBD-C6-Cer into viable epidermis as described previously 
in mice in vivo [12], an equimolar mixture of NBD-Cer, cholesterol and lignoceric acid at the 
total concentration of 1% was applied to the skin, which corresponds to 6.3-7.5 mM 
concentration of each lipid. 
Indeed, this high-concentration donor sample resulted in reproducible penetration of the short-
chain NBD-C6-Cer into the nucleated epidermal layers in both intact and acetone-treated skin. 
However, the longer-chain lipids were only found in SC (Figure 3). 
 
 
DISCUSSION 
 
Topical skin lipid supplementation may provide opportunities for controlling Cer 
deficiency and improving skin condition in diseases such as atopic dermatitis or psoriasis [1]. 
Indeed, it has been shown that a Cer-dominant barrier repair emollient significantly alleviated 
severity of atopic dermatitis [10, 11]. The mechanisms by which exogenous Cer correct the 
barrier abnormalities have been under debate for some time. In contrast to petrolatum, which 
remained restricted to SC, short-chain NBD-C6-Cer penetrated into the nucleated epidermal 
cells, was transported to the distal Golgi apparatus and then reprocessed [19]. However, the 
recent findings showed substantial differences between short and long-chain ceramides [23]. 
Thus, it is questionable whether topical application of long-chain Cer can also have an impact 
on the underlying proliferation/differentiation responses of the epidermis in addition to a 
direct, physical supplementation of SC lipids. These long-chain sphingolipids are considered, 
due to their extremely hydrophobic nature, unlikely to penetrate through intact SC [30, 31]. 
Thus, we aimed at studying skin penetration of NBD-labeled Cer with different chain length 
and of the pseudoCer 14S24.  
In the first experiment, with the lipids applied at 10 μM concentration for 2 h, that is 
under similar conditions as described previously [12], none of the lipids penetrated into the 
viable epidermal layers. Thus, the exposure to NBD-Cer was prolonged to 12 h, but still no 
reproducible penetration of the NBD-Cer into the nucleated human epidermis was observed. 
This may be due the different barrier properties of mice and human skin [32, 33]. Moreover, 
other studies with this short-chain Cer also gave contradictory results suggesting that this 
effect may be vehicle and concentration-dependent. For example, no uptake of NBD-C6-Cer 
into hairless mice epidermis from petrolatum was found [34]. In contrast, when using a 
complex lipid vehicle for 2 h [34] and 1.7% solution in dimethyl sulfoxide, which is actually a 
potent permeation enhancer, for 4 h [35], respectively, the fluorescence was visible in the 
viable epidermis.  
It should be noted that although ex vivo human skin was used in this study, viability of 
the tissue was maintained throughout the experiment. Only when using acetone-treated skin, 
its viability decreased to 63±13% at 12 h. Similar effect of short-term acetone treatment was 
described in tissue engineered skin [36]. Nevertheless, no significant difference was found 
between the penetration of NBD-lipids through intact and acetone-treated skin. In addition, 
one experiment was performed on a non-viable skin leading to similar distribution of the 
fluorescent lipids in the skin. Despite the inability of neither the short- nor the long-chain Cer 
to traverse SC, chain length-dependence was observed with the shorter analogues penetrating 
deeper into SC. 
In order to obtain reliable penetration of NBD-C6-Cer into nucleated epidermal layers of 
the ex vivo human skin, i.e. to reproduce the previous in vivo results [12] and to be able to 
distinguish between the Cer homologues, the tissue was exposed to an equimolar mixture of 
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NBD-Cer, cholesterol and lignoceric acid at the total lipid concentration of 1% for 12 h. 
Under these conditions, fluorescence of the short-chain NBD-C6-Cer was observed within the 
viable epidermis. On the contrary, the long-chain lipids were not able to penetrate through SC, 
either intact or acetone-treated. Notably, both NBD-C24-Cer and NBD-14S24 stayed in 
several upper SC layers irrespective of the three orders of magnitude higher concentration 
applied.  
The reason for the observed chain length-dependence in Cer penetration may be the 
difference in partitioning and mobility of the short- and long-chain Cer. First, the long-chain 
Cer are likely too hydrophobic to partition from SC into a hydrophilic viable epidermis. 
Indeed, free natural long-chain Cer cannot exist in solution in biological fluids or in cytosol. 
In addition, they belong to the category of non-swelling amphiphiles [37], implying that they 
cannot even give rise to micelles or other aggregates in aqueous suspension, as do, for 
example phospholipids and short-chain Cer [21]. For example, long-chain Cer stays relatively 
tightly bound to the membrane where it is generated [38, 39], while short Cer can leave the 
membrane and translocate to other membranes.  
Based on the studies with NBD-C6-Cer, exogenous Cer are believed to be uptaken by 
nucleated epidermal cells, transported to the distal Golgi apparatus, metabolized and 
incorporated into lamellar bodies [19]. However, an elegant study comparing the effects of 
short- and long-chain Cer showed that although exogenous NBD-C6-Cer taken up via the 
plasma membrane was converted into glucosylCer in the Golgi, long-chain Cer generated in 
the plasma membrane did not reach the Golgi and thus were not glycosylated [40]. These data 
illustrate that short-chain Cer do not exactly mimic the behavior of naturally occurring long-
chain Cer species. 
Second, long-chain Cer were probably unable to traverse the rigid array of long-chain SC 
lipids since both NBD-C24-Cer and NBD-14S24 were only found in the upper SC layers. The 
better penetration of shorter analogues through the membranes and SC lipid lamellae may be 
explained by their smaller molecule and faster exchange between the lipidic bilayers. It has 
been found that the exchange of natural Cer between lipid membranes requires days [41], 
while it takes less than a minute for short chain, fluorescent Cer to exchange between lipid 
vesicles [42]. The easier transbilayer movement of C6 Cer than C16 Cer was observed in 
phospholipid membranes [43]. Short chain Cer were also found to decrease the skin barrier 
properties [23], which may explain their higher penetration. Such chain length dependence 
may be explained by stronger hydrophobic interactions between longer Cer chains. Since the 
hydrophobic interactions are caused by the attraction of induced dipoles in the hydrophobic 
chains, they strongly depend on the chain length. Thus, the shorter the chain, the weaker the 
interaction is expected to be, causing an increased permeability. 
In conclusion, these findings imply that the mechanism of action of the long-chain Cer 
and Cer analogue 14S24 is likely a direct, physical supplementation of SC lipids. Moreover, 
these lipids are not able to penetrate into viable epidermis, which increases their overall safety 
in the treatment of the skin barrier diseases.  
However, it should be kept in mind that these results were obtained using NBD-labeled 
lipids and should be confirmed using more physiological fluorescent Cer, e.g. with polyene 
fluorophores, or radiolabeled lipids (for an excellent comparison and discussion on these Cer 
tools, see [44]). Nevertheless, these results showed different behavior of short and long chain 
NBD-Cer in the human skin. Although short-chain Cer are useful experimental tools in many 
sphingolipid studies, they cannot be used as general Cer mimics, particularly when 
considering Cer effects in lipid membranes including SC lipid lamellae. 
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MATERIALS AND METHODS 
 
Chemicals, instrumentation and synthesis of fluorescent lipids 
See Supplementary Materials and Methods 
 
Skin 
Human skin from Caucasian female patients, who had undergone abdominal plastic surgery, 
was used. The procedure has been approved by the Ethics Committee of the University 
Hospital Hradec Králové, Czech Republic (No. 200609 S09P) and conducted according to the 
Declaration of Helsinki Principles. After excision, the subcutaneous fatty tissue was removed 
by a scalpel. Before the start of the experiment, the skin was maintained at 4°C for maximum 
of 8 h. No significant decrease in viability was observed during this period. 
The penetration experiments were performed on intact and acetone-treated skin, 
respectively. Acetone-extracted skin was prepared by gentle rubbing of the skin surface for 1 
min [45] with 1.0 ml of acetone in a cotton ball.  
 
NBD-Cer samples 
The NBD-Cer donor samples were prepared in propylene glycol/ethanol 7:3 (v/v) [12]. Two 
series of samples were prepared for each compound, a) 10µM solution of NBD-C6-Cer, 
NBD-C12-Cer, NBD-C24-Cer, and pseudoCer NBD-14S24, respectively, and b) equimolar 
mixture of Cer, cholesterol and lignoceric acid with total lipid amount being 1% w/v. The 
samples were allowed to equilibrate for 24 h at 32°C before application to the skin. 
 
Penetration of fluorescent lipids 
The tissue samples were transferred into cell culture dishes filled with Dulbecco‘s Modified 
Eagle‘s Medium (DMEM) supplemented with penicilline, streptomycine and amphotericine 
B. The level of the medium was adjusted so that the tissue specimens were incubated at the 
air-liquid interface [46]. After 1 h equilibration at 32°C, 50 µl of Cer donor samples were 
applied using rings with 1 cm
2
 diameter glued to the skin surface. The skin was then 
incubated at 32°C for 2 h and 12 h, respectively. All the experiments were performed at least 
in triplicate using skin from two donors. At the end of the experiment, the donor Cer solution 
was wiped off with a cotton stub and the skin surface was gently washed with water. Skin 
specimens of approximately 10 mm
2
 area were excised and immersed in Optimal Cutting 
Temperature embedding medium (Leica, Prague, Czech Republic), snap-frozen in liquid 
nitrogen and stored at −80 °C.  
 
Skin viability 
Viability of the skin was assessed by TTC reduction assay [47]. Briefly, punch biopsies of 5 
mm diameter (6 replicates) were incubated in 1 ml of 1.5% TTC and 3% sodium succinate in 
phosphate-buffered saline at pH 7.4 (PBS) at 37°C under nitrogen. After 1 h, the skin 
specimens were blotted dry and the dark red formazan derivative formed by mitochondrial 
enzymes was extracted with 1 ml Methyl Cellosolve (2-methoxyethanol) overnight. The 
absorption at 490 nm was measured and corrected using skin specimens devitalized by boiling 
as a negative control. During the experiment, no significant decrease in viability was 
observed. 
 
Fluorescence microscopy 
Sections of 7 μm thickness were cut on a cryostat and placed on gelatin-coated slides. Slides 
were air-dried and fixed in acetone at −20 °C for 30 min. After being rinsed in PBS the slides 
were counterstained with Hoechst 33258 dye and examined under a fluorescence microscope. 
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Photo documentation and image digitizing from the microscope were performed with the 
Olympus AX 70, with a digital firewire camera Pixelink PL-A642 (Vitana Corp. Ottawa, 
Canada) with image analysis software NIS ver. 3.0 (Laboratory Imaging, Czech Republic). 
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SUPPLEMENTARY INFORMATION 
 
Chemicals and instrumentation 
All chemicals were purchased from Sigma-Aldrich (Schnelldorf, Germany). Silica gel 60 
(230-400 mesh) for column chromatography, TLC plates (silica gel 60 F254, aluminium back) 
and HPLC columns were obtained from Merck (Darmstadt, Germany). The reaction under 
microwave activation was carried out in a Milestone MicroSYNTH Ethos 1600 URM reactor. 
The structure and purity of the synthesized compounds were confirmed by FTIR (Nicolet 
Impact 400 spectrophotometer), MS (Quattro Micro triple quadrupole, Waters Micromass) 
and 
1
H and 
13
C NMR spectra (Varian Mercury-Vx BB 300 instrument, operating at 300 MHz 
for 
1
H, 75 MHz for 
13
C). The melting points were measured with a Kofler apparatus and are 
uncorrected. 
 
Synthesis 
12-bromododecan-1-ol (1). Dodecan-1,12-diol (15.0 g, 74.1 mmol) in toluene (220 ml) with 
48% HBr (10 ml, 89.0 mmol) was refluxed in microwave reactor at 600 MW for 2x20 min. 
Further HBr (3.3 ml, 29.4 mmol) was then added and the reaction was refluxed for additional 
20 min at 600 MW. The mixture was cooled to room temperature (RT), the toluene layer 
separated and extracted with saturated NaHCO3 (150 ml). The organic phase was dried over 
Na2SO4 and concentrated under vacuum. Pure compound was obtained after column 
chromatography, using hexane/ethyl acetate (4:1). Mp = 29-30°C. Yield = 76%. 1H NMR 
(300 MHz, CHCl3): δ 3.64 (t, J = 6.6 Hz, 2H), 3.41 (t, J = 6.9 Hz, 2H), 1.80-1.90 (m, 2H), 
1.52-1.61 (m, 2H), 1.27-1.44 (m, 16H); 
13
C NMR (75 MHz, CHCl3): δ 63.1, 34.1, 32.8, 29.6, 
29.5, 29.4, 28.1, 25.7. 
 
12-bromododecanoic acid (2). The alcohol (1) (4.0 g, 15.1 mmol) in acetone (15 ml) was 
slowly added to a stirred ice-cold mixture of CrO3 (5.85 g, 58.5 mmol), acetic acid (52.4 ml) 
and water (6 ml). The mixture was stirred at 5°C for 2.5 h, warmed up to RT and stirred 
overnight. The reaction was poured into water (250 ml) and extracted with diethyl ether 
(3x200 ml). The crude was purified on silica column, eluting with hexane/ethyl acetate (4:1). 
Mp = 49-50°C. Yield = 82%. 1H NMR (300 MHz, CHCl3): δ 3.41 (t, J = 6.9 Hz, 2H), 2.35 (t, 
J = 7.5 Hz, 2H), 1.80-1.90 (m, 2H), 1.58-1.68 (m, 2H), 1.27-1.44 (m, 14H); 
13
C NMR (75 
MHz, CHCl3): δ 180.1, 34.1, 34.0, 32.8, 29.4, 29.3, 29.2, 29.0, 28.7, 28.1, 24.6. 
 
2-(12-bromododecyloxy)tetrahydro-2H-pyran (3). Dihydro-2H-pyran (3.21 ml, 33.6 mmol) 
and pyridinium p-toluensulfonate (180 mg, 0.72 mmol) was added to alcohol (1) (5.93 g, 22.4 
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mmol) in chloroform (55 ml) at 0°C. The reaction was slowly warmed up to RT, stirred for 
additional 3h and then extracted with water (200 ml). The aqueous phase was washed with 
chloroform (2x200ml). Combined organic layers were washed with brine, dried over Na2SO4 
and concentrated under reduced pressure. The product was obtained after column 
chromatography on silica with hexane/ethyl acetate (19:1). Yield = 96%. 
1
H NMR (300 MHz, 
CHCl3): δ 4.57 (t, J = 3.6 Hz, 1H), 3.83-3.91 (m, 1H), 3.69-3.77 (m, 1H), 3.46-3.53 (m, 1H), 
3.36-3.43 (m, 3H), 1.79-1.89 (m, 3H), 1.49-1.61 (m, 7H), 1.27-1.44 (m, 16H); 
13
C NMR (75 
MHz, CHCl3): δ 98.8, 67.7, 62.3, 34.1, 32.8, 30.8, 29.7, 29.5, 29.4, 28.7, 28.2, 26.2, 25.5, 
19.7. 
 
24-(tetrahydro-2H-pyran-2-yloxy)tetracosanoic acid (4). The protected bromide (3) (9.36 
g, 26.8 mmol) and dibromomethane (0.2 ml, 2.88 mmol) were dissolved in dry THF (15 ml). 
Magnesium (0.71 g, 29.2 mmol) was added and the reaction was refluxed until most of  the 
metal dissolved (approx. 3 h). The bromoacid (2) (6.73 g, 22.34 mmol) was suspended in dry 
THF, cooled to -20°C under nitrogen and 3M solution of methylmagnesium chloride in THF 
(8.2 ml, 24.6 mmol) was added. After the cessation of gas evolution, freshly prepared 2M 
solution of Li2CuCl4 in THF (2.23 ml, 4.46 mmol) was added, followed by dropwise addition 
of Grignard compound prepared from (3). The mixture was stirred for 24 h at -20°C. The 
reaction was poured into 0.5M H2SO4 (400 ml) and extracted with diethyl ether (3x400 ml). 
The organic phase was dried over Na2SO4 and concentrated under reduced pressure. The 
crude was separated on column using hexane/ethyl acetate (25% to 80% of ethyl acetate). Mp 
= 69-70°C. Yield = 58%. 1H NMR (300 MHz, CHCl3): δ 4.58 (t, J = 3.4 Hz, 1H), 3.84-3.91 
(m, 1H), 3.69-3.77 (m, 1H), 3.47-3.54 (m, 1H), 3.34-3.42 (m, 1H), 2.34 (t, J = 7.5 Hz, 2H), 
1.49-1.87 (m, 12H), 1.25-1.39 (m, 36H); 
13
C NMR (75 MHz, CHCl3): δ 179.0, 98.8, 67.7, 
62.3, 33.9, 30.8, 29.7, 29.5, 29.4, 29.2, 29.0, 26.2, 25.5, 24.7, 19.7; IR (ATR): νmax 2912, 
2846, 1701, 1691, 1471, 1034. 
 
Methyl 24-hydroxytetracosanoate (5). Thionylchloride (0.71 ml, 9.8 mmol) was added 
dropwise to dry methanol (150 ml) under nitrogen not to exceed -15°C. Acid (4) (1.88 g, 4.0 
mmol) was added and stirred at -20°C for additional 0.5 h, slowly warmed up to RT and 
stirred overnight. The resulting suspension was cooled to 0°C, the solid was filtered off, 
washed with cold methanol and dried under vacuum. The product was obtained as a colorless 
solid. Mp = 77-79°C. Yield = 90%. 1H NMR (300 MHz, CHCl3): δ 3.66 (s, 3H), 3.63 (t, J = 
6.7 Hz, 2H), 2.29 (t, J = 7.5 Hz, 2H), 1.51-1.63 (m, 4H), 1.24-1.36 (m, 38H); 
13
C NMR (75 
MHz, CHCl3): δ 174.3, 63.1, 51.4, 34.1, 32.8, 29.7, 29.6, 29.4, 25.7, 24.9; IR (ATR): νmax 
2914, 2847, 1736, 1461, 1173. 
 
23-carboxytricosan-1-aminium chloride (6). Freshly prepared 1.2M solution of azoimide in 
benzene (2.51 ml, 3.0 mmol) was added to the solution of hydroxy acid (5) (1.0 g, 2.51mmol) 
in dry THF (1.25 ml), followed by triphenylphosphine (1.45 g, 5.52 mmol) in dry THF (8 ml). 
Subsequently, di-isopropyl azodicarboxylate (0.57 ml, 2.76 mmol) in THF (1.25 ml) was 
added and stirred for 3h, followed by further addition of triphenylphosphine (0.66g, 2.51 
mmol). The reaction was stirred at 50°C for 3h. Then, 1M HCl (4 ml) was added and stirred 
overnight at RT. The mixture was concentrated under vacuum, suspended in THF/1M KOH 
(10 ml), refluxed for 3h, cooled to RT and neutralized with 1 M HCl. The solid was filtered 
off, recrystallized from acetic acid and dried over NaOH, giving a colorless solid. Mp = 151-
155°C. Yield = 49%. 1H NMR (300 MHz, DMSO): δ 7.75 (br s, 3H), 2.68-2.78 (m, 2H), 2.17 
(t, J = 7.3 Hz, 2H), 1.41-1.53 (m, 4H), 1.16-1.29 (m, 38H). IR (KBr): νmax 3428, 2917, 2850, 
1729, 1472, 720.  
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6-(7-nitrobenzo[c][1,2,5]oxadiazol-4-ylamino)hexanoic acid (7a). 6-Aminohexanoic acid 
(50mg, 0.38 mmol), 4-chloro-7-nitrobenzofurazan (NBD-Cl) (76 mg, 0.38 mmol) and 
NaHCO3 (96 mg, 1.14 mmol) were stirred in methanol (5 ml) at 0°C for 0.5 h, at RT for 1.5 h 
and then at 50°C for additional 1.5 h. The reaction was cooled to RT and carefully acidified 
with 0.1 M HCl. The solid was filtered off, purified on silica, eluting with chloroform-
chloroform/methanol (50:1) and recrystallized from aqueous methanol giving an orange solid. 
Mp = 158-159°C. Yield = 63%. 1H NMR (300 MHz, CHCl3): δ 
1
H NMR (300 MHz, CHCl3): 
δ 9.52 (s, 1H), 8.48 (d, J = 8.8 Hz, 1H), 6.38 (d, 8.8 Hz, 1H), 3.44 (m, 2H), 2.21 (t, J = 7.2 Hz, 
2H), 1.62-1.72 (m, 2H), 1.49-1.59 (m, 2H), 1.34-1.41 (m, 2H); 
13
C NMR (75 MHz, CHCl3): δ 
174.6, 145.4, 144.6, 144.3, 138.1, 120.7, 99.3, 43.4, 33.7, 27.6, 26.1, 24.4; IR (ATR): νmax 
3348, 2927, 2856, 1729, 1697, 1585, 1492, 1290, 1256, 1168, 1117, 994. 
 
12-(7-nitrobenzo[c][1,2,5]oxadiazol-4-ylamino)dodecanoic acid (7b). 12-
Aminododecanoic acid was converted to compound 7b using the same procedure as for 7a. 
Mp = 94-96°C. Yield = 81%. 1H NMR (300 MHz, CHCl3): δ 8.50 (d, J = 8.7 Hz, 1H), 6.34 
(m, 1H), 6.18 (d, J = 8.7 Hz, 1H), 3.49 (q, J = 6.6 Hz, 2H), 2.35 (t, J = 7.5 Hz, 2H), 1.76-1.86 
(m, 2H), 1.58-1.68 (m, 2H), 1.25-1.50 (m, 14H); 
13
C NMR (75 MHz, CHCl3): δ 179.1, 144.2, 
143.9, 143.8, 136.5, 123.9, 98.5, 44.0, 33.8, 29.3, 29.2, 29.1, 29.0, 28.9, 28.5, 26.9, 24.6. IR 
(ATR): νmax 3300, 2921, 2848, 1708, 1617, 1585, 1495, 1466, 1227, 1181, 905, 724. 
 
24-(7-nitrobenzo[c][1,2,5]oxadiazol-4-ylamino)tetracosanoic acid (7c). ω-Amino acid 
hydrochloride (6) (150 mg, 0.36 mmol), NBD-Cl (71 mg, 0.36 mmol) and NaHCO3 (90 mg, 
1.07 mmol) were refluxed in methanol (15 ml) for 3.5h. The reaction was cooled to RT and 
carefully acidified with 0.1 M HCl. The solid was filtered off, purified on silica, eluting with 
chloroform/methanol (50:1) and recrystallized from chloroform/hexane giving a brownish 
solid. Mp = 116-117°C. Yield = 56%. 1H NMR (300 MHz, CHCl3): δ 8.50 (d, J = 8.5 Hz, 
1H), 6.26 (s, 1H), 6.17 (d, J = 8.5 Hz, 1H), 3.48 (q, J = 6.6 Hz, 2H), 2.35 (t, J = 7.5 Hz, 2H), 
1.76-1.86 (m, 2H), 1.58-1.68 (m, 2H), 1.25-1.52 (m, 38H). IR (ATR): νmax 3300, 2921, 2848, 
1708, 1617, 1585, 1495, 1466, 1227, 1181. MS: ESI (pos) m/z 569.5 (M+Na)
+
, 601.52 
(M+2Na)
+ 
MS: ESI (neg) m/z 545.6 (M-H)
- 
 
General procedure for the preparation of the NBD-labeled acid succinimidylesters (8a-
c). To a 0°C solution of ω-NBD-amino acid (7a-c) (0.11 mmol), N-hydroxysuccinimide (13 
mg, 0.11 mmol) and 4-dimethylaminopyridine (2 mg, 0.016 mmol) in chloroform (6 ml) was 
added dicyclohexylcarbodiimide (26 mg, 0.13 mmol). The reaction was stirred at 0°C for 0.5h 
and then at RT overnight. The suspension was concentrated under vacuum and separated on 
silica, eluting with chloroform/methanol (50:1). 
 
2,5-dioxopyrrolidin-1-yl 6-(7-nitrobenzo[c][1,2,5]oxadiazol-4-ylamino)hexanoate (8a). 
Mp = 189-191°C. Yield = 85%. 1H NMR (300 MHz, CHCl3): δ 8.50 (d, J = 8.8 Hz, 1H), 6.44 
(m, 1H), 6.19 (d, J = 8.8 Hz, 1H), 3.54 (q, J = 6.2 Hz, 2H), 2.87 (s, 4H), 2.67 (t, J = 6.8 Hz, 
2H), 1.82-1.92 (m, 4H), 1.57-1.69 (m, 4H). 
 
2,5-dioxopyrrolidin-1-yl 12-(7-nitrobenzo[c][1,2,5]oxadiazol-4-ylamino)dodecanoate 
(8b). Mp = 162-164°C. Yield = 95%. 1H NMR (300 MHz, CHCl3): δ 8.51 (d, J = 8.8 Hz, 1H), 
6.26 (m, 1H), 6.19 (d, J = 8.8 Hz, 1H), 3.50 (q, J = 6.6 Hz, 2H), 2.85 (s, 4H), 2.61 (t, J = 7.4 
Hz, 2H), 1.67-1.87 (m, 4H), 1.25-1.56 (m, 14H). 
 
2,5-dioxopyrrolidin-1-yl 24-(7-nitrobenzo[c][1,2,5]oxadiazol-4-ylamino)tetracosanoate 
(8c). Mp = 146-148°C. Yield = 96%. 1H NMR (300 MHz, CHCl3): δ 8.51 (d, J = 8.8 Hz, 1H), 
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6.17 (d, J = 8.8 Hz, 1H), 3.48 (q, J = 6.2 Hz, 2H), 2.84 (s, 4H), 2.60 (t, J = 7.5 Hz, 2H), 1.69-
1.85 (m, 4H), 1.25-1.56 (m, 38H). 
 
General procedure for the preparation of NBD-labeled Cer. Succinimidyl ester (8a-c) 
(0.085 mmol) was dissolved in dry CHCl3 (5 ml) and sphingosine (26 mg, 0.087 mmol) was 
added. The solution was stirred at RT for 48 h. Then, the reaction was concentrated under 
vacuum and purified on silica eluting with chloroform/methanol (0 to 2% of methanol) 
yielding an orange solid. 
 
(2S,3R,4E)-N-(1,3-dihydroxyoctadec-4-en-2-yl)-12-(7-nitrobenzo[c][1,2,5]oxadiazol-4-
ylamino)hexanamide (NBD-C6-Cer). Mp = 85-88°C. Yield = 54%. 1H NMR (300 MHz, 
CHCl3): δ ): δ 8.48 (d, J = 8.7 Hz, 1H), 6.74 (m, 1H), 6.36 (d, J = 7.4 Hz, 1H), 6.17 (d, J = 8.7 
Hz, 1H), 5.80 (dt, J = 14.6, 7.2 Hz, 1H), 5.55 (dd, J = 15.5, 6.3 Hz, 1H), 4.36 (br s, 1H), 3.93-
4.02 (m, 2H), 3.71 (m, 1H), 3.53 (q, J = 6.3 Hz, 2H), 2.75 (br s, 2H), 2.31 (t, J = 6.9 Hz, 2H), 
2.06 (q, J = 6.7 Hz, 2H), 1.72-1.89 (m, 4H), 1.49-1.59 (m, 2H), 1.21-1.39 (m, 22H), 0.87 (t, J 
= 6.7 Hz, 3H); 
13
C NMR (75 MHz, CHCl3): δ 173.6, 144.2, 143.9, 136.8, 134.3, 128.6, 74.4, 
62.2, 54.5, 36.1, 32.3, 31.9, 29.3, 29.2, 29.1, 27.7, 26.2, 24.8, 22.7, 14.1. IR (KBr): νmax 3397, 
2922, 2851, 1637, 1623, 1589, 1309, 1271. 
 
(2S,3R,4E)-N-(1,3-dihydroxyoctadec-4-en-2-yl)-12-(7-nitrobenzo[c][1,2,5]oxadiazol-4-
ylamino)dodecanamide (NBD-C12-Cer). Mp = 92-93°C. Yield = 75%. 1H NMR (300 MHz, 
CHCl3): δ 8.48 (d, J = 8.5 Hz, 1H), 6.72 (m, 1H), 6.38 (d, J = 7.4 Hz, 1H), 6.17 (d, J = 8.7 Hz, 
1H), 5.77 (dt, J = 15.5, 6.6 Hz, 1H), 5.52 (dd, J = 15.5, 6.3 Hz, 1H), 4.31 (t, J = 3.8 Hz, 1H), 
3.89-3.97 (m, 2H), 3.70 (dd, J = 10.6, 2.3 Hz, 1H), 3.49 (q, J = 6.6 Hz, 2H), 2.22 (t, J = 7.6 
Hz, 2H), 2.03 (q, J = 6.6 Hz, 2H), 1.75-1.85 (m, 2H), 1.56-1.66 (m, 2H), 1.24-1.47 (m, 36H), 
0.86 (t, J = 6.4 Hz, 3H); 
13
C NMR (75 MHz, CHCl3): δ 174.0, 144.2, 144.1, 136.7, 134.2, 
128.7, 98.5, 74.5, 62.4, 54.5, 44.0, 36.7, 32.3, 31.9, 29.6, 29.5, 29.3, 29.2, 29.1, 29.0, 28.4, 
26.8, 25.6, 22.6, 14.1; IR (KBr): νmax 3374, 2921, 2850, 1643, 1624, 1586, 1508, 1466, 1309, 
1272. 
  
(2S,3R,4E)-N-(1,3-dihydroxyoctadec-4-en-2-yl)-24-(7-nitrobenzo[c][1,2,5]oxadiazol-4-
ylamino)tetracosanamide (NBD-C24-Cer). Mp = 92-94°C. Yield = 50%. 1H NMR (300 
MHz, CHCl3): δ 8.49 (d, J = 8.5 Hz, 1H), 6.41 (s, 1H), 6.30 (d, J = 6.6 Hz, 1H), 6.17 (d, J = 
8.5 Hz, 1H), 5.78 (dt, J = 15.5, 6.7 Hz, 1H), 5.52 (dd, J = 15.3, 6.3 Hz, 1H), 4.30-4.33 (m, 
1H), 3.89-3.97 (m, 2H), 3.70 (dd, J = 10.6, 2.3 Hz, 1H), 3.48 (q, J = 6.6 Hz, 2H), 2.23 (t, J = 
7.6 Hz, 2H), 2.05 (q, J = 6.9 Hz, 2H), 1.76-1.86 (m, 2H), 1.58-1.68 (m, 2H), 1.25-1.49 (m, 
62H), 0.87 (t, J = 6.5 Hz, 3H); 
13
C NMR (75 MHz, CHCl3): δ 174.0, 143.9, 136.5, 134.2, 
128.8, 98.5, 74.6, 62.5, 54.5, 44.0, 36.8, 32.3, 31.9, 29.7-29.1, 28.5, 26.9, 25.7, 22.7, 14.0; IR 
(KBr): νmax 3420, 2919, 2850, 1654, 1624, 1585, 1571, 1467, 1302, 1271; MS: ESI (pos) m/z 
851.0 (M+Na)
+
; MS: ESI (neg) m/z 827.0 (M-H)
-
. 
 
Tetradecyl (2S)-3-hydroxy-2-(24-(7-nitrobenzo[c][1,2,5]oxadiazol-4-
ylamino)tetracosanamido)propanoate (NBD-14S24). 3-hydroxy-1-oxo-1-
(tetradecyloxy)propan-2-aminium chloride (27 mg, 0.080 mmol) and 4-
dimethylaminopyridine (11 mg, 0.090 mmol) were stirred in dry chloroform (5 ml) at RT for 
15 min. The reaction was cooled to 0°C and NBD acid (7c) (50 mg, 0.091 mmol) and 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (14 µl, 0.080 mmol) were added. The reaction was 
stirred for 48 h at RT, and then extracted with water (20 ml). The aqueous phase was washed 
with chloroform (2x20 ml), the combined organic layers were dried over Na2SO4, filtered, 
concentrated in vacuum, and the crude was purified on silica with chloroform/methanol 
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(50:1). Mp = 101-104°C. Yield = 71.5%. 1H NMR (300 MHz, CHCl3): δ 8.49 (d, J = 8.6 Hz, 
1H), 6.43 (d, J = 6.9 Hz, 1H), 6.35 (s, 1H), 6.18 (d, J = 8.8 Hz, 1H), 4.67 (dt, J = 7.0, 3.4 Hz, 
1H), 4.17 (t, J = 6.7 Hz, 2H), 3.95 (d, J = 3.0 Hz, 2H), 3.48 (q, J = 6.7 Hz, 2H), 2.66 (s, 1H), 
2.27 (t, J = 7.6 Hz, 2H), 1.76-1.86 (m, 2H), 1.59-1.69 (m, 4H), 1.25-1.51 (m, 60H), 0.87 (t, J 
= 6.7 Hz, 3H); 
13
C NMR (75 MHz, CHCl3): δ 173.8, 170.5, 144.2, 136.5, 123.9, 98.5, 66.1, 
64.0, 54.9, 44.0, 36.5, 31.9, 29.7-29.2, 28.5, 26.9, 25.8, 25.5, 22.7, 14.1; IR (ATR): νmax 3308, 
2915, 2849, 1723, 1647, 1625, 1556, 1470, 1249; MS: ESI (pos) m/z 851.0 (M+Na)
+
, 869.0 
(M+K)
+
; MS: ESI (neg) m/z 828.9 (M-H)
-
. 
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